University of Wisconsin Milwaukee

UWM Digital Commons
Theses and Dissertations
December 2021

Protein-Ligand Binding as a Tool to Identify Antiviral Drugs.
Rajdeep Virdi
University of Wisconsin-Milwaukee

Follow this and additional works at: https://dc.uwm.edu/etd
Part of the Biochemistry Commons

Recommended Citation
Virdi, Rajdeep, "Protein-Ligand Binding as a Tool to Identify Antiviral Drugs." (2021). Theses and
Dissertations. 2845.
https://dc.uwm.edu/etd/2845

This Dissertation is brought to you for free and open access by UWM Digital Commons. It has been accepted for
inclusion in Theses and Dissertations by an authorized administrator of UWM Digital Commons. For more
information, please contact scholarlycommunicationteam-group@uwm.edu.

PROTEIN-LIGAND BINDING AS A TOOL TO IDENTIFY ANTIVIRAL DRUGS
by
Rajdeep S. Virdi

A Dissertation Submitted in
Partial Fulfillment of the
Requirements for the Degree of

Doctor of Philosophy
in Chemistry

at
The University of Wisconsin-Milwaukee
December 2021

ABSTRACT
PROTEIN-LIGAND BINDING AS A TOOL TO IDENTIFY ANTIVIRAL DRUGS
by
Rajdeep S. Virdi
The University of Wisconsin- Milwaukee, 2021
Under the Supervision of Professor David N. Frick

Viruses are the most abundant biological entities on the planet. A virus is a collection of
essential genetic material encapsulated in a protein coat that is incapable of replicating without
a host. A virus must inject its genetic material into a suitable host cell to utilize host machinery
to replicate. During the process of replication, a virus hijacks cellular functions, avoids or inhibits
host antiviral defenses, and sometimes causes disease in the host organism. One effective way
to fight viral infection is to identify molecules that inhibit the function of essential viral proteins.
The studies described in this dissertation focus on identifying such molecules. Even if such
molecules are not developed into drugs, they could be useful as molecular probes to study the
biological role of these viral protein targets. The two targets studied here were helicases, which
bind ATP and nucleic acids, and macrodomains, which bind ADP-ribose. The proteins were
isolated from either the hepatitis C virus (HCV) or SARS-CoV-2, the virus that causes COVID-19.
To facilitate similar drug discovery screens with helicases, two assays were designed to
monitor DNA and ATP binding to viral helicases. DNA binding was monitored with Förster
resonance energy transfer (FRET), fluorescently labeled HCV helicase, and fluorescently labeled
oligonucleotides. Factors effecting binding were examined, such as the length of the duplex, the
ii

length of a single-stranded overhang, and whether the overhang had a 5’ or 3’ end. Less FRET
was observed with longer length duplex, and longer length single-stranded overhang.
To monitor the interaction of ATP and a helicase, the steady state rates of ATP hydrolysis
catalyzed by nsp13, a helicase from SARS-CoV-2, were measured. Based on the rates of helicasecatalyzed ATP hydrolysis, the catalytic rate constant, Kcat, was calculated. To monitor the binding
of DNA (or RNA) to nsp13, rates of ATP hydrolysis were examined in the presence and absence
of various oligonucleotides. Oligonucleotides with a length of 18–20 base pairs stimulated the
helicase-catalyzed ATP hydrolysis by increasing rates of ATP hydrolysis, but poly(U) and other
longer polynucleotides had no impact.
In the similar binding studies, Isothermal Titration Calorimetry (ITC) was used to show
ADP-ribose binding to the macrodomain (Mac1) of SARS-CoV-2 was enthalpy (ΔH) driven. The
interactions between Mac1 and nucleotides similar to ADP-ribose were also investigated with
ITC. However, their interaction was not similar to that of ADP-ribose. The next step was to screen
a library of 2,500 compounds in search of potential antiviral candidates or compounds that would
bind to Mac1, blocking its interaction with ADP-ribose using Differential Scanning Fluorimetry
(DSF). Compound effects were confirmed with DSF and ITC, and imatinib methane sulfonate was
shown to bind Mac1 in a similar manner to that of ADP-ribose.
In this dissertation, multiple methods were employed to examine the interaction
between protein and small molecule, protein-DNA, and protein-RNA. Even though not all
methods and techniques employed resulted in identifying potential antivirals, these are the initial
studies required to move forward before proceeding to identify potential antivirals.
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1. Introduction
The interaction of biological macromolecules with one another or with other small
molecules to form a complex is the basis for all activities in living organisms. Proteins are an
important class of biological macromolecules that perform their tasks by interacting with other
molecules. These interactions may take place between identical proteins, i.e., homodimers,
homotrimers, etc., between two separate proteins, i.e., heterodimers, or between proteins and
a small molecule, referred to as a protein-ligand interaction. The interaction of protein with a
variety of ligands such as DNA, RNA, and small molecules is investigated using Förster resonance
energy transfer (FRET), isothermal titration calorimetry (ITC), and differential scanning
fluorimetry (DSF), and the effect of this interaction on protein activity is also examined using an
ATPase activity assay. The macrodomain from SARS-CoV-2 nsp3, the helicase from SARS-CoV-2
nsp13, and Hepatitis C Virus (HCV) NS3 were utilized to study their interactions with small
molecules, DNA, and DNA/RNA, respectively.
The factors affecting the protein-DNA interaction between the helicase domain of
hepatitis C virus (HCV) nonstructural protein 3 (NS3h) and DNA were examined. Such factors
include the length of the duplex, the length of a single-stranded overhang, and whether the
overhang had a 5’ or 3’ end. The study presented here is preliminary, but similar assays can be
used to screen for compounds in search of antivirals that may prevent helicase function by
blocking ATP binding site, helicase binding to the nucleic acid, or blocking conformational
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changes required for helicase transition on nucleic acid, thereby disabling one of the crucial
components required in HCV viral replication.
The HCV is a blood-borne pathogen that infects the liver. Its genome consists of 96,000
bases that encodes for 3000 amino acids (Moradpour & Penin, 2013). Upon infection, the whole
genome is translated from a single open reading frame encoding for ten structural and nonstructural proteins flanked by 5' and 3' untranslated regions. NS3 is the third non-structural
protein co-translated with NS4A as part of a larger polyprotein but is then cleaved into two
distinct mature proteins by the NS3 serine protease (Suzich et al., 1993a). NS3 is a 70 kDa, 630
aa multifunctional protein having an N-terminal serine protease and a C-terminal helicase. The
protease found at NS3's N-terminal is 180 amino acids long, whereas the helicase located at NS3's
C-terminal is 430 amino acids long (Suzich et al., 1993a). Despite being covalently bound as part
of the same nonstructural protein, both helicase and serine protease can be expressed and
isolated independently of each other. For the studies presented here, the helicase domain was
expressed independently of the protease domain, and the yellow fluorescent protein was
covalently attached to the N-terminal with an His-tag on the C-terminal (Corby et al., 2017).
The interaction between the helicase and DNA was monitored using FRET. FRET is a process
in which energy is transferred from donor to acceptor. Since the non-radiative transfer of energy
from donor to acceptor cannot be measured directly, FRET is estimated by comparing the
magnitude of the donor and acceptor fluorescence. If there is an interaction, the donor's
emission will decrease and the acceptor's emission will increase, producing a composite donor
plus acceptor emission spectra. The extent of the interaction is estimated based on the value of
2

FRET efficiency. An experiment with a lower FRET efficiency conducts less FRET. Therefore, we
assume that the helicase is bound farther from the acceptor, whereas in an experiment with the
higher FRET efficiency value, we assume that the helicase is bound closer to the acceptor. The
FRET efficiency is typically calculated by spectral unmixing of the composite donor and acceptor
emission spectra. In the studies presented here, FRET efficiency is estimated based on donor
quenching only. Therefore, approximations to the FRET theory were made to accommodate the
absence of spectral unmixing. The details and explanation of the approximations are discussed
in chapter 3.5.
Next, the interaction between a protein and a small molecule was investigated using
Isothermal Titration Calorimetry (ITC). ITC is used to experimentally investigate the complete
thermodynamic profiles consisting of the binding free energy, entropy, and enthalpy, and to
accurately predict the binding affinity. In an ITC experiment, a complete thermodynamic profile
is estimated by directly measuring the heat exchange during complex formation at a constant
temperature, and it has established itself as the gold standard for identifying the forces involved
in complex formation (Velázquez‐Campoy et al., 2004).
The protein under investigation is a macrodomain from SARS-CoV-2's nsp3. SARS-CoV-2
is a virus that is responsible for the COVID-19 pandemic that has killed millions of patients
worldwide. COVID-19 is a respiratory disease that affects the respiratory tract, including the
lungs, causing symptoms such as breathing problems and loss of taste and smell. Upon infection,
the SARS-CoV-2 viral genome encodes 16 non-structural proteins that are essential for viral
survival and replication (Lal, 2010). Nsp3 is one of the 16 nonstructural proteins with three
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macrodomains located towards the n-terminal, which are later processed into mature proteins
by one of the viral proteases. To avoid confusion among three macrodomains, the first
macrodomain located towards the n-terminal of nsp3 is Mac1.
Macrodomains in general are not specific to coronavirus, or even viruses; they are found
in the majority of living organisms, including bacteria and humans. A macrodomain is a threelayered α/β/α sandwich fold and it is not restricted to one function. Some macrodomains have
been shown to have ADP-ribose-1″-phosphate phosphatase activity. It was also demonstrated
that macrodomains from several positive sense ssRNA viruses are also capable of hydrolyzing
single ADPr (de-MARylation) or multiple ADPr residues from proteins (de-PARylation).
MARylation and PARylation are reversible posttranslational protein modifications usually utilized
by host cells as a signal for various cellular processes, including the initiation of antiviral immune
response by PARPs.
Previously, other labs have shown macrodomain from other coronaviruses bound to ADPribose (M.P. Egloff et al., 2006; Cho et al., 2016a). However, Mac1 from SARS-CoV-2 had the
largest sequence variation compared to other coronaviruses. Our initial study on the Mac1 was
decided based on large sequence variations with respect to its closest member in the coronavirus
family. Despite the largest sequence variation, we confirmed ADP-ribose binding to Mac1 with a
complete thermodynamic profile. To further investigate ADP-ribose binding, similar nucleotides
were also investigated. According to our ITC data, only the binding of ADP-ribose was enthalpydriven, whereas the binding of other nucleotides was significantly different. To support the
thermodynamic differences in binding between ADP-ribose and other nucleotides. A crystal
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structure of cAMP bound to mac1 was compared with a crystal structure of ADP-ribose bound to
mac1 by Michalska et al. (2020). Upon comparison, the thermodynamic differences we measured
with ITC reflected key differences in binding also seen in crystal structures.
After it was confirmed that the thermodynamic differences that we measured via ITC
accurately reflect the binding differences, our next goal was to screen a library of 2500
compounds in search of drugs or drug-like ligands that can bind to Mac1, replacing ADP-ribose.
While ITC is an excellent tool for examining the underlying interaction between a protein and a
ligand, it cannot be used to screen a library of compounds since each test takes an inordinate
amount of time. As a result, we employed differential scanning fluorimetry (DSF), on the premise
that the protein is stabilized upon binding. The protein's stability is determined by assessing the
temperature at which it unfolds, and the degree of unfolding was measured by the degree of
fluorescence change in SYPRO orange dye (Boivin et al., 2013; Li & Zhang, 2021). The observed
increase in fluorescence of SYPRO orange dye is directly correlated with the concentration of
unfolded protein or hydrophobic groups exposed during protein unfolding.
After the binding of ADP-ribose to Mac1 was confirmed via ITC, we investigated if similar
binding parameters could also be obtained via DSF. Fortunately, the binding parameters
determined using DSF were equivalent to those determined via ITC. The next task was to screen
small libraries of drugs and drug-like compounds using DSF. The screen makes use of the
following libraries: the National Institutes of Health (NIH) clinical collection (726 compounds), the
National Cancer Institute (NCI) mechanistic set (540 compounds) and Sigma-Aldrich’s 1280
compound Library of Pharmacologically Active Compounds (LOPAC).
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2546 compounds from three libraries were screened, with several compounds giving an
impression of change in melting temperature. Other methods were also employed to eliminate
false positives. These hits were carefully screened again and, if the results were verified, these
compounds were bought fresh to be used with ITC. Imatinib ends up being one of the compounds
with similar thermodynamic parameters as ADP-ribose, and it has been reported by other labs to
have some antiviral efficacy against SARS-CoV-2 (Emadi et al., 2020.; Gasmi et al., 2020; MoralesOrtega et al., 2020). On the other hand, some laboratories have also concluded that Imatinib is
not a very effective SARS-CoV-2 drug (Zhao et al., 2020).
Lastly, we evaluated the activity of the SARS-CoV-2 helicase in the presence and absence
of DNA and RNA. To examine the helicase activity, the concentration of inorganic phosphate
released upon ATP hydrolysis was measured against time using the malachite green assay. In this
experiment, free inorganic phosphate reacts with ammonium molybdate to generate a
phosphomolybdate complex. This complex subsequently interacts with three molecules of
malachite green dye, resulting in a change in color at 630nm. The resulting change in absorbance
at 630 nm is directly correlated to the concentration of inorganic phosphate in the solution.
Malachite green assay is an ATPase assay that was used to assess the activity of SARSCoV-2 helicase. It is a 601 amino acid long multidomain protein. It is a helicase of superfamily 1
that unwinds RNA and DNA duplexes unidirectionally in the 5' to 3' direction, and the
translocation is powered by dNTP hydrolysis (Mickolajczyk et al., 2020; Weber & McCullagh,
2021). After it was confirmed that nsp13 is active, DNA and RNA of various sizes were added to
the sample to investigate if oligonucleotides can be used to stimulate helicase activity. Based on
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the data, 18-20 base pair long oligonucleotides tend to stimulate the helicase by increasing its
activity to hydrolyze ATP, whereas poly(U) and other polynucleotides longer in length had no
effect.
In this dissertation, Förster resonance energy transfer (FRET), isothermal titration
calorimetry (ITC), and differential scanning fluorimetry (DSF) were utilized to study protein-DNA,
protein-RNA, and protein-ligand interactions with macrodomain and helicase from SARS-CoV-2,
and helicase from Hepatitis C Virus (HCV), and the effect of this interaction on protein activity
was examined using an ATPase activity assay. Even though not all methods and techniques
employed resulted in identifying potential antivirals, these are the initial studies required to
move forward before proceeding to identify potential antivirals.
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2. Literature Review: Biology
2.1.Hepatitis C Virus (HCV)
The hepatitis C virus is a blood-borne pathogen that infects the liver. The viral particle's
surface is composed of viral envelope glycoproteins, and within glycoprotein is a nucleocapsid
composed of core proteins that interacts with the viral RNA genome. It is transmitted via blood
and it is transported to the liver via the bloodstream. The virus circulates in the bloodstream as
a component of very-low-density lipoproteins and low-density lipoproteins. Once the viral
particle reaches the liver, its entry into the hepatocytes requires binding of viral glycoproteins E1
and E2 with host scavenger receptor SCARB1 and the tetraspanin protein CD81. After the viral
particle is bound to the entry factors, it further interacts with claudin 1 (CLDN1) and occludin
before gaining entry into the hepatocytes via clathrin-mediated endocytosis (Miao et al., 2017).
Upon entry, a clathrin-coated endosomal membrane vesicle containing a viral particle is
transported near the endoplasmic reticulum with the assistance of the motor protein called
dynein. Acidification of the clathrin-coated endosomal membrane causes a conformational
change leading to the fusion of viral nucleocapsid glycoprotein and endosomal membranes,
resulting in uncoating and release of the viral genome into the cytosol. The positive sense viral
RNA in the cytosol serves as a template for RNA replication. The translation of the viral genome
is initiated in a cap independent fashion upon the assembly of the host ribosome on the viral
genome internal ribosomal entry site located at the 5’untranslated region (J.-C. Cheng et al.,
1999) (Yi & Lemon, 2003). A signal sequence at the start of the translated polyprotein enables
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the ribosome to recognize and attach to the translocon on the endoplasmic reticulum membrane
(Beales et al., 2001; Suzich et al., 1993a).
The rest of the viral genome is translated as a polyprotein in the host ER membrane. The
resulting polypeptide is about 3,000 amino acids long and consists of both structural and nonstructural proteins. NS3, NS4A, NS4B, NS5A, and NS5B are non-structural proteins that are
necessary for viral genome replication. Structural proteins include the core protein and the
envelope glycoproteins E1 and E2, which are integrated into the viral particle, as well as support
proteins p7 and NS2, which aid in viral particle synthesis but are not incorporated into the viral
particle. After translation, the polyprotein undergoes proteolytic processing via viral proteases
releasing 10 mature proteins inside the host ER membrane (Zeisel et al., 2013).
The accumulation of viral proteins on the ER membrane induces a rearrangement of the
membrane, resulting in the formation of double membrane vesicles (DMV). These vesicles cluster
together to form the membranous web, with each vesicle containing HCV non-structural
proteins, HCV RNA, and lipid droplets. The membranous web of vesicles results in a protected
environment for viral replication (Gosert et al., 2002).
The HCV genome is replicated inside DMV, initiated by RNA-dependent RNA polymerase
(NS5B) as part of the replicase complex. During RNA replication a negative-strand intermediate
is generated which in turn serves as a template for the synthesis of multiple progeny positive
sense viral RNA. After the viral genome is replicated, it is used for translation, or be packaged
into a new viral particle (Stoeck et al., 2018).
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The viral particle assembly initially takes place at the host ER membrane with the help of
a lipid droplet. Synthesis of a new viral particle is initiated with the aggregation of the core
proteins and their interaction with the lipid droplet containing E1, E2 P7, and NS2, copies of viral
RNA at the host ER membrane. After the HCV viral particle is assembled, it is transported to the
Golgi apparatus to be packaged into an endosome and transported outside of the cell
(Moradpour & Penin, 2013).
2.1.1. Hepatitis C Virus Genome
HCV is a member of the genus hepacivirus, which is part of the Flaviviridae family. As is
the case with all members of the Flaviviridae family, HCV is an enveloped virus with surfaceanchored envelope proteins. The virus's surface is composed of a lipid bilayer surrounding the
core protein and viral RNA genome in a nucleocapsid. The HCV genome is 9.6 thousand
nucleotides long which encodes for 3000 amino acids. The whole genome is translated from
single open reading frame encoding for ten structural and non-structural proteins flanked by 5'
and 3' untranslated regions (Moradpour & Penin, 2013). The untranslated region is critical for
viral infection as it plays crucial role in ribosome binding, translation, and replication (Zeisel et
al., 2013). The structural proteins involved in encapsulating the virus and identifying a host
include the core protein and the envelope glycoproteins E1 and E2. NS3, NS4A, NS4B, NS5A, and
NS5B are non-structural proteins that are essential for viral replication or play a role in the viral
life cycle. The viral genome and its encoded proteins are explored in greater depth in the sections
that follow, beginning with the 5' and 3' untranslated regions (Moradpour & Penin, 2013).
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The 5’UTR of HCV contains four highly structured domains. Together with the core coding
regions, they fold into a complex secondary structure. The complex secondary structure forms
an internal ribosome entry site (IRES) that mediates the binding of ribosomes in the host cell
cytosol (Honda et al., 1996). The HCV internal ribosome entry site (IRES) is able to bind directly
to the 40s ribosomal subunit without needing translation initiation factors, subsequently
initiating the translation of the HCV genome. The HCV 3'UTR is approximately 200 nucleotides
long and varies in length. HCV 3’UTR is divided into three regions: a 30-40nt long variable region,
Poly (U/UC) region and 3’X-tail. The 3’ untranslated region mediates the replication of the viral
genome by interacting with NS5B RNA-dependent RNA polymerase (RdRp) (Cheng et al., 1999).
The 3’X tail and poly (U/UC) region of the 3’ end are essential for viral replication, whereas the
rest of the 3’-UTR appears to modulate the activity of viral replication (Yi & Lemon, 2003).
2.1.2. Hepatitis C Virus Structural Proteins.
The core protein is the first structural protein translated from a viral open reading frame.
The mature core protein is roughly 177 amino acids in length and has a molecular mass of 21
kilodaltons. It is a membrane protein with a dimetric alpha-helical structure maintained by a
disulfide bond (Boulant et al., 2005). The core protein is made of two domains: domain 1 has a
high concentration of basic residues, while domain 2 is very hydrophobic. Domain 1 interacts
with various cellular factors to facilitate viral particle structural remodeling and packaging
(Chassey et al., 2008). The more hydrophobic domain 2 facilitates the interaction with lipid
droplets at the phospholipid interface (Boulant et al., 2005).
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E1 and E2 envelop glycoproteins are required for viral infection because they recognize
the host and facilitate viral entry. Both E1 and E2 are transmembrane proteins containing an
ectodomain at the n-terminus and a 30 amino acid-long transmembrane domain at the cterminus. E1 measures roughly 160aa in length, while E2 measures approximately 360aa in
length. On the basis of disulfide mapping, a model of the E2 ectodomain's structure was
presented, implying three domains (Krey et al., 2010). Domain 1 has eight beta strands that
include the bulk of known CD81 interaction determinants. Domain 2 is a fusion loop between
domains 1 and 3. Domain 3 is the CD81-binding domain that is also connected to the
transmembrane domain through a flexible stem loop at the C-terminal. Both E1 and E2 are
required for viral infection and for binding specifically to the entry host receptors CD81 and
SCARB1, as well as for interacting with occluding and claudin-1 (Miao et al., 2017).
P7 is a homo-oligomer trans membrane protein with an ion channel-like structure.
According to its cation channel activity, it is believed to be a member of the viroporin family. P7
is a transmembrane protein composed of two alpha helices joined by a positively charged
cytosolic loop with both N and C terminals towards the ER lumen (Carrère-Kremer et al., 2002).
Although the specific function of p7 is unknown, it is likely to be an ion channel that enables
proton movement inside the virion during virion assembly (Voisset & Dubuisson, 2004).
2.1.3. Hepatitis C Virus non-structural proteins.
NS2 is the first non-structural protein translated after structural proteins, and it is the only
non-structural protein not necessary for viral genome replication and translation. NS2 is a
cysteine protease that acts soon upon translation to cleave the NS2/NS3 junction. Cleavage at
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the NS2/NS3 junction is required for fully functional NS3 protein to be produced. Additionally, in
vitro studies suggests that the N-terminal of NS3 significantly enhances the catalytic activity of
NS2 (Schregel et al., 2009).
NS3 and NS4A are co-translated as part of a larger polyprotein but are then cleaved into
two distinct mature proteins by the NS3 serine protease. After separating NS3 and NS4A, they
create the noncovalent complex NS3-NS4A, with NS4A acting as a cofactor for NS3 protease. NS3
is a 70 kDa, 630 amino acid multifunctional protein having an N-terminal serine protease and a
C-terminal helicase (Raney et al., 2010). The protease found at NS3's N-terminal is 180 amino
acids long, whereas the helicase located at the NS3's C-terminal is 430 amino acids long. Despite
being covalently bound as part of the same nonstructural protein, both helicase and serine
protease can be expressed, and isolated independently of each other. Additionally, in-vitro
studies indicate that the presence of protease does affect helicase's activity (Frick et al., 2004;
Kuang et al., 2004).
After viral genome translation in the ER, NS4A with NS3 protease is responsible for
cleaving the remainder of the polyprotein. The NS4A cofactor for ns3 protease modulates the
protease activity by directing the substrate towards its active site (Love et al., 1998). Due to the
fact that protease at the n-terminus influences the activity of the C-terminal helicase. It is stated
that NS4a, which binds to the protease, also stimulates the helicase activity as well. The NS3
helicase is a member of the DExH/D-box helicase superfamily (Raney et al., 2013). With the aid
of ATP hydrolysis, the NS3 helicase separates double-stranded RNA (Singleton et al., 2007).
Although the NS3 helicase is required and plays a critical role as a component of the replication
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machinery, its specific function throughout the viral life cycle remains unknown. The helicase and
its function will be explored in more detail in the next part of this chapter.
NS4B is a poorly characterized integral membrane protein with a molecular mass of 27kDa
and a sequence length of 261 amino acids. Structurally, NS4B is separated into three sections:
the N-terminus, which contains 70 amino acids, the middle portion, which contains 70-190 amino
acids, and the C-terminus, which contains 191-261 amino acids(Lundin et al., 2003). A portion of
the N-terminal is specifically associated with the ability to traverse the membrane bilayer, most
likely following oligomerization, and it interacts with the replication complex, while the
remainder of the protein, including the N-terminal, is associated with transmembrane domains.
While NS4B is the primary inducer of membranous web or double membrane vesicles, it is not
NS4b alone that participates in the formation of the membranous web it is assisted by the other
viral nonstructural proteins. NS4B initiates the formation of the membranous web, whereas
other nonstructural proteins contribute to its formation (Lundin et al., 2003).
NS5A is a membrane-associated multifunctional RNA-binding phosphoprotein that lacks
any detectable enzymatic activity. NS5A is composed of three domains and an amphipathic
alpha-helix membrane anchor at the N-terminus (Lundin et al., 2006). NS5A is a 447-amino-acidlong protein composed of a 36-amino-acid-long membrane anchor, a 36-213-amino-acid-long
domain 1, a 250-342-amino-acid-long domain 2, and a 356-447-amino-acid-long domain 3.
Domain 1 is important in viral replication and interacts with the lipid droplet, domain 2 is involved
in viral replication, and domain 3 is required for viral assembly through interaction with the core
protein (Masaki et al., 2008). The central and C-terminal regions of the HCV NS5A are
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phosphorylated, indicating that the NS5A influences HCV replication, potentially via modulating
the interaction with replication-specific host factors, while the C-terminal region interacts with
assembly-specific host factors (Appel et al., 2005; Evans et al., 2004).
NS5B is a 591 amino acid viral RNA-dependent RNA polymerase with a molecular mass of
68 kDa. A 40-amino acid linker between the catalytic domain and the C-terminal membrane
anchor, NS5B mimics the traditional finger, palm, and thumb subdomain arrangement of a right
hand (Simister et al., 2009). The three-dimensional structural model indicates extensive contact
between the finger and thumb subdomains, resulting in an encircling active site that is restricted
by the linker through interaction with the beta-flap of the thumb domain. The replication of the
viral genome utilizes positive sense RNA as a template to synthesize the complementary negative
strand in a primer-dependent manner. Upon binding of positive sense RNA, initiation of viral
replication directly involves the linker in the formation of first dinucleotide primer. Transition
from initiation to elongation phase requires the rearrangement and removal of linker and beta
flap blocking the exit. The rearrangement and RNA synthesis requires high concentration of GTP
binding to the allosteric site on NS5B contributing to the switch from initiation to elongation
phase. The rearrangement and significant conformational changes allow for newly formed dsRNA
to exit (Harrus et al., 2010).
2.1.4. Hepatitis C Virus non-structural protein 3 helicase (NS3h).
Non-Structural Protein 3 is a critical component in HCV replication (NS3). The helicase
domain of the NS3 protein is referred to as NS3h. Helicases are recognized as motor proteins that
utilize the energy generated by nucleotide hydrolysis to catalyze the separation of double

15

stranded nucleic acids. Helicases are engaged in a wide variety of biological activities involving
nucleic acids and are critical in the metabolism of DNA and RNA, including genome replication,
transcription, translation, and DNA repair (Gorbalenya et al., 1989).
Helicases are divided into six superfamilies based on their sequence and structure.
Helicases from superfamily 1 and 2 do not form ring type structures, whereas helicases from
superfamilies 3-6 need to be assemble and oligomerize into a ring like structures (Singleton et
al., 2007). Our focus is on helicase from superfamily 2 (HCV) superfamily 2 (SARS-CoV-2).
Superfamily 2 is the largest and the most diverse of the helicase superfamilies and it is divided
further based on sequence homology. HCV NS3h is a member of the SF2 helicase with conserved
RecA-like folds. The RecA-like fold is common among proteins that have ATPase activity and
utilize energy from ATP hydrolysis to translocate along the nucleic acid backbone (Suzich et al.,
1993b).
Structurally, NS3h folds into three subdomains. When viewed as y-shaped molecule,
subdomains 1 and 2 of NS3h are on top, and consist of RecA-like folds common among SF1 and
SF2 helicases with an ATP binding site in the middle (Singleton et al., 2007). Subdomain 3 contains
residues that make key contacts with the nucleic acid. Upon binding, the single stranded nucleic
acid binds in the center of all three subdomains. The 5’ end of the oligonucleotide sits at the
interface between subdomains 2 and 3, while the 3’ end sits at the interface between
subdomains 1 and 3. The interaction between the subdomains and the oligonucleotide is
primarily through the nucleotide backbone, with no interaction with the 2’ hydroxyl group when
the RNA is bound, thereby explaining the non-specific binding with both DNA and RNA (Frick,
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2006). However, the mechanism by which NS3h translocates and the mechanism of strand
separation is still unclear (Kim et al., 1998).
One theory for the mechanism of NS3h translocation is that the helicase harnesses the
energy generated by ATP hydrolysis to exert force directly on the base pairs at the ss/ds junction,
disrupting the hydrogen bond between the two strands (Amaratunga & Lohman, 1993). This
model was first presented as the inchworm model, based on the conformational flexibility of
subdomain 2 in comparison to subdomains 1 and 3. According to this model, NS3h subdomains
1 and 3 bind to nucleic acid with a lesser affinity than subdomain 2 (Kim et al., 1998). However,
the rearrangement mediated by ATP binding modulates the binding affinity between subdomain
2 and subdomain 1-3 (Xie, 2016). When the oligonucleotide attaches in the middle of three
subdomains in the absence of ATP, subdomain 2 binds more strongly to the nucleotide than
subdomains 1 and 3. When ATP binds, it triggers a structural rearrangement between
subdomains 1 and 3, resulting in pinching onto the nucleic acid and a shift along the nucleic acid
from 3' to 5' direction. Following hydrolysis, the cleft between subdomains 1 and 3 reopens, while
oligonucleotide-bound subdomain 2 turns, creating a shift in the 3' to 5' direction, culminating in
unwinding or separation at the ss/ds junction (Raney et al., 2013).
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2.2. Severe Acute Respiratory Syndromes Coronavirus 2 (SARS-CoV-2)
2.2.1. Introduction to Coronavirus
Coronaviruses belong to the Coronaviridea family. Coronaviridea includes viruses with a
large RNA genome consisting of 25,000–32,000 nucleotides in an enveloped nucleocapsid (Artika
et al., 2020a; Payne, 2017). Coronaviridea is divided into two subfamilies called coronavirinae
and torovirinae, which are distinguished by their nucleocapsid shape. Coronavirinae are roughly
spherical, while torovirinae are more donut-shaped (Payne, 2017). The nucleocapsid of these
viruses is covered by a phospholipid bilayer with multiple glycoproteins embedded in the
membrane.
Coronaviruses get their names from the spike protein found in their membrane that
extends outwards and give them the appearance of a crown when seen under an electron
microscope. Coronavirinae subfamily is divided into four genera: alpha, beta, gamma, and delta
coronavirus (Woo et al., 2012). Bats and birds were found to be common hosts to all four genera
of coronavirus, but only alpha and beta coronaviruses can infect humans (Woo et al., 2010).
For a long time, the alpha coronaviruses have been circulating in the human population,
inducing mild respiratory diseases such as the common cold (Paules et al., 2020). However,
outbreaks, epidemics, and pandemics of severe acute respiratory syndromes (SARS) and Middle
East respiratory syndrome (MERS) have been caused by viruses belonging to the beta genus of
the Coronaviridae family. These occurred in 2002, 2014, and 2019, and were caused by severe
acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome
coronavirus (MERS-CoV), and SARS-CoV-2, the causative agent of COVID-19.
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2.2.2. Coronavirus infection and life cycle
2.2.3. Spike Protein initiating host infection
The CoV virion contains a 30 kilobase (kb) positive sense RNA genome. The RNA is coated
with a nucleocapsid protein (N) and forms a helical pattern. The nucleocapsid is encased in a
phospholipid bilayer membrane envelope that contains spike (S), membrane (M), and envelop
(E) proteins (Siu et al., 2008). Spike is a trimeric protein (Delmas & Laude, 1990) that recognizes,
binds to, and fuses with host cells. The spike protein's upper portion (furthest from the envelope)
is made up of a globular receptor binding domain that recognizes and binds to the host ACE2
protein. Spike’s lower section (nearest the envelope) is a fusion domain with a hydrophobic
peptide in the center that assists in the entry process (Cai et al., 2020).
The spike protein of SARS-CoV and SARS-CoV-2 binds to the host cell's angiotensin
converting enzyme 2 (ACE2), which acts as the viral receptor first. Following that, a cellular
protein known as transmembrane serine protease 2 (TMPRSS2) is recruited. TMPRSS2 cleaves
the connection between the receptor binding domain and the fusion domain. Following the
exposure of the fusion domain, TMPRSS2 cleaves yet another site on the fusion domain, resulting
in the expansion of the hydrophobic fusion peptide (Glowacka et al., 2011; Hoffmann et al.,
2020). The hydrophobic fusion protein extends and penetrates the host cell membrane before
retracting and fusing the two membranes. The viral genome is then deposited into the host cell's
cytoplasm after the two membranes fuse (Lal, 2010).
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2.2.4. Translation of nonstructural proteins (NSP’s) and structural Proteins (SP).
After entry and uncoating, the viral genome is translated and replicated. Replication of
the viral genome requires an RNA-dependent RNA Polymerase (RdRp), which the host cell lacks,
so the viral genome must first be translated. The viral genome is a capped, positive-sense RNA.
It is recognized by the host cell machinery and is immediately translated (Artika et al., 2020; Lal,
2010).
The SARS-CoV-2 genome possesses ~14 open reading frames encoding 27 proteins, but
not all 27 proteins are translated directly from the genomic RNA. Only nonstructural proteins
(nsps), which are essential for viral survival, are translated directly from genomic RNA, starting
with ORF1a. Downstream of ORF1a and before its stop codon is a sequence with a complex
secondary structure in which the host ribosome tends to slip 20%–25% of the time, causing one
nucleotide frameshift. ORF1a encodes a single large polyprotein that is processed into 11 nonstructural proteins. If the ribosome slips, a much longer RNA is translated, encoding a polyprotein
processed into 16 nsps (Irigoyen et al., 2016; Plant et al., 2013). The large polyproteins are
cleaved by viral proteases, releasing individual proteins (Ziebuhr et al., 2000).
Genes that encode structural proteins are present towards the 3’ end of the viral genome.
These genes are first transcribed into (-) RNA, which in turn is transcribed into mRNAs. One subgenomic mRNA encodes only for each structural protein (Sola et al., 2015).
To summarize, the 5' end of the viral genome encodes for nonstructural proteins. It is
translated into two large polyproteins, which are cleaved into individual nonstructural proteins
by viral proteases. The 3’ end of the genome is first transcribed into a smaller sub-genomic
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negative sense RNA, which in turn are transcribed into sub-genomic mRNAs that are translated
into various, mainly structural, proteins (Sola et al., 2015).
2.2.5. Replication and transcription complex (RTC)
A subset of proteins released from ORF1a and ORF1b form the replication and
transcription complexes (RTC). The core of RTC is composed of RNA dependent RNA Polymerase
(RdRp) called nsp12. Nsp12 shows minimal activity on its own, however. Its activity is greatly
stimulated in the presence of nsp7 and nsp8 (Subissi et al., 2014) Nsp12 is bound to Nsp8 at the
N-terminal and a second Nsp8 heterodimerized with nsp7 at the opposite end. The two nsp8
proteins bind in different structural conformations based on the location of binding sites on
nsp12 (Kirchdoerfer & Ward, 2019). In addition to the RdRp core complex, replication and
transcription complexes also include a helicase (nsp13), single-stranded binding protein (nsp9),
and exonuclease (nsp14), as well as other cofactors and capping enzymes (Hartenian et al., 2020).
The replication and transcription complexes are anchored in membranes known as convoluted
membranes. These membranes are generated by reshaping the host endoplasmic reticulum in a
process mediated by viral nsp3, nsp4, and nsp6 (Hagemeijer et al., 2014).
2.2.6. Formation of DMVs and assembly of virion
Nsp3, nsp4, and nsp6 remodel the host ER to create convoluted membranes and double
membrane vesicles (DMVs) (Ulasli et al., 2010). These membranes and vesicles surround the viral
genome, replication and transcription complex, and other proteins required for viral replication,
protecting them from host pathogen sensors (Snijder et al., 2006). It was recently discovered that
viral transcription occurs inside DMVs, and a new viral genome was visualized using radio labeling
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and electron microscopy radiography in SARS-CoV-2 (Snijder et al., 2020). After the viral genome
is fully replicated, it is then transported out of the DMVs. However, the transport mechanism is
not yet identified. The nucleocapsid-coated positive sense genomic RNA buds into the
endoplasmic-reticulum–Golgi intermediate compartment, an organelle in eukaryotic cells, which
is rooted in structural proteins S, E, and M. The enveloped virion is then exported from the cell
through an exocytic pathway (Snijder et al., 2020).
2.2.7. SARS-CoV-2 non-structural proteins:
2.2.7.1. Nsp1
SARS-CoV-2 non-structural protein 1 (nsp1) is the first protein cleaved from the Orf1a/b
polyprotein that is translated upon host entry. Schubert et al. demonstrated that nsp1 might
inhibit host gene expression by physically blocking the entry site to the host ribosome and by
degrading host mRNA (Schubert et al., 2020). They used cryo-microscopy to show that nsp1 binds
to the human ribosome, effectively inhibiting cellular mRNA translation by blocking the mRNA
entry point (Schubert et al., 2020). The C terminal area of nsp1 appears to be the central domain
that blocks and interacts with the ribosome entry point. Their findings showed that nsp1 is an
important inhibitor of the host ribosome. As a result, reducing the availability of host ribosomes
and increasing the concentration of viral RNA explains why infected cells are more likely to
translate viral proteins (Artika et al., 2020b).
2.2.7.2. Nsp2
Graham et al. (2005) investigated the function of nsp2 by testing whether nsp2 is needed
for viral replication. They modified the mouse hepatitis virus (MHV) and SARS-CoV nps2 by
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removing the nsp2 coding region. The mutated virus lacks not only nsp2 expression but also the
nsp2-nsp3 precursor. It was hypothesized that the nsp2-3 precursor might be needed for
replication, perhaps performing distinct roles, or regulating the availability of mature nsps 2 and
3. Further studies done by Graham et al. (2006) using peak titers showed that the nsp2 coding
sequences of MHV and SARS-CoV are not required for viral replication in cell culture, but deletion
of the nsp2 coding gene limits viral growth (Graham & Denison, 2006).
Next, nsp1-nsp2 and nsp2-nsp3 cleavage sites were investigated also with deletion
mutants. Deleting nsp1-nsp2 cleavage site decreased viral replication by 10-fold, whereas
deleting nsp2-nsp3 cleavage site delayed the initial increase in viral replication but was able to
recover compared to wildtype (Graham & Denison, 2006). These findings suggest that RNA
encoding the nsp2 protein and the cleavage sites nsp 1-2 and nsp 2-3 is not essential for viral
replication in cell culture (Graham et al., 2008).
2.2.7.3. Nsp3
Nsp3 is the 213-kDa multifunctional polypeptide encoded by SARS-CoV genome. It is
encoded as part of a large polyprotein from Orf1a or Orf1b. It is cleaved into separate protein by
a papain-like protease which is also part of nsp3 (Ziebuhr et al., 2000). Nsp3 interacts with
multiple host and viral proteins. It is essential in the formation of viral replication and
transcriptional complexes (van Hemert et al., 2008) and helps with the formation of double
membrane complex (Angelini et al., 2013) Nsp3 is a multifunctional polyprotein that consists of:
Ubiquitin-like domain (UBl1), Glu-rich acidic region or (HVR), PL1Pro, Mac1 (X domain), Mac2
(SUD-N), Mac3 (SUD-M), DPUP (SUD-C), Ubl2-PL2pro (Artika et al., 2020b).
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2.2.7.3.1. Ubiquitin-like domain 1 with glutamic acid rich domain.
UBl1 is the first domain located at nsp3’s N-terminus. Ubl1’s core is composed of residues
20–108, which form a typical ubiquitin-like structure. Following Ubl1 is a highly flexible glutamic
acid-rich domain spanning residues 113–183, which is often referred to as a hypervariable area
(HVR). It is well documented that the UBL1 domain is a multifunctional protein that facilitates
viral genome transmission to RTC but also plays a role in suppressing the host’s innate immune
response.
Serrano et al. (2009) used nuclear magnetic resonance (NMR) to identify chemical shift
perturbations in a sample containing both UBL1 and ssRNA. The existence of RNA caused a
chemical change perturbation, which may mean an association between Ubl1 and RNA. Hurst et
al. also found an association between UB1 and N-protein however deletion of UBL1 domain
inhibited MHV replication. According to (Hurst et al., 2013) the association of UBL1 with N protein
coated genome enables the passage of viral genome coated in N-protein to RTC.
The viral Ubl1 domain resembles the human ubiquitin domain in its usual ubiquitin-like
fold. The human ubiquitin domain is essential in innate antiviral immunity (Heaton et al., 2016).
It is possible for viral Ubl1 to imitate the action of the human Ubiquitin domain and modulate
host immune response, causing host antiviral signaling to be disrupted (Lei et al., 2018).
2.2.7.3.2. Papain-like protease domains 1 and 2.
Papain-like-protease is an enzyme that is translated as part of nsp3. It is responsible for
cleaving a long polypeptide chain and releasing nonstructural proteins such as itself. (Barretto et
al., 2005). PL1pro and PL2pro are two proteases that are commonly found in coronaviruses. They
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have differing substrate specificities and are used to cleave a section of nonstructural proteins.
However, PL1pro is missing from coronaviruses belonging to the beta genera. In the alpha-CoV
transmissible gastroenteritis virus, both PL1pro and PL2pro are responsible for cleaving and
releasing different nonstructural proteins with varying substrate specificity but this is not true for
SARS-CoV (Lei et al., 2018)
2.2.7.3.3. Macrodomain 1 (Mac1, X domain)
Macrodomains are domains found in the majority of living organisms, including viruses,
bacteria, and humans. Due to its larger size than histone 2A, it was first recognized as a
component of histone 2A and was termed macroH2A. Later, it was recognized that this was a
domain present in other proteins, and the term macrodomain was established. Macrodomains
are present not only as standalone proteins, but also as modules inside multidomain proteins
such as PARPs (Chakravarthy et al., 2005a)
A macrodomain is a three-layered α/β/α sandwich fold and it is not restricted to one
function. Some macrodomains have been shown to have ADP-ribose-1″-phosphate phosphatase
activity (Saikatendu et al., 2005). More recently, it was demonstrated that macrodomains from
several (+) ssRNA viruses are also capable of hydrolyzing single ADPr (de-MARylation) or multiple
ADPr residues from proteins (de-PARylation) (Fehr et al., 2016). MARylation and PARylation are
reversible posttranslational protein modifications usually utilized by host cells as a signal for
various cellular processes including initiation of antiviral immune response by PARPs (Liu & Yu,
2015).
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Fehr et al. (2016) reported that the SARS-CoV wild-type Mac1 domain prevents the
production of innate-immunity genes in vitro, thus inhibiting the host immune response (Fehr et
al., 2016). It is also possible for macrodomains to only bind to the ADPr already bound to acceptor
protein blocking an essential signal. More recently, SARS-CoV-2 Mac1 domain has been shown to
bind to ADPr via various binding techniques (Frick et al., 2020). Based on the capacity of the viral
macrodomain to simply bind to ADPr or to catalyze MARylation, PARylation, and association with
PARPS, it has been proposed that the viral macrodomain modulate the host cellular immune
response (Fehr et al., 2016; Fehr & Perlman, 2015).
2.2.7.3.4. Macrodomains II and III, and the DPUP (SUD-N, SUD-M, SUD-C)
Initially when the SARS CoV genome was sequenced, there were three domains suspected
to be unique to the SARS virus thus they were named “SARS unique domain” (SUD-N, SUD-M,
SUD-C) (Snijder et al., 2003a). SUD-N, SUD-M, and SUD-C were the names given to the three
subdomains, which represent the N-terminal, middle, and C-terminal regions of SUD,
respectively. Later it was discovered that SUD-N and SUD-M was also present in other genera of
coronavirus. Thus, Cheng et al. recommended to rename these three domains to macrodomain
2 (Mac2), macrodomain 3 (Mac3) and domain preceding Ubl2 and PL2pro (DPUP) (W. Cheng et
al., 2015).
Although Mac2 and Mac3 have the same fold as Mac1, the residues that would contact
ADPr are absent, so Mac2 and Mac3 lack the ADPr-binding functionality of Mac1 (Tan et al.,
2009). Kusov et al. discovered that the Mac3 is essential for viral replication since a mutation in
the lysine patch, which is involved in binding oligo(G) or G-Quadruplex RNA, prevented SARS-CoV
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replication (Kusov et al., 2015). Additionally, DPUP may play a role in modulating Mac3 binding
to RNA as deletion of DPUP domain greatly reduces RNA Synthesis (M. A. Johnson et al., 2010;
Kusov et al., 2015).
2.2.7.3.5. Nucleic acid-binding (NAB) domain and betacoronavirus-specific marker (βSM)
domain.
Nucleic acid-binding (NAB) domain and betacoronavirus- specific marker (βSM) domain
only exists in genus betacoronavirus. According to (Neuman et al., 2008) the domain binds to
ssRNA and unwinds dsDNA. According to (Neuman et al., 2008) the domain binds to ssRNA and
unwinds dsDNA. The RNA binding behavior is like Mac3 domain of SARS CoV as it interacts with
Oligo (G). No information regarding betacoronavirus- specific marker (βSM) domain is available
(Tan et al., 2007).
2.2.7.4. Nsp4
Modifying host’s cellular membrane is a common feature of all enveloped positive sense
RNA viruses including coronavirus. Viral nsp’s develop double-membrane vesicles (DMVs) and
convoluted membranes (CMs), which together create a broad reticulovesicular network that is
involved in viral replication and transcription (Miller & Krijnse-Locker, 2008). Coronavirus
genome encodes for 16 nonstructural proteins, three of which seem to be active in cellular
membrane modification (nsp3, nsp4, and nsp6) (Angelini et al., 2013). Gadlage et al. discovered
that nsp4 plays a significant role in the organization and stability of DMVs (Gadlage et al., 2010).
Gadlage et al. (2010) modified MHV nsp3 and discovered abnormal morphology of virus-induced
double membrane vesicles as compared to wild type.

27

2.2.7.5. Nsp5
The coronavirus protease nsp5 is a 30 kDa, three domain cysteine protease that is
structurally and functionally conserved in all identified coronaviruses (Fehr & Perlman, 2015).
Nsp5 is known as Mpro, a major protease in coronavirus gene expression, or 3CLpro, a 3C-like
protease based on homology to 3C proteases in picornavirus (Anand et al., 2003). While nsp5
consists of three domains, dimerization of domain 1 and 2 is essential for nsp5 function. Domain
3 has been shown to direct and stabilize the dimerization (Anand et al., 2003). The active sites of
the protomers are facing outwards away from each other while domain 3 is holding and
stabilizing the structure (Stobart et al., 2013). Nsp5, after it is translated as part of the long
polyprotein is responsible for its own autoproteolytic cleavage. It is proposed that nsp5 forms a
homodimer and anchors itself in the membrane with the assistance of nsp4 and nsp6 (Hsu et al.,
2005). It is then responsible for cleaving all downstream nonstructural proteins.
2.2.7.6. Nsp6
Autophagy is a normal cellular function that aids in the maintenance of cell homeostasis.
it is a biochemical mechanism that lets cells turn unnecessary or damaged components into
energy which it can use to expand and divide. Autophagy needs to be initiated by initiation
factors. Upon initiation a semicircular membrane known as isolation membrane is formed which
is expanded by ATG family of proteins. This expanded isolation membrane then engulfs damaged
components forming what is called Autophagosome (Ichimiya et al., 2020). The autophagosome
then fuses with a lysosome which contains digestive enzymes that break down the
autophagosome's contents the resultant molecules are the released back into the cytosol to be
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recycled. Cottam et al. demonstrated nsp6 from MHV and SARS in infected cell generates
autophagosomes (Cottam et al., 2014). They compared autophagosomes from viral nsp6 induced
cells and starvation controls. They observed greater number of autophagosomes in infected cells
but the with smaller diameter (Cottam et al., 2014). To summarize, nsp6 restricts the expansion
of autophagosome and plays a role in DMV formation with nsp3 and nsp4.
2.2.7.7. Nsp7 and Nsp8
SARS-COV nsp7 and nsp8 were reported to form hollow ring hexadecameric structure
when mixed 1:1 in solution. Velthuis et al. measured and compared the activity of nsp7-8 in
probable hexadecameric form to nsp12-RdRp and their data suggests nsp12 to be about 20-fold
faster (te Velthuis et al., 2012). Nsp7 and nsp8 are also part of the replication and transcription
complex. Nsp7 and nsp8 form a heterodimer that binds to RNA-dependent RNApolymerase
(nsp12).
Another nsp8 molecule interacts with nsp12 but at the opposite end of nsp7-8
heterodimer. Shi et al. characterized that it is the specific interaction between nsp7 of nsp7-8
heterodimer and nsp8 monomer that undergoes conformational change, and these
conformational changes allow RTC movement (Shi et al., 2020). Additionally, nsp7 and nsp8
cofactors might also play a regulatory role in polymerase activity of nsp12 (Kirchdoerfer & Ward,
2019; Q. Peng et al., 2020; te Velthuis et al., 2012).
2.2.7.8. Nsp9
Nonstructural protein 9 (nsp9) of SARS-CoV was discovered to be an essential protein with
RNA/DNA binding activity. The interaction of parallel alpha-helices carrying the protein-protein
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interaction motif GXXXG causes Nsp9 to form a dimer. Miknis et al., designed site-directed
mutants to determine which amino acids are essential for dimerization and if the dimerization
was necessary for viral replication. They found dimerization of nsp9 was not essential for RNA
binding however it is essential for replication (Miknis et al., 2009).
2.2.7.9. Nsp10
SARS-CoV nsp10 is a 148-residue subunit with two zinc fingers. Nsp10 interacts with both
nsp14 and nsp16 and this interaction is conserved among all four genera in Coronaviridae (Lugari
et al., 2010). Nsp14 is an exoribonuclease and nsp16 is a 2’-O-methyltransferase and they are
both part of the replication and transcription complex. Both nsp14 and nsp16 bind to the same
site on nsp10 therefore nsp10 can only interact with either nsp14 or nsp16 at a time. However,
it is believed that nsp14 and nsp16 do not compete for nsp10 because nsp10 is present at a much
higher concentration than both nsp14 and nsp16. This is because nsp10 is encoded as part of
ORF1a, while nsp14 and 16 are only translated as part of ORF1b if ribose slips on the "frameshift
site" (Sawicki et al., 2007).
Using a bioluminescence resonance energy transfer assay and pulldown assays, Bouvet et
al. established nsp10 residues involved in the association with nsp14. They also performed an
enzyme activity assay to see whether nsp10 stimulates nsp14 (Bouvet et al., 2014). They inferred
that the relationship between nsp10 and nsp14 is critical because changes to the binding site on
nsp10 culminated in nsp14 losing its ExoN-activity. Removing nsp14 completely cripples the
replicating virus, while disrupting the association between nsp10 and nsp14 is lethal to the virus
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(Donaldson et al., 2007). This suggests that there are additional unknown functions mediated by
the nsp10 and nsp14 interaction that are vital for viral replication (Bouvet et al., 2014).
2.2.7.10. Nsp12
SARS-CoV nsp12 is a 932 amino acid long RNA-dependent RNA polymerase that is
expressed only after ribosomal frameshift. This means that nsp12, as well as all the proteins
expressed as part of ORF1b, are generated at considerably lower quantities than non-structural
proteins translated as part of ORF1a. The catalytic domain of nsp12 is located at the C-terminus
and contains conserved RdRp motifs creating a cupped right hand with palm-finger-thumb
structure enclosing a nucleotide binding site, but the N-terminal has no known counterpart in
RdRps (Xu et al., 2003). Cheng et al. demonstrated that bacterially produced nsp12 could extend
an oligo primer coupled to a template (Cheng et al., 2005).
2.2.7.11. Nsp13
SARS-CoV nsp13 is a 601 amino acid long multidomain protein with a zinc binding domain
at the N-terminus and conserved motifs comparable to those seen in superfamily 1 helicases at
the C-terminus. This superfamily 1 helicase unwind RNA and DNA duplexes unidirectionally in the
5' to 3' direction (Seybert et al., 2000; Weber & McCullagh, 2021), and the translocation is
powered by dNTP hydrolysis. Ivanov et al. (2004) demonstrated that nucleic acids promote the
activity of nsp13 and that it also has RNA 5'-triphosphatase activity, which could catalyze the
initial step in viral RNA 5'-capping (Ivanov et al. 2004a). The N-terminal region of nsp13 includes
a zinc binding domain that is required for helicase function. This domain comprises 12 conserved
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cysteine and histidine residues that are assumed to form a binuclear zinc binding cluster (Seybert
et al., 2005).
2.2.7.12. Nsp14
The N-terminal of nsp14 is a 3’-to-5’ exoribonuclease that is related to DEDD superfamily
with zinc finger in the middle of conserved motif II and motif III (Snijder et al., 2003b). The
catalytic activity of nsp14 is shown to be specific to RNA and requires two Mg2+ ions per molecule.
It is believed that coronavirus encode for 3’-to-5’ exoribonuclease to maintain their large genome
and nsp14 might be involved in proofreading mechanisms during replication. Studies done by
(Minskaia et al., 2006) shown modification in HCoV-229E ExoN active site failed to produce viable
virus. Consistent with other studies by (Almazán et al., 2006) showing reduction in genome
replication and transcription by 10-fold.
2.2.7.13. Nsp15
Nsp15 is a second conserved ribonuclease called NendoU. NendoU is a conserved domain
found in the members of the order Nidovirales and it stands for NidoViral endoribonuclease,
specific for U (Snijder et al., 2003b). It is known to be an endoribonuclease that cleaves
preferentially 3’ of uridylates and generates 2’-3’ cyclic phosphate ends (Ivanov, Hertzig, et al.,
2004). It’s been proposed that nsp15 and Bovine RNase A use the same catalytic mechanism due
to the homology in residues forming a catalytic triad (Ricagno et al., 2006). However, the
difference between nsp15 and Bovine RNase A is that the catalytic activity of nap15 is enhanced
in the presence of Mg2+ and upon formation of hexameric structures (Guarino et al., 2005).
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Formation of hexameric structure enhances the activity of nsp15 however it is believed that the
presence of nsp15 is not essential for viral replication.
2.2.7.14. Nsp16
Nsp16 is the last non-structural protein translated as part of the ORF1ab-encoded big
polypeptide. Nsp16 is believed to be ribose-2'-O-methyltransferases since it has been shown to
methylate

7MeGpppAC

n

at the ribose-2'O-moiety of adenosine, changing a cap-0 to a cap-1

structure (Decroly et al., 2008). Nsp16 seems to be required for viral replication, since deletion
or alteration of a single residue in the catalytic region results in the inability to synthesize RNA
(Almazán et al., 2006). Nsp16 is essential for viral replication because viruses that replicate in the
cytoplasm must supply the enzymes necessary to produce RNA cap structures or utilize an
alternate strategy.
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2.3.Macrodomain from MacroH2A.
Macrodomains are found in the majority of living organisms, including viruses, bacteria,
and humans. It was first discovered as part of the histone, due to its larger size than histone, it
was recognized as a component of histone and was termed macroH2A. MacroH2A is one of the
known variants of H2A histone. With its molecular weight of ~40kDa, it is almost three times the
size of canonical H2A histone. the N-terminal of macroH2A consists of histone region with 64%
homology to canonical H2A, in the middle is a linker region and at the C-terminal is the
Macrodomain. In total, macroH2A consists of 371 amino acids. Amino acids 1-122 form a histone
domain, amino acids 123-160 are linkers, and amino acids 161-371 are the macrodomain. This
macrodomain on the histone variant of MacroH2A consists of 7 beta sheets that are sandwiched
between 5 alpha helices. Most of the beta sheets are surrounded by the alpha helices. However,
some of it is exposed to the surface. This exposed surface of beta sheets exhibits an extended
hydrophobic region. This hydrophobic region includes two patches of three (182–185) and four
residues (355–359) (Rack et al., 2016).
2.3.1. Structural differences between MacroH2A and canonical H2A.
MacroH2A's histone domain is 64% similar to nonvariant H2A from Xenopus laevis and
Mus musculus. Two regions have been identified by sequence analysis as having the potential to
induce structural and functional variations. One of these regions is L1 loop, which is involved in
the primary interaction that forms the H2A-H2B dimer. The differences in L1 loop consist of three
residues, 83, 84, and 88, which correspond to residues 80, 81, and 84 in macroH2A. In nonvariant
H2A, the interaction between L1-L1 is stabilized by salt bridges, whereas in variant MacroH2A it
34

is stabilized by hydrophobic interaction. These changes thus influence the stability of the histone
octamer. The second region of structural and functional variation is the ladle-shaped H2A docking
domain that consists of residues 83–108. This region interacts with the H3-H4 heterotetrametric
and guides its interaction with nucleosome DNA. The changes in docking domain does not affect
the interaction between histones when forming an octamer (Gamble, 2013; Li et al., 2013; Rack
et al., 2016).
2.3.2. Structural changes in MacroH2A affecting protein-protein interaction.
Chakravarthy & Luger et al. (2006) showed that the L1 loop in MacroH2A's histone domain
has an important impact on the assembly and dynamics of nucleosomes. This is attributed to a
four-amino-acid exchange in the L1 loop. The L1 loop stabilizes the nucleosome core particle,
rendering it resistant to histone exchange facilitated by chaperones. Structural experiments
confirmed that although the altered L1 loop has little effect on the overall structure of the
nucleosome core, it does change the protein-protein interaction between histones in the histone
domain of the MacroH2A-H2B dimer (Chakravarthy et al., 2005b; Chakravarthy & Luger, 2006).
NAP-1 is a yeast nucleosome assembly protein that is capable of exchanging H2A-H2B
dimers in chaperone-mediated histone exchange. However, it was found that nucleosome core
particles containing MacroH2A were resistant to chaperone mediated histone exchange by NAP1 (Abboott et al., 2005). Additionally, it was suggested that the linker domain of MacroH2A might
also interfere with chromatin remodeling machines through steric hindrance. The research found
lower affinity in nucleosome core particles that contain MacroH2A for chromatin remodeling
machines, reducing transcription initiation (Doyen et al., 2006).
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2.3.3. MacroH2A interaction with HDAC proteins.
The nonhistone "macro" domain of macroH2A protein is composed of 130–190 amino
acids and has a structure consisting of 7 beta sheets sandwiched between 3 or more alpha
helices.Following genome sequencing, two of the seven beta strands are expected to be leucine
zippers (Pehrson & Fuji, 1998), with one side of the beta strand pointing inwards facing alpha
helices and the other side exposed to the surface. A total of 7 (182-185 [FTVL]) and 355–359
[IGIYV]) hydrophobic residues from the beta sheet are exposed to the surface, exhibiting an
extended hydrophobic region. Chakravarthy et al. (2005) discovered that an expanded
hydrophobic area on nonhistone domains would help in the recruitment, interaction, and
stabilization of HDAC proteins in vitro. To test this hypothesis, they expressed three class I HDACS,
but only HDAC1 and HDAC2 were found to associate with MacroH2A's nonhistone domain.
Additionally, to confirm their results, they decided to modify the hydrophobic amino acids with
hydrophilic amino acids. Mutations in the extended hydrophobic region had a major effect on
HDACs and nonhistone domain interaction. They also discovered that mutations in the 160–180
area eliminated the repressive activity of this domain using transcriptional repression assays
(Buschbeck & di Croce, 2010).
2.3.3.1.

MacroH2A Inhibit gene expression by interacting with HDAC.

The MacroH2A variant was initially found in a high concentration on chromosome X. It
was hypothesized that MacroH2A might interact with and recruit proteins that play a role in
inactivating chromosome X. One of the known modifications to suppress gene expression is deacetylation, carried out by histone deacetylases (HDACs). They expressed three class I HDACs:
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HDAC1, HDAC2 and HDAC3, along with histone lysine methyl transferase and Suv39h1. They
found HDAC1 and HDAC2 interacted with the non-histone region of MacroH2A as these proteins
were copurified together. The interaction between HDACs and MacroH2A was also confirmed
with a western blot using anti-HDAC1, -2, and -3 antibodies on the supernatant of
erythroleukemia cells. Following that, they mutated MacroH2A to identify regions that could be
involved in association with HDACs. They found residues 182-185 and 355–359 to be involved in
interaction. These are the same residues residing in the exposed beta sheet of the macrodomain,
forming an extended hydrophobic region. When these residues were then substituted with polar
amino acids, the association between HDACs and the nonhistone region of MacroH2A was lost.
In vivo transcriptional repression experiments showed residues in 355–359 to be essential for
repression activity. These and other immunoprecipitation studies revealed a connection between
MacroH2A-mediated HDAC recruitment and chromatin hypoacetylation (Buschbeck & di Croce,
2010).
2.3.4. MacroH2A inhibits gene expression by masing regulatory region.
Almost every cell in our body contains the same genetic information provided by our
mother and father. However, not every cell in our body looks or behaves the same. It is because
of the cell-specific gene expression system that dictates what genes will be encoded. One way
that the cell-specific gene expression system controls gene expression is by modifying the
chromatin structure via recruiting histone variant MacroH2A (Agelopoulos & Thanos, 2006).
Thanos et al. (2006) discovered a new mechanism of gene expression that uses ubiquitous
transcription factors to recruit histone variants for gene regulation. Namalwa B cells and
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epithelial HeLa cells were infected with the virus and the expression of INF-B and IL8 genes was
observed. Activation of IL8 and INF-B genes is mediated by a simple enhancer bound by
transcriptional factors such as NF-KB, C/EBP and ATF/AP1, and all these factors are present in
both cells. Both genes were expressed in Hela cells, but only INF-B was expressed in Namalwa B
cells (Agelopoulos & Thanos, 2006).
The Thanos lab suspected transcription factors might be the reason the IL8 gene was not
expressed in Namalwa B cells and carried out a chromatin immunoprecipitation (ChIP)
experiment. A Chromatin Immunoprecipitation (ChIP) experiment was conducted to determine
the interaction of these transcription factors with the promoter region of each gene. As
suspected, all the basal transcription machinery was recruited to the IL8 promoter region of the
hela cell but not the B cell. Instead, they observed an ATF-2/Jun-D heterodimer bound to the
promoter region of the IL8 gene on B cells along with GCN5 histone acetyltransferase protein.
GCN5 tends to acetylate K9 and K14 on H3, signaling the recruitment of the TFIID complex. The
following step was to look into the nucleosomal organization in this cell type.In HeLa cells, the
promoter site of IL8 was nucleosome free, whereas in B cells, the promoter site was masked by
a nucleosome, making it inaccessible to transcriptional machinery (Agelopoulos & Thanos, 2006).
In other studies, it’s been shown that a macro variant of H2A in a nucleosome core particle
could potentially make the gene inaccessible to transcriptional factors. They suspected this might
be the case with IL8 as well and decided to carry out a ChIP assay using an antibody specific to
MacroH2A. Their results showed no MacroH2A on the IL8 promoter in HeLa cells, contrary to B
cells. A MacroH2A-containing nucleosome was found in the coding region of the IL8 gene in B
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cells. To examine the role of MacroH2A in IL-8 gene expression, siRNA was used to inhibit the
expression of MacroH2A. It was confirmed beforehand that the inhibition of MacroH2A would
not affect other histones. By depleting MacroH2A from B cells, the IL-8 gene was successfully
expressed. This confirmed that MacroH2A does play a role in IL8 gene inhibition (Agelopoulos &
Thanos, 2006).
2.3.5. MacroH2A interaction with Activating transcription factor 2 (AF2).
The ATF/AP1 location was thought to play a role in positioning the macroH2A nucleosome
to the IL-8 promoter region in B cells. Following viral infection, a change in ATF/AP1 position
resulted in activation of the IL-8 promoter in Namalwa B cells but not in HeLa cells. Additional
nucleosome mapping experiments identified loss of MacroH2A in the nucleosome following
ATF/AP1 modification. Protein–protein interaction assays were conducted to see whether ATF-2
specifically recruits macroH2A. Histone composition was evaluated by Western blotting using
antibodies specific for macroH2A and canonical histones after nucleosome reconstitution. When
ATF-2 was not present, the assembled chromatin did not contain macroH2A on the IL-8 or IFN-b
promoters. On the other hand, the addition of recombinant ATF-2 during the nucleosome
reconstitution reaction resulted in the induction of a macroH2A nucleosome on the IL-8 enhancer
but not the IFN-b enhancer (Agelopoulos & Thanos, 2006).
Next, ATF sites were swapped between IL8 and INF-B as previous studies have shown
proteins containing the b-zip motif acquire distinct conformations based on the sequence of the
binding site. They evaluated the histone composition again via Western blotting using antibodies
specific for macroH2A and canonical histones after nucleosome reconstitution. They discovered
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that macroH2A-containing nucleosomes are recruited by ATF-2 on the IFN-b template with an
ATF site sequence taken from IL-8 (Agelopoulos & Thanos, 2006).
These results demonstrate that the bZip DNA-binding domain of ATF-2 is responsible for
the recruitment of macroH2A-containing nucleosomes and that this recruitment depends on the
specific sequence of the ATF DNA site, thus implying a DNA-induced protein allostery mechanism.
These results indicate that the ATF-2 bZip DNA-binding domain is accountable for the recruitment
of macroH2A-containing nucleosomes and that this recruitment is dependent on the precise
sequence of the ATF DNA site (Agelopoulos & Thanos, 2006).
2.3.6. Macrodomains as standalone proteins.
Macrodomains are found in the majority of living organisms, including viruses, bacteria,
and humans. Macrodomains are present not only as standalone proteins, but also as modules
inside multidomain proteins such as PARPs (Chakravarthy et al., 2005a). A macrodomain is a
three-layered α/β/α sandwich fold and it is not restricted to one function. Some macrodomains
have been shown to have ADP-ribose-1-phosphate phosphatase activity (Saikatendu et al., 2005).
More recently, it was demonstrated that macrodomains from several (+) ssRNA viruses are also
capable of hydrolyzing single ADPr (de-MARylation) or multiple ADPr residues from proteins (dePARylation). (Fehr et al., 2016). MARylation and PARylation are reversible posttranslational
protein modifications usually utilized by host cells as a signal for various cellular processes,
including the initiation of antiviral immune responses by PARPs (Liu & Yu, 2015).
Fehr et al. reported that the SARS-CoV wild-type Mac1 domain prevents the production
of innate-immunity genes in vitro, thus inhibiting the host immune response (Fehr et al., 2016).
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It is also possible for macrodomains to only bind to the ADPr already bound to the acceptor
protein, blocking an essential signal. The SARS-CoV-2 Mac1 domain has been shown to bind to
ADPr via various binding techniques (Frick et al., 2020). Based on the capacity of the viral
macrodomain to simply bind to ADPr or to catalyze MARylation, PARylation, and association with
PARPS, it has been proposed that the viral macrodomain modulates the host cellular immune
response (Kraus, 2009).
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3. Literature Review: Chemistry
3.1. Background Thermodynamics
3.1.1. Energy
Energy is often defined as the capacity to do work. In chemistry, work is defined as the
change in energy that occurs as a process. Potential and kinetic energy are two forms of energy,
while the others are varying combinations of the two. For example, chemical energy is the
potential energy stored within the structural units of chemical substances, whereas thermal
energy is the kinetic energy associated with the random motion of atoms and molecules.
Additionally, all forms of energy can be converted into one another. A ball rolling down a hill is
an example of potential energy converted into kinetic energy. Although one form of energy can
be converted into another, scientists have concluded that energy can neither be created or
destroyed and this principle is called the law of conservation of energy . The first law of
Thermodynamics is based on the law of conservation of energy, which states that energy can be
converted from one form into another, but it cannot be created or destroyed. The First and the
second law of thermodynamics were established by 1860 as formalized in the work of scientists
such as Rudolf Clausius (Clausius, R., 1865) and Kevin, William T (Kevin, William T., 1849). (Chang
& Overby, 2011)
3.1.2. The First Law of Thermodynamics:
The first law of thermodynamics states that the energy (𝑈) of the universe is a constant.
The universe includes the system and the surroundings. Therefore, the energy of the universe is
equal to the sum of the energy of the system and the surroundings (Equation 3.1-1).
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∆𝑈𝑈𝑛𝑖𝑣𝑒𝑟𝑠𝑒 = ∆𝑈𝑆𝑢𝑟𝑟𝑜𝑢𝑛𝑑𝑖𝑛𝑔 + ∆𝑈𝑆𝑦𝑠𝑡𝑒𝑚 = 0

Equation 3.1-1

Energy change (DU) can occur in two different ways: via heat (𝑞) and through work (𝑤).
When a system experiences a change in energy, it is either because the system gained or lost
heat, or the work was done on or by the system (Equation 3.1-2).
∆𝑈𝑆𝑦𝑠𝑡𝑒𝑚 = 𝑞 + 𝑤

Equation 3.1-2

When studying a chemical reaction, one way to demonstrate mechanical work is to
examine the expansion or compression of the system. This can be illustrated in terms of volume
and pressure (Equation 3.1-3).
𝑤 = −𝑃∆𝑉

Equation 3.1-3

Substituting equation 3.1-2 into equation 3.1-3 for work (𝑤) yields equation 3.1-4, which
can be applied to laboratory processes.
∆𝑈𝑆𝑦𝑠𝑡𝑒𝑚 = 𝑞 − 𝑃∆𝑉

Equation 3.1-4

The next step is to apply the first law of thermodynamics to chemical reactions. Most
chemical reactions in a laboratory take place under either constant volume or constant pressure
conditions. If a chemical reaction is carried out under constant volume 𝛥𝑉 = 0, the internal
energy of the system is then proportional to the heat of the reaction (Equation 3.1-5).
𝛥𝑈𝑆𝑦𝑠𝑡𝑒𝑚 = 𝑞𝑣

Equation 3.1-5

The subscript “𝑣” in equation 3.1-5 indicates that it is a constant volume process.
Constant volume processes are sometimes impossible to achieve, and chemical reactions must
instead be performed under constant pressure. To help with this situation, a new state function,
Enthalpy change (∆𝐻) was introduced (Equation 3.1-6).
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𝐻 = 𝑈 + 𝑃𝑉

Equation 3.1-6

Enthalpy is defined by equation 3.1-6, where 𝑈 is internal energy, 𝑃 is pressure and 𝑉 is
the volume of the system. Enthalpy for a system is always calculated as a change in enthalpy
(Equation 3.1-7) and for a system under constant pressure, enthalpy is given by Equation 3.1-8.
𝛥𝐻 = 𝛥𝑈 + 𝛥(𝑃𝑉)

Equation 3.1-7

𝛥𝐻 = 𝛥𝑈 + 𝑃𝛥𝑉

Equation 3.1-8

When Equation 3.1-4 is applied to a constant-pressure system, it is transformed and
simplified to Equation 3.1-9. Equation 3.1-10 is obtained by substituting 𝑈 from Equation 3.1-8
into Equation 3.1-9 and simplifying.
𝑞𝑝 = 𝛥𝑈 + 𝑃𝛥𝑉
𝑞𝑝 = 𝛥𝐻

Equation 3.1-9

Equation 3.1-10

There is now a way of applying the first law of thermodynamics to a system and quantifying
energy under various conditions. If a chemical reaction is performed at a constant volume, the
change in heat is equal to 𝛥𝑈 (Equation 3.1-5). If a reaction is performed under a constant
pressure, then the change in heat is equal to 𝛥𝐻 (Equation 3.1-10). Calorimetry is a frequently
used technique in laboratories to measure the heat changes caused by chemical and physical
processes (Velázquez‐Campoy et al., 2004). Constant-volume calorimetry can be used to estimate
one value describing the process's thermodynamic: enthalpy change (𝛥𝐻).
3.1.3. The Second Law of Thermodynamics
The second law of thermodynamics introduces a new thermodynamic quantity called
Entropy (𝑆) in conjunction with spontaneity (Chang & Overby, 2011). According to the second
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law of thermodynamics, a spontaneous reaction increases the entropy of the universe (Equation
3.1-11). Entropy is often used to indicate the degree to which a system's energy is distributed
across the many potential ways that system may hold energy.
For a spontaneous reaction: 𝛥𝑆𝑈𝑛𝑖𝑣𝑒𝑟𝑠𝑒 = 𝛥𝑆𝑆𝑦𝑠𝑡𝑒𝑚 + 𝛥𝑆𝑆𝑢𝑟𝑟𝑜𝑢𝑛𝑑𝑖𝑛𝑔𝑠 > 0
Equation 3.1-11
As with other thermodynamic quantities, entropy in terms of spontaneity is of primary
interest. A new thermodynamic function for Gibbs free energy was introduced (Equation 3.1-12).
When applied to a system, Gibbs free energy may be used to assess whether a chemical reaction
will occur spontaneously.
For a spontaneous reaction:

𝛥𝐺 = 𝛥𝐻 + 𝑇𝛥𝑆 < 0

Equation 3.1-12

As shown in equation 3.1-12, a spontaneous reaction would give a negative change in
Gibbs free energy (𝛥𝐺), where 𝛥𝐻 is the change in enthalpy of a system, 𝑇 is the temperature
and 𝛥𝑆 is the entropy change of the system. In this case, free energy refers to the energy available
to do work, and if a reaction is accompanied by the release of useable energy, i.e., 𝛥𝐺 is negative,
this alone establishes its spontaneity (Chang & Overby, 2011). While a system's free energy
change may be determined under any set of conditions, when data is gathered under standard
conditions, the result is standard-state free energy of reaction (Equation 3.1-13).
𝛥𝐺ᵒ = 𝛥𝐻ᵒ + 𝑇𝛥𝑆ᵒ

Equation 3.1-13

The significance of the equation describing a system's free energy lies in its ability to
identify the relative relevance of the enthalpy and entropy components as driving factors in each
reaction. In other words, the change in the system's free energy indicates the balance of two

45

driving factors that decide whether a chemical reaction is spontaneous. The following table
highlights the effect of entropy and enthalpy changes on spontaneity of a chemical process
(Atkins & Paula, 2006).
𝛥𝐻

𝛥𝑆

Positive

Positive

Spontaneity

At high temperatures, the reaction occurs spontaneously at low
temperatures, it occurs in reverse.
Positive Negative The reaction occurs spontaneously in the opposite direction at all
temperatures.
Negative Positive The reaction occurs spontaneously at all temperatures.
Negative Negative At low temperatures, the reaction occurs spontaneously at high
temperatures, it occurs in reverse.
Table 3.1-1 Enthalpy (𝚫𝐇), Entropy (𝚫𝐒) dictates reaction spontaneity.
A summary of how Enthalpy (𝚫𝐇), Entropy (𝚫𝐒), and Temperature (𝐓) affect a chemical reaction's
spontaneity.
Using Gibbs free energy, one can also identify the direction of a chemical process that are
not in standard states. In equation 3.1-14, 𝛥𝐺 is the Gibbs free energy change of a chemical
process not in standard state, 𝛥𝐺ᵒ is the Gibbs free energy of chemical process in standard state,
𝑅 is the gas constant, 𝑇 is the absolute temperature of the reaction and 𝑄 is the reaction
quotient. At equilibrium, ∆𝐺 = 0 and 𝑄 = 𝐾. When applied to equation 3.1-14 and simplified,
this results in equation 3.1-15, where 𝐾 is the equilibrium constant. Equation 3.1-15 allows us to
determine the equilibrium constant of a reaction given the change in standard free energy, or
vice versa. Table 3.1-2 summarizes the relationship between Gibbs free energy and equilibrium
constant based on equation 3.1-15 (Chang & Overby, 2011).
𝛥𝐺 = 𝛥𝐺ᵒ + 𝑅𝑇 𝑙𝑛(𝑄)

Equation 3.1-14

𝛥𝐺ᵒ = − 𝑅𝑇 𝑙𝑛(𝐾) Equation 3.1-15
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K

ln(K)

ΔG

At Equilibrium

>1

Positive

Negative

Products are favored

=1

0

0

Products and reactants are equally favored

<1

Negative

Positive

Reactants are favored

Table 3.1-2 Summary of ΔG and ln(K) based on equation 3.1-15.
3.1.4. Calorimetry
Calorimetry is a technique used for determining the quantity of heat emitted or absorbed
during a chemical reaction. A calorimeter is a device that was developed especially for this
purpose. Numerous calorimeters are available on the market, including differential scanning
calorimeters (DSC) and isothermal titration calorimeters (ITC). In our studies, an isothermal
titration calorimeter (ITC) was utilized. The ITC measures the change in heat of a solution, which
can be related to a chemical reaction. For example, when one molecule is titrated with another
and they react, heat is either released or absorbed, and from this, the free energy, enthalpy, and
entropy of binding may be determined accurately with ITC (Velázquez‐Campoy et al., 2004).
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3.2.Isothermal Titration Calorimetry (ITC)
ITC is a useful tool to determine energy changes when two molecules bind in a solution.
The advantages of using ITC for binding studies over other methods are that it is label-free, there
is no molecular weight limitation, and it is not influenced by the color or the optical clarity of the
sample (Velázquez‐Campoy et al., 2004). One ITC experiment can provide whether a binding
event occurs along with thermodynamic parameters of the interaction. However, accurate
measurements of thermodynamic quantities associated with intermolecular interaction require
careful standardization of the instrument. This can be achieved by evaluating the instrument
response with the measurement of well-known physico-chemical processes such as Ca2+-EDTA
chelation (Ràfols et al., 2016).
ITC consists of two identical cells encased in an adiabatic jacket. These cells are
constructed of a highly efficient, thermally conductive, and chemically inert material. The
temperature of both cells is measured with very high accuracy and heaters are used to maintain
a constant temperature.
In a typical ITC experiment, macromolecules such as proteins are kept in the sample cell
and water or buffer without protein and ligand in the reference cell. Before initiating the
experiment, both cells are equilibrated to ensure the same temperature. The reference cell is
kept closed for the duration of the experiment, whereas the sample cell is open from the top,
accessible for delivery of small molecules via a syringe. The addition of a very precisely known
aliquot of small molecules into the sample cell initiates an experiment. Upon interaction between
two molecules, heat is either generated or absorbed. A miniscule change in temperature is
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detected and heaters are activated to equilibrate both cells (Velázquez‐Campoy et al., 2004). The
amount of heat required to maintain an exact temperature between the sample and reference
cells is then recorded in a time-dependent manner.

Figure 3.2-1 Example of raw data collected from ITC
(A) The top panel illustrates typical raw data from an ITC experiment, while the bottom panel
illustrates the integrated heat plot produced by measuring the area under each peak. Enthalpy,
binding constant, and stoichiometry may all be estimated directly from the figure as shown in
(B). This data was accompanied by Ca2+ and EDTA titration done to measure equipment response.
An example of raw data is shown in the top section of Fig. 3.2-1a. The x-axis is time in
seconds and the y-axis is the change in raw heat observed over time in micro joules per second,
with each spike corresponding to an injection from a syringe into the sample cell. The size and
the direction of the peak are based on the magnitude of heat that was either released or
absorbed upon ligand binding in the sample cell. Each peak is then integrated and plotted against
the molar ratio, which is shown as the bottom part of Fig. 3.2-1a. Initially, all the titrant added to
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the sample cell binds to the macromolecule, resulting in a relatively high heat output. As the end
point is reached, the quantity of ligand bound per injection diminishes beyond the end point, a
continuous heat of dilution is often observed and eliminated during analysis (Velázquez‐Campoy
et al., 2004).
A rough estimate of molar enthalpy, stoichiometry and binding constant can be deduced
from the first few peaks in the titration, the position of the equivalence point and the slope of
the curve at the equivalence point, respectively (Figure 3.2-1b). Calculating parameters using ITC
data requires choosing a model that is appropriate for the system under investigation and fitting
a function that will be utilized in the non-linear least square regression analysis (Velázquez‐
Campoy et al., 2004). In our studies, a model based on the premise that a single macromolecule
has just one binding site was utilized (Equation 3.2-1). Equation 3.2-2 expresses an equilibrium
constant that characterizes the binding of a ligand to a macromolecule with a single binding site.
M + L ↔ ML Equation 3.2-1
[𝑀𝐿]

𝑘𝑎 = [𝑀][𝐿]

Equation 3.2-2

An ITC experiment involves injecting a ligand into a sample cell containing a
macromolecule, resulting in a concentration change. Equations 3.2-3 and 3.2-4 are used to
determine the total concentrations of macromolecule, [𝑀]𝑡 and ligand, [𝐿]𝑡 in the sample cell
after each injection (i).
𝑣 𝑖

[𝑀] 𝑇,𝑖 = [𝑀]𝑂 (1 − 𝑉)

𝑣 𝑖

[𝐿] 𝑇,𝑖 = [𝐿]𝑂 (1 − [1 − 𝑉] )
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Equation 3.2-3
Equation 3.2-4

𝑣

In the preceding equation, (1 − 𝑉) is the dilution factor that considers the change in
reactant concentrations caused by each sample injection, where (𝑉) is the volume of the sample
cell and (𝑣) is the injection volume. The concentration of macromolecule and ligand in the
sample cell is determined by Equations 3.2-3 and 3.2-4, and binding results in a minute change
in temperature. The power required to compensate for the change in temperature is referred to
as heat (𝑞). As stated in equation 3.2-5, the heat (𝑞) is proportional to the difference in
concentration of the complex formed upon each injection [𝑀𝐿]𝑖 , the volume of the sample cell
(𝑉), and the binding enthalpy (∆𝐻𝑎 ).
𝑣

𝑞𝑖 = 𝑉∆𝐻𝑎 ([𝑀𝐿]𝑖 − [𝑀𝐿]𝑖−1 [1 − 𝑉])

Equation 3.2-5

The binding enthalpy can therefore be determined from the heats measured upon each
injection and complex concentration (Equation 3.2-5), which can be determined, based on the
mass action law and conservation of mass for each species. (Velázquez‐Campoy et al., 2004)
(Equation 3.2-6)
1 + 𝑛[M]T,𝑖 𝐾𝑎 + 𝐾𝑎 [L]T,𝑖 − √(1 + 𝑛[M]T,i 𝐾𝑎 + 𝐾𝑎 [L]T,𝑖 )2 − 4𝑛[M]T,𝑖 𝐾𝑎 2 [L]T,𝑖
[𝑀𝐿]𝑖 =

2𝐾𝑎
Equation 3.2-6

Equation 3.2-6 describes binding events in which ligands bind to a macromolecule with 𝑛
equivalent and independent binding sites and thermodynamic parameters such as 𝐾𝑎 , ∆𝐻𝑎 , and
𝑛 may be determined via fitting. The binding affinity is then related to the free energy ∆𝐺 of
binding as shown in equation 3.2-7.
∆𝐺 = −𝑅𝑇𝑙𝑛(𝑘𝑎 )
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Equation 3.2-7

In Equation 3.2-7, 𝑅 is the gas constant, 𝑇 is the absolute temperature. Gibbs free energy
is also related to other thermodynamic parameters such as Enthalpy ∆𝐻 and Entropy ∆𝑆 as
shown in Equation 3.2-8.
∆𝐺 = ∆𝐻 − 𝑇∆𝑆

Equation 3.2-8

3.2.1. Example Analysis of data
In a typical ITC experiment, data is collected, analyzed, and fitted to an equation to
determine Gibbs free energy, enthalpy, and entropy pertaining to a specific molecular binding.
Below are three possible scenarios:

Figure 3.2-2. Example analysis of ITC data.
Illustration of three distinct compounds binding to the same target with the same affinity or
Gibbs free energy but with varied enthalpy and entropy.

If all three molecules shown in Fig. 3.2-2 were ranked only based on their affinity, they
would be identical. However, the variation lies in their enthalpy and entropy values. Entropy and
enthalpy offer further information on the binding mechanism. The binding mechanism
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determines how effectively the molecule adheres to the binding pocket and the interactions that
are made between the ligand and the macromolecule.
Molecule A's binding is strongly enthalpically driven. Enthalpy substantially contributes to
binding affinity and Gibbs free energy, suggesting that the ligand and macromolecule are closely
associated through hydrogen bonds and van der Waals interactions. Additionally, there is a
negative entropy contribution, which may be attributed to a reduction in the degrees of freedom
of both the macromolecule and the ligand, as indicated by positive −𝑇∆𝑆. Compound B binding,
on the other hand, is highly entropic, and therefore the binding affinity is determined by
nonspecific hydrophobic contact and desolvation of water molecules upon binding. Additionally,
compound B has an unfavorable enthalpy. This is due to the surface being dehydrated or loss of
hydrogen bonding. Compound C binds with a balanced affinity due to the presence of both
favorable hydrogen and hydrophobic contacts.
3.2.2. The significance of Entropy and Enthalpy.
ITC is often used to determine the binding energies of biological processes directly. These
biological processes include, but are not limited to, protein-ligand and protein-protein binding,
where the ligand is usually a small organic molecule. Binding energies of biological processes can
be calculated using equation 3.2-9 in terms of binding affinity. Binding affinity is a combined
function of the enthalpy (𝛥𝐻) and entropy (𝛥𝑆)
𝛥𝐺 = −𝑅𝑇 𝑙𝑛 𝐾𝑑 = 𝛥𝐻 − 𝑇𝛥𝑆

Equation 3.2-9

This is an important way of evaluating a compound's binding properties, since the
equilibrium dissociation constant (𝐾𝑑 ) as determined by Gibbs free energy (𝛥𝐺), enables the
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identification of the binding's dominant forces, change in Entropy (𝛥𝑆) and change in Enthalpy
(𝛥𝐻). A drug molecule with extremely high binding affinity (i.e. a low Kd) requires favorable
contribution from both enthalpy change (𝛥𝐻) and entropy change (𝛥𝑆) (Voet et al., 2018).
The total enthalpy change is calculated as the sum of the positive and negative enthalpic
contributions. The positive enthalpy changes are due to the formation of hydrogen bonds and
van der Waals interactions between the ligand and the protein, while the unfavorable enthalpic
contribution is due to the ligand being desolvated or removed from solution in order to form a
complex (Freire, 2008).
The challenge is in synthesizing ligands that contribute significantly to enthalpy changes
(Ruben et al., 2006). In other words, the ligand needs to be covalently bonded to a very
electronegative atom such as a N, O, or F. If these atoms can form hydrogen bonds with amino
acids at the binding site, they almost certainly already do so with water or other buffer molecules.
To bind to the binding site of a protein, the ligand breaks bonds with the solvent and then
establishes new hydrogen bonds with amino acids in the protein's binding site. The penalty for
desolvating a polar molecule is very large, therefore the beneficial contribution upon binding
must be much higher to achieve a favorable enthalpic contribution overall. The hydrogen bonding
is also very fastidious in terms of bond angle and distance if the bond angle and distance are not
optimal, the favorable enthalpy contribution diminishes and suddenly turns unfavorable. Thus,
for a molecule to have a significant favorable enthalpic contribution, it must fit precisely into the
binding pocket. Loose fitting would result in a unfavorable enthalpic contribution (Freire, 2008).
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A favorable enthalpy change upon complex formation is proportional to the ability of a
ligand and protein to maximize van der Walls forces and hydrogen bonding while preserving an
exact geometric fit inside the binding pocket. This is an indication that the molecule establishes
a stable bond with the target and that the bonds are sufficiently strong to compensate for the
unfavorable enthalpy associated with desolvation. Even when the binding enthalpy of a molecule
is increased, this does not necessarily translate into an increase in binding affinity, since the gain
in enthalpy may be countered by a loss of entropy (Freire, 2008).
On the other hand, the entropic contribution is dependent on desolvation, conformation,
and the number of individual particles in solution. Desolvation of a ligand usually results in a
favorable change in entropy due to the release of a water molecule from the binding site upon
ligand binding. On the other hand, conformational entropy change is nearly always unfavorable
to ligand binding. This is because, although the ligand has rotatable bonds and can adopt many
conformations in solution, it will be limited to occupying a single conformation upon binding. This
leads in a reduction in degrees of freedom and entropy. Due to the loss of conformational
degrees of freedom in both the drug molecule and the protein, the conformational entropy
change that occurs after ligand binding is almost always unfavorable (Freire, 2008).
To conclude, the binding affinity, enthalpy and entropy changes describing a ligand
binding to a protein may be estimated by determining heat changes in a binding isotherm.
Enthalpy is related to by the contribution of hydrogen bonds and van der Waals interactions, as
well as the contribution of ligand desolvation from solution. As will be discussed next, it is
considerably more difficult to design an enthalpic-driven ligand with a polar functional group

55

because if the ligand is not fitted optimally into the binding site, it will acquire a high enthalpic
penalty, while the enthalpic penalty for non-polar ligands is orders of magnitude smaller.
Optimizing a ligand for favorable entropic contribution is considerably simple since most negative
contributions are due to conformational or degree of freedom loss in solution. A molecule may
be constructed in a limited conformation that matches the binding conformation, preventing the
molecule from changing shape upon binding.
3.2.3. The significance of Enthalpy in Drug Discovery
Enthalpy plays a significant role in determining the ligand attributes in terms of binding.
Favorable enthalpy is contributed by having strong hydrogen bond and van der Walls interaction
from a tight fit however large penalty is given for a loose fit. Favorable contribution from
enthalpic energy is an important way of evaluating a compound binding property (Ohtaka &
Freire, 2005). Let us consider two instances from the literature on the advancement of HIV
protease inhibitors and statins, inhibitors for HMG-CoA reductase. Taken together, Fig 3.2-3 and
Fig. 3.2-4 demonstrate a connection between binding affinity and thermodynamic parameters.
Another example that demonstrates the change in thermodynamics as improvements
were made to the compound is β-Hydroxy β-methylglutaryl-CoA (MHG-CoA) reductase inhibitors
also known as statins (Ohtaka & Freire, 2005). As shown in Fig. 3.2-5, Fluvastatin was one of the
first MGH-CoA inhibitor however as improvements were made there was shift in thermodynamic
signature. Fluvastatin is entropy driven whereas rosuvastatin, an improved MGH-CoA inhibitor is
enthalpically driven.
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Figure 3.2-3. The progression of HIV inhibitors' binding affinity.
The dissociation constants of HIV inhibitors with wild type (WT) and a drug resistant mutant
(MDR) HIV-Protease are shown. This figure has been adapted with permission from (Ohtaka &
Freire, 2005)

Figure 3.2-4 The development of HIV inhibitors is measured by thermodynamic data.
Shows thermodynamic information associated with inhibitors binding to HIV protease. This figure
has been adapted with permission from (Ohtaka & Freire, 2005)
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In both instances, It is seen that the modifications were made to the compounds to
increase their affinity and selectivity to shift in thermodynamic signature. This shift in
thermodynamic signature happens to be from first compound being entropically driven whereas
the improved version being more enthalpically driven. This evidence indicates that the most
effective drugs in their class are usually enthalpically driven. This does not always imply that the
therapeutic molecules were developed with pure intent toward increasing enthalpy rather,
advances in compounds with high selectivity and potency are generally enthalpically driven
(Freire, 2008).

Figure 3.2-5 The development of statins is measured by thermodynamic data.
Carbonell & Freire et al. shows the inhibitor constant and associated thermodynamic values
associates with statins, inhibitor of HMG-CoA reductase. This figure has been adapted with
permission from (Carbonell & Freire, 2005)
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3.3.Compound optimization in drug discovery
3.3.1.1.

Thermodynamic Optimization Plot

In general, the thermodynamic optimization plot enables the correlation of structural
activity with enthalpy, entropy, and affinity in a single graph (Freire, 2009). This information
enables the mapping of compounds and the correlation of changes in the thermodynamic
signature with changes in each molecular region. This may be visually instructive in terms of
deciding which functional groupings should be implemented and which should be avoided. For
instance, if a certain functional group at a particular region on the molecule produces beneficial
results, the functional group should be implemented. On the other hand, if a functional group in
a certain area result in a penalty, it should be avoided.

Figure 3.3-1 A Thermodynamic Optimization Plot.
An example of a typical Thermodynamic Optimization Plot, with the only lead chemical in the
center and a diagonal optimization line.
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Thermodynamic optimization plot is easy to implement, all is needed is enthalpy (∆𝐻) on
the y-axis, and −𝑇∆𝑆 on the x-axis. The enthalpy and entropy data of the lead compound is placed
on the graph and line is drawn through it as shown above. The optimization line intersects
(−𝑇∆𝑆, ∆𝐻) of the lead compound and a point at (0, ∆𝐺). (0, ∆𝐺) is obtained using ∆𝐺 = ∆𝐻 −
𝑇∆𝑆 (Equation 3.3-1) and setting −𝑇∆𝑆 = 0 (Equation 3.3-2) giving ∆𝐺 = ∆𝐻 (Equation 3.3-3).
This results in a line with a negative slope of one. In our study (Chapter 6), ADPr was used as the
"lead" compound to compare alternative nucleotides with slightly different structures and
different binding affinity.
∆𝐺 = ∆𝐻 − 𝑇∆𝑆

Equation 3.3-1

−𝑇∆𝑆 = 0

Equation 3.3-2

∆𝐺 = ∆𝐻

Equation 3.3-3

The optimization line is a simple line that is not fitted to any equation but only intersects
(−𝑇∆𝑆, ∆𝐻) of the lead compound and at (0, ∆𝐺). If there are any compounds on the
optimization line, that means it has a similar binding affinity same as of a lead compound but
different enthalpy and entropy.
Compounds that are above the optimization line have a lower binding affinity, whereas
those that are below the optimization line have a higher binding affinity. The graph is further
classified by drawing horizontal and vertical lines across the lead compound. This distinguishes
the contribution of enthalpy and entropy to affinity, allowing for the assignment of particular
chemical modifications to a limited category. The functional group under this category may then
be optimized further, implemented as-is, or ignored entirely.
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The optimization plot is more helpful when there are many compounds with multiple
modifications. These advantageous changes may then be pooled and evaluated to improve the
design of the molecule. The thermodynamic optimization plot, as defined by (Freire, 2009),
serves as a platform for identifying the region and type of compound modification that increases
enthalpy and entropy contribution, thus increasing binding affinity.

Quadrant Entropy

Enthalpy

1
2
3
4
5
6

Worse
Worse
Worse
Better
Better
Better

Better
Better
Worse
Worse
Worse
Better

Binding
affinity
Better
Worse
Worse
Worse
Better
Better

Table 3.3-1 Summary of each quadrant of the thermodynamic optimization plot.
3.3.1.2.

LipE Plot

The logD value or lipophilicity is obtained empirically by measuring the distribution of
molecules between the hydrophilic and hydrophobic phases at a physiologically appropriate pH
of 7.4. Water and octanol are usually used as the hydrophilic and hydrophobic phases,
respectively. Lipophilicity is a metric that quantifies the hydrophobicity, polarity, and ionic
interaction of molecules. Molecular hydrophobicity is favored by dispersion or van der Waals
forces, while molecular ionic interaction due to attractive/repulsive forces or polarity due to
hydrogen bonding or inductive forces are favored by hydrophilicity. Typically, lipophilicity is
obtained for a molecule that has not yet been synthesized. In these situations, it is possible to
61

predict computationally and then measure empirically after synthesizing the analogs. The
calculated lipophilicity of a compound is denoted by the abbreviation cLogP (Lipinski et al., 2001).
Numerous publications discuss the optimum lipophilicity range for producing "druglikeness," since lipophilicity influences not only ligand-protein affinity, but also absorption,
distribution, metabolism, and excretion (ADME). According to Johnson et al. (2018), the optimum
molecular LogD value for improving ADME features in an oral medicine is between 1 and 3.
Because the goal of drug design is to optimize ADME properties while simultaneously maximizing
potency, it is critical to assess potency in relation to lipophilicity.
Lipophilic efficiency (LipE) is a measure that normalizes potency according to the
molecule's lipophilicity (T. W. Johnson et al., 2018). LipE can be estimated using the following
equations:
𝐿𝑖𝑃𝐸(𝑃) = −𝐿𝑜𝑔(𝐼𝐶50) – 𝑐𝐿𝑜𝑔𝑃

Equation 3.3-4

𝐿𝑖𝑃𝐸(𝐷) = −𝐿𝑜𝑔(𝐸𝐶50) − 𝐿𝑜𝑔𝐷 Equation 3.3-5
Usually, 𝐿𝑖𝑝𝐸 along with 𝑐𝑙𝑜𝑔𝑃 and potency are visualized together on single plot, all is
needed is 𝑐𝑙𝑜𝑔𝑃 on the x-axis, potency on the y-axis and LipE visualized as a diagonal line
between x-y-axis with slope of 1. For example: 𝑌 = 𝑚𝑥 + 𝑏 is an equation for a linear line. 𝑌 =
(1)𝑥 + 1 would identify as LipE of 1 and 𝑌 = 1𝑥 + 2 would identify as LipE of 2. A LipE Plot is
shown below:

62

Figure 3.3-2 An example of LIPE Plot.
Illustrates an example of a typical LipE plot with calculated lipophilicity (cLogP) on the x-axis and
pEC50 on the Y-axis.
LipE is a measure that is used to assess the drug-likeness of a molecule by correlating its
potency with lipophilicity (Lipinski et al., 2001). A therapeutic molecule's desirable characteristic
is a balance of high potency and low clearance. While high potency reduces the likelihood of
nonspecific binding, low clearance, in part defined by lipophilicity, has an impact on how a
chemical interacts in a number of biological processes or on ADME properties (Lipinski, 2000).
Additionally, Shultz (2013) published an article establishing a connection between LipE and
enthalpy-driven binding (Shultz, 2013). Consequently, it is believed that compounds having a high
LipE value are likely to be driven by enthalpy and have higher specificity.
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3.4.Chromatography
3.4.1. Introduction
Chromatography is a popular technique that is utilized as part of a scientific method to
separate individual components from a mixture (Skoog et al., 2007) Chromatography can be used
alone or in tandem with other instruments. If chromatography is used to separate and purify
components that could be collected for later use, it is called preparatory chromatography. An
example of a preparatory chromatography in biochemistry is the use of nickel beads to purify
His-tagged fused protein. If chromatography is used in tandem with other instruments, and a
small volume of sample in microliters is injected. The sample is separated via chromatography
and individual components are identified using other instruments, this is referred to as analytical
chromatography. An example of analytical chromatography is LCMS. In LCMS, different types of
columns can be used with different solvents to separate a mixture. Shortly after the mixture is
separated, it is automatically injected into the mass spectrometer for identification.
Chromatography is a technique that is only used to separate a mixture. However, another
technique or instruments is needed for identification (Skoog et al., 2007).
3.4.2. Mobile and stationary phase.
In chromatography different techniques are utilized to separate a mixture and a mixture
is separated based on its interaction with stationary phase (Skoog et al., 2007). Every
chromatography includes a mobile phase and a stationary phase. A mobile phase could either be
a gas or a liquid that is utilized to carry the sample through the column (among other things). A
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stationary phase on the other hand could be liquid or solid and could be arranged as a packed
column, adhered on the side of the column or on a flat surface.
Thin layer chromatography is an example of planar chromatography it is one of the
simplest and oldest chromatography techniques used to monitor the progress of a chemical
reaction. In planar chromatography, the mobile phase moves through the stationary phase by
capillary action or gravity. On the other hand, if the stationary phase is packed or adhered to the
side of the tube, with the mobile phase running through it under pressure or with gravity, it is
called column chromatography. Column chromatography employs either a liquid or a gaseous
mobile phase. Size exclusion chromatography is one type of liquid column chromatography
(Skoog et al., 2007).
The type of stationary phase one can utilize depends on the purpose of the experiment
and the condition requirements of the sample. For example, thin layer chromatography utilizes
a flat surface that is used to monitor the progress of a chemical reaction, and it can only be used
using a liquid mobile phase. The purpose of the experiment utilizing TLC was to monitor the
progress of chemical reaction and the condition requirement was that the sample be stable in
liquid. Furthermore, this is an analytical chromatography technique in which the sample used is
no longer viable for use. On the other hand, if the purpose of the experiment is to purify a
component from a mixture by size, it would be best if a packed column is used (Skoog et al.,
2007).

65

3.4.3. Separation of components.
The separation of mixture is based on the interaction of components with stationary and
mobile phase. The components with greater affinity to the stationary phase tend to elute later
than the components with less affinity. After the sample is passed through the column, it is eluted
and the elution passes the detector giving a chromatogram. On a typical chromatography
chromatogram, the x-axis is the time and the y-axis is the signal. The eluted components in the
sample are identified as peaks and the time it takes for a sample to elute with respect to when it
was injected, is called retention time (tR).

Figure 3.4-1. A typical chromatogram of a mixture containing two components.
The small peak in the chromatogram was eluted much earlier than the larger peak indicating little
to no interaction with the stationary phase. Additionally, the area of each peak can be used as an
indication of difference in concentration of each component eluted from column.
Figure above shows a typical chromatogram of a mixture containing two components.
One of the components had little to no interaction with the stationary phase, therefore it was
eluted shortly after it was injected. The elution time for a component with little to no interaction
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with the stationary phase is called dead or void Time (𝑡𝑀 ). This is an important parameter that
can be used to calculate the time a component spends in the stationary phase (Skoog et al., 2007).
Adjusted retention time: 𝑡𝑅′ = 𝑡𝑅 − 𝑡𝑀

Equation 3.4-1

𝑡𝑅′ as shown in equation 3.4-1, is called adjusted retention time and it represents the
actual time an analyte was retained in the column. Another experimental quantity that is widely
used to compare the migration rates of solutes in columns is called retention factor (k). The
retention factor is more ideal to use when comparing elution times as it doesn’t depend on
column geometry or volumetric flow rate. Therefore, results from different columns exhibiting
different conditions should have a similar retention factor (Skoog et al., 2007).
Retention factor: 𝑘𝐴′ =

𝑡𝑅 −𝑡𝑀
𝑡𝑀

Equation 3.4-2

Retention factor (𝑘𝐴′ ) is calculated by dividing adjusted retention time for a component
by void time as shown in equation 3.4-2. Furthermore, the retention factor between two analytes
from one sample can be used in comparison, providing a value called the selectivity factor (𝛼).
The selectivity factor is calculated by dividing the retention factor of the analyte that was retained
in the column for a longer period of time by the retention factor of the less strongly held analyte.
According to the definition, it is always the larger value of the retention factor divided by the
smaller value, therefore the selectivity factor is always greater than unity. The equation used to
calculate the selectivity factor is shown below.
Selectivity factor: 𝛼 =

′
𝑘𝐵
′
𝑘𝐴

Equation 3.4-3

The selectivity factor 𝛼 and the Retention factor 𝑘 are typically used to calculate and to compare
the resolving power or resolution of a column. The resolving power or the resolution of a column
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is based on the spacing and the width between two peaks. This brings in the idea of column
efficiency (Skoog et al., 2007)
3.4.4. Calculations for Column efficiency.
Column efficiency is the measure of the dispersion of a peak. It is usually explained using
the concept of theoretical plates. This model assumes that a column is split into a large number
of plates, with the sample being equilibrated between the stationary and mobile phases within
each plate. The analyte descends the column as the equilibrated mobile phase is transferred from
one plate to the next. A column with a high efficiency would have a high number of theoretical
plates, so more peaks can be separated. The number of theoretical plates is related to the length
of the column and the height of the individual plates, as shown in equation 3.4-4.
Numbers of Plates: 𝑁 =

𝐿
𝐻

Equation 3.4-4

The number of plates in a column is directly proportional to the length of the column (𝐿)
and inversely proportional to the height of each plate (𝐻). Since the plate is theoretical and not
visible to the eye, it is suggested that the height of the theoretical plate can be visualized and
measured using a peak shaped like a gaussian distribution. The suggested measurement of plate
height is proportional to the variance squared divided by the length of a column.
𝐻=

𝜎2

Equation 3.4-5

𝐿

Unfortunately, Equation 3.4-5 cannot be applied directly to an experimental chromatogram since
the length of a column is not one of the variables. Therefore, it needs to be converted. One can
obtain the variance of a solute peak in terms of time (𝜏) and relate it to the variance in terms of
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length (𝜎). The proposed correlation between the variance in terms of time (𝜏) and the variance
in terms of length (𝜎) is as follows:
𝜏=

𝜎

Equation 3.4-6

𝐿/𝑡𝑅

𝐿/𝑡𝑅 is the average linear velocity of the solute. Using figure 3.4-3 (𝜏) can be approximated as:
𝑊 = 4𝜏

Equation 3.4-7

Solving equation 3.4-7 for (𝜏) and replacing (𝜏) in equation 3.4-6 and solving for (𝜎) gives:
𝐿𝑊

𝜎 = 4𝑡

Equation 3.4-8

𝑅

Replacing variance (𝜎) in equation 3.4-5 with Equation 3.4-8 gives:
𝐿𝑊 2

𝐻 = 16𝑡

𝑅

2

Equation 3.4-9

Lastly plate height in equation 3.4-4 is replaced with equation 3.4-9 giving us:
𝑡

2

𝑁 = 16 (𝑊𝑅 )

Equation 3.4-10

Equation 3.4-10 provides a way of calculating the number of theoretical plates (𝑁) from
an experimental chromatogram using the width (𝑊) and retention time (𝑡𝑅 ) of an analyte peak.
(Skoog et al., 2007)
3.4.5. Factors affecting column efficiency
So far, it has been discussed how the analyte peak's shape may be utilized to determine
the number of theoretical plates. However, the factors that can influence the peak's shape have
yet to be discussed. The peak of an analyte is generally shaped like a gaussian distribution, in
which the band width is attributed to random fluctuations in the duration that the analyte spends
in the stationary or mobile phase. The Van Deemter equation is focused on identifying the causes
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of random fluctuation, as well as how these factors vary depending on flow rate and their
influence on theoretical plate height. The Van Deemter equation 3.4-11 that relates the flow rate
to theoretical plate height.
𝐻 ≅𝐴+

𝐵
𝑢𝑋

+ 𝐶𝑢𝑋 Equation 3.4-11

According to Van Deemter Equation, the height of the theoretical plates is affected by the
flow rate 𝑢𝑋 due to: Multiple path term (A), longitudinal Diffusion (B), and Resistance to mass
transfer (C) (Skoog et al., 2007).
The multiple path term in the Van Deemter equation assumes that a sample while passing
through the column takes multiple paths. If there are irregularities in the path, the path length
will vary and the analyte will spread, increasing the width of the band and elution time, and
therefore raising the value of the multiple path term. This could be minimized if the column is
packed properly without any irregularities in the bed and if the smaller bead size is used. Multiple
path term only applies to packed columns, typically in liquid chromatography. Additionally,
multiple path term is independent of the flow rate, as shown in Figure 3.4-4.
The term longitudinal diffusion (B) defines how a sample or analyte diffuses as it travels
through a column. Diffusion rate is strongly reliant on mobile phase speed. The higher the flow
rate, the less time a sample must diffuse. Longitudinal diffusion can be reduced by raising the
flow rate so that components have less time to diffuse across the column. Figure 3.4-4 depicts
the longitudinal diffusion term and its impact on the height of the theoretical plate as flow rate
increases. This term is almost insignificant in liquid chromatography it is primarily used in gas
chromatography.
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Lastly, resistance to mass transfer consists of two terms: stationary phase and mobile
phase mass transfer. When applied to a column with a solid stationary phase and a liquid mobile
phase, the stationary phase mass transfer term is directly proportional to the time required for a
species to be adsorbed and desorbed, whereas the mobile phase mass transfer is proportional
to the square of the particle diameter of the packing material. To simplify, resistance to mass
transfer is based on the equilibration time of an analyte and it is highly dependent on the flow
rate. If the flowrate is very high, not all particles would have enough time to interact with the
stationary phase and some would even leave behind causing an increase in band width. The
adsorption and desorption of the sample can be controlled with temperature, decreasing the
equilibration time by increasing the temperature would lead to smaller resistance to mass
transfer term.
To summarize, the Van Deemter equation suggests that to reduce plate height and
increase the number of plates, one can use packing material with smaller diameters and choose
an optimum flow rate that is slow enough for the entire sample to interact with the stationary
phase but fast enough to avoid unnecessary diffusion.
3.4.6. Calculations for resolution from a chromatogram.
Resolution is how well our peaks are separated. The basis of calculating resolution is the
estimate of standard deviation of the peak with respect to time. Resolution or resolving power
for a column can be calculated using the equations below:
𝑅𝑆 =

2[(𝑡𝑅 )𝐵 − (𝑡𝑅 )𝐴 ]
𝑊𝐵 +𝑊𝐴

∆𝑡

= 𝑊𝑅

𝑎𝑣
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Equation 3.4-12

The retention time between two peaks is compared using Equation 3.4-12, which divides the
retention time by the sum of the widths of each peak. Equation 3.4-12 may be simplified further
by dividing both the top and bottom by 2, with the denominator becoming the average width of
the two peaks and the numerator change in retention time.
3.4.7. Ion Exchange Chromatography
Ion exchange chromatography is one of the ways of separating a mixture into its
components. It is a form of liquid column chromatography in which the mobile phase is liquid,
and the stationary phase is a solid packed into a column. Ion exchange chromatography in our
studies is used to extract proteins of interest from a mixture containing contaminants such as
other proteins or nucleotides.
Ion exchange chromatography separates mixtures based on charge. Therefore, the
number of options that are available in ion exchange chromatography is governed by the extent
to which the charge can be manipulated on the protein. Proteins are delicate molecules that
require specific buffer conditions to remain active and avoid denaturation. As a result, it is crucial
to establish these conditions in order to avoid protein damage (Marshak, 1996)
The very first factor that needs to be considered before utilizing protein purification via
ion exchange is the pH range for the protein of interest. An initial rough estimate can be made
based on the nature of the natural environment of the protein. For a protein from a cell at
physiological pH, a pH of 7.4 is a good guess and the choices of buffers can then be determined.
Empirical activity experiments at pH of 7.4 must be performed using different choices of buffers
to determine the best buffer with the most activity. Furthermore, more experiments need to be
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done to test the stability of proteins under different pHs to determine the pH range (Marshak,
1996).
The charge on the protein is the next parameter that must be obtained. This is influenced
by the pH of the buffer and the protein's isoelectric point (pI). The isoelectric point of a protein
is ruled by the amino acid content. This may be calculated by averaging the pK a values of each
amino acid within the protein, or sometimes it can be obtained empirically. The protein is
positively charged if the pH of the buffer is lower than the pI. The protein is negatively charged if
the pH of the buffer exceeds the protein’s pI.
The following step is to identify which type of stationary phase is appropriate for our
protein of interest. The stationary phase for ion exchange chromatography is composed of a
polymer material having functional groups attached to the surface. For cation exchange, the
functional groups are acidic, while for anionic exchange, they are basic. If the protein's surface
charge is positive, a cation exchange stationary phase is employed, and if it is negative, an anion
exchange column is used. It is also advised to employ a buffer with a buffering ion with the same
charge as the charge on the column matrix. The TRIS buffering ion, for example, is positively
charged and is a suitable candidate for anion exchange chromatography because it does not
compete with negatively charged proteins for positively charged stationary phase.
So far, we've classified the optimum pH range and buffer compatibility, which would allow
proper interaction between the matrix and the protein while also maintaining protein stability.
The next step is to identify the ideal conditions that can be used to remove the protein from the
matrix. As previously described, in ion exchange chromatography, the protein is separated based
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on the surface charge. The greater the charge difference, the tighter the binding. The pH of the
buffer regulates (to a certain extent) the strength of the interaction and aids in protein binding
to the matrix. However, once the protein is bound to the matrix, salt is used to overcome the
matrix-protein interaction and to replace the protein with its ion. Mini purification procedures in
an Eppendorf tube can be used to experimentally test the range of salt concentrations needed
to elute a protein of interest.
Typically, a 1.5ml Eppendorf tube with 1 ml of matrix and a total 1.5 ml sample size can
be used with a variation in salt concentration. After spinning the Eppendorf tubes, the
supernatant from the top can be collected and tested for protein activity. Typically, the protein
should be absent at a low salt concentration and present at a high salt concentration. If the results
do not give good yield or separation, they can be further modified by using different types of salt,
changing the buffer pH or by using a stronger or weaker ionic matrix. After the necessary
optimizations are made, the protein of interest can then be separated from a mixture and elution
with the protein of interest can then be detected using a UV detector for preparatory ion
exchange chromatography (Marshak, 1996)
Ion exchange chromatography separates a mixture based on charge. The charge of a species
depends on pH, and the pH determines the choices of available buffers that can be used. From
the multiple choice of buffers, buffers with the same charge on buffering ion as the matrix are
recommended. Lastly, a salt gradient or isocratic conditions can be used to purify and extract
proteins of interest.
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3.4.8. Gel Filtration Chromatography
Gel filtration chromatography, or size exclusion chromatography, is another term for this
technique. As the name implies, the mixture is separated according to the size of the
components. The larger molecules are eluted faster than the smaller molecules. This is due to
the longer path taken by the smaller molecule through the stationary phase. After the sample
mixture is loaded, the sample is pushed by the mobile phase where smaller molecules are pushed
into the pores of the porous beads and larger molecules are pushed into the space between the
beads. The space between the beads is referred to as the void volumes. Molecules travelling in
void volume tend to travel at the same speed as the mobile phase. The large molecule's elution
time may be used to determine the spacing between the beads, whilst the smaller molecule's
elution can be used to calculate the column’s total volume. Typically, the void volume of the
majority of gel filtration resins is 1/3rd of the resin's total packed volume (Marshak, 1996)
3.4.9. Gel Filtration Selection of stationary phase.
Gel filtration chromatography separates mixtures by utilizing the pores in the matrix
hence, the resin is the most critical component of gel filtration. The type of resin that may be
employed is dictated by the equipment, the size of the target protein, and the desired resolution.
Before utilizing the protein purification via size exclusion, it is important to determine the
optimum resin. There are different resins available with variable range of particulates that can
be separated. The first step is to ensure that the target protein is within the resin range of
purification. It is recommended that the size of the target protein is somewhere in the middle of
the recommended resin range of purification. Next it is to determine the size of the beads.
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Usually, smaller beads tend to give better separation however they also have higher back
pressure with slow flow rate. therefore, it depends on the equipment and the backpressure a
column can handle. Additionally, all beads have a recommended range of pressure, exceeding
the range of pressure may destroy the beads, the packing of the column or both. Lastly, there are
different types of beads available with composition implemented hydrophobic and hydrophilic
properties.
3.4.10. Gel Filtration Tips for better separation.
Lastly, when utilizing gel chromatography for protein purification, certain things can be
done to improve the resolution or separation. Among them is column packing. A gel filtration
column must be evenly packed without bubbles. Having bubbles in the column would increase
the width of the elution peak. As mentioned before, the choice of beads should be based on the
size of the target protein and the size of the target protein should be in the middle of the
recommended range of purification. However, this is not always true. It is possible for a molecule
smaller in size to elute faster than a larger molecule. This is possibly due to the shape of the
molecule. The better way of determining the optimum beads for purification is to run the sample
and the target protein should elute somewhere in the middle of the void and total volume.
Another thing that can impact the resolution is the dimensions of the column. To improve the
resolution, it is usually recommended to use a longer and taller column than a wider column
(Marshak, 1996)
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3.5. Förster resonance energy transfer (FRET).
Fluorescence resonance energy transfer or Förster resonance energy transfer (FRET) is a
method that makes use of fluorescence to identify the interaction of two molecules (Lakowicz,
2006a). The level of interaction is identified based on the amount of energy transferred. The
energy is transferred without the use of photons and is the consequence of a long-range dipoledipole interaction between two molecules. These two molecules are identified as donor and
acceptor. The donors and acceptors are chosen depending on their excitation and emission
characteristics (Piston & Kremers, 2007). The donor's emission should be at the same
wavelength as the acceptor's absorption. As a result, as the donor is about to emit, the energy
is transferred to the acceptor, and the acceptor, rather than the donor, emits light (Lakowicz,
2006b). The quantity of energy transferred between two molecules is inversely proportional to
their distance. As a result, if two molecules contact, the interaction may be detected using
FRET. FRET is characterized by a decline in donor and a gain in acceptor emission fluorescence.
3.5.1. FRET as a molecular ruler
As mentioned above, FRET is utilized to identify interactions between two fluorescently
labeled molecules, although it cannot be directly quantified. FRET or FRET efficiency (Eapp) is
determined by monitoring the magnitude of the acceptor's and donor's intensity changes
(Lakowicz, 2006b). FRET efficiency (Eapp) is defined in general as the proportion of excited
donors that transfer energy to the acceptor. More specifically, FRET efficiency is calculated
using the equation below.
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𝐸𝑎𝑝𝑝 =

𝑅0 6
𝑅0 6 +𝑟 6

Equation 3.5-1

FRET efficiency is shown to be equal to the ratio of Forster radius (𝑅0 ) divided by the
sum of Forster radius (𝑅0 ) and the distance between acceptor and donor (𝑟). This equation is
significant because it establishes a relationship between changes in the magnitude of
fluorescence and the distance between acceptor and donor, and therefore between two
molecules.
Forster Radius (𝑅0 ) used to calculate FRET Efficiency represents the distance at which
half the excited donor molecule transfers energy to the acceptor. It is calculated specifically
using the equation below:
𝑅0 = 9.7 ∙ 102 (𝜅 2 ∙ 𝑛−4 ∙ 𝑗 ∙ 𝑞𝑑 )

1⁄
6

Equation 3.5-2

Forster Radius is affected by the donor's orientation factor (𝜅 2 ), index of reflection
(𝑛−4 ), overlap integral (𝑗), and quantum yield (𝑞𝑑 ) (Lakowicz, 2006b; RM, 1995). The
orientation factor refers to the angle of the dipole moment between acceptor and donor. The
orientation factor ranges between 0 to 4. If the dipole moments of the acceptor and donor are
perpendicular, the value is zero if they are parallel, the value is four. In other words, if the
dipole moments are aligned, the transfer of energy becomes very efficient. Typically, a constant
value of 2/3 is used for the orientation factor. Overlap integral (𝑗) is the calculated overlap of
the area between donor fluorescence emission and acceptor excitation. The greater the
overlap, the more efficient the energy transfer is (Lakowicz, 2006a).
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To recap, FRET is a technique used to determine the interaction of two molecules. This
interaction is quantified in terms of energy transfer between acceptor and donor. The acceptor
and donor are chosen based on the maximum overlap of donor emission and acceptor
excitation, as well as geometry, a high quantum yield for the donor and a high extinction
coefficient for the acceptor. FRET can only detect an interaction between an acceptor and a
donor if they are within 10 nm of one another (Lakowicz, 2006b). This means that a solution
containing both acceptor and donor at concentrations of up to 1 mM can be used before both
donor and acceptor are less than 10 nm apart introducing significant background, making this
technique useful in studying molecular interaction in biological studies.
3.5.2. FRET Efficiency.
As previously stated, FRET is a process in which energy is transferred from donor to
acceptor. FRET is determined indirectly by comparing the magnitude of the donor and
acceptor's fluorescence. If there is an interaction, the donor's fluorescent emission will
decrease and the acceptor's fluorescent emission will increase. As a result, FRET efficiency may
be determined solely by the change in the magnitude of the donor or acceptor fluorescence
intensity (Lakowicz, 2006a).
If the FRET efficiency is measured solely based on the increase in the magnitude of the
acceptor fluorescence, it is called sensitized emission. In a perfect world, one would excite the
donor and the increase in acceptor emission would be a pure measurement of the transfer of
energy. However, this is not true. The observed change in the magnitude of acceptor emission
is contaminated by the direct excitation of the acceptor and bleed through of the donor
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emission into the acceptor detection channel. In the studies presented here, FRET efficiency
was calculated based only on donor quenching with negligible bleed through of the acceptor at
this observed wavelength therefore corrections that are typically needed for sensitized
emission are no longer necessary. FRET efficiency based on donor quenching is calculated using
the following equation:

𝐸𝑎𝑝𝑝 = (1 −

𝐹𝐷𝐴 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 )
𝐹𝐷 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 )

),

Equation 3.5-3,

where 𝐹𝐷𝐴 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 ) is the emission of the donor in the presence of acceptor integrated over
the entire emission wavelength range; similarly, 𝐹𝐷 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 ) is the integrated emission of the
donor in the absence of the acceptor. Using the expressions 𝐹𝐷𝐴 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 ) = 𝑘𝐷𝐴 𝑤 𝐷 and
𝐹𝐷 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 ) = 𝑘𝐷 𝑤 𝐷 with 𝑘𝐷𝐴 and 𝑘𝐷 being adjustable parameters and 𝑤 𝐷 is the area under
the normalized donor emission we obtain (Raicu et al., 2009):
𝐹𝑅𝐸𝑇𝑎𝑝𝑝 = (1 −

𝑘𝐷𝐴 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 )
𝑘𝐷 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 )

)

Equation 3.5-4

In our analysis hereafter, in the absence of spectral unmixing of the composite donor plus
acceptor emission spectra, we make the approximation that 𝑘𝐷𝐴 is equal to the fluorescence
intensity detected at maximum of the donor emission. After calculating 𝐹𝑅𝐸𝑇𝑎𝑝𝑝 , the data is
fitted to equation 3.5-5 defined in Raicu et al. (Raicu & Singh, 2013) using non-linear regression
(GraphPad Prism). Fits were used to estimate pairwise FRET efficiency (EAD), based on total
concentration of the donor (DT), and the concentration of the complex ([AD]). The concentration
of the complex is calculated using equation 3.5-11.
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𝐹𝑅𝐸𝑇𝑎𝑝𝑝 =

1
𝐷𝑇

∙ ([𝐴𝐷] ∙ 𝐸𝐷𝐴 )

Equation 3.5-5

The equation above is used to calculate FRET between donor acceptor under the
assumption that the interaction is between one donor and one acceptor and the donor always
binds next to the acceptor within in the allowable space (Raicu et al., 2007).
3.5.3. Estimating complex concentration [AD].
The interaction between helicase and DNA was monitored using FRET. The helicase is part
of HCV NS3 fused with yellow fluorescent protein (YFP-NS3h) titrated with fluorescently labeled
single stranded or partially double stranded oligonucleotide. YFP-NS3h used in this study is
identified as a donor while fluorescent molecule on the oligonucleotide is an acceptor.
Titration were performed by adding 1-2 µl of fluorescently labeled oligonucleotide to YFPNS3h in the cuvette. The sample is excited at 450 nm and an initial emission spectrum is collected,
with subsequent spectra taken after adding oligonucleotide. Typically, if there is an interaction
between helicase and oligonucleotide the emission of the donor YFP-NS3h would decrease with
an increase in acceptor emission. The data is then collected as a batch of spectra with a decrease
in donor emission and an increase in acceptor emission. We assume that the observed decrease
in donor emission is due to the helicase binding with the oligonucleotide. The correlation of
acceptor and donor binding and forming a complex can be interpreted as:
𝐴 + 𝑛𝐷 ↔ 𝐴𝐷𝑛

Equation 3.5-6

Equation above, does not account for all different type of interaction possible between
acceptor and donor but assumes that only one form of donor acceptor complex is formed when
n donors bind to one acceptor. The “n” in equation 3.5-6 is the stoichiometry coefficient.
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Unfortunately, equations above cannot be applied as-is since it is impossible to measure the
concentration of each free species in the cuvette. However, while performing the experiment,
the total concentration of donor and acceptor is known. Using the known total concentration of
donor and acceptor added to the cuvette, the concentration of free donor and acceptor can be
calculated using the relationship below.
[𝐴] = [𝐴𝑇 ] − [𝐴𝐷𝑛 ]

Equation 3.5-7

[𝐷] = [𝐷𝑇 ] − 𝑛[𝐴𝐷𝑛 ]

Equation 3.5-8

Furthermore, the interaction between acceptor and donor is identified by calculating the
binding affinity or dissociation constant as shown in Equation 3.5-9 and Equation 3.7-10
respectively.
[𝐴𝐷 ]

𝑛
𝐾𝑎 = [𝐴][𝐷]
𝑛

𝐾𝑑 =

Equation 3.5-9

[𝐴][𝐷]𝑛

Equation 3.5-10

[𝐴𝐷𝑛 ]

In our studies, dissociation constant Kd is typically used which is the reciprocal of binding
affinity Ka. Equation 3.5-8 through 3.5-10 were then used to derive the Equation 3.5-11 to
calculate complex concentration in the cuvette from the known total acceptor and donor
concentration added to the cuvette.
[𝐴𝐷𝑛 ] =

(𝐾𝑑 +[A𝑇 ]+n[D𝑇 ])±√(𝐾𝑑 +[A𝑇 ]+n[D𝑇 ])2 −4𝑛[𝐷𝑇 ][𝐴𝑇 ]
2

Equation 3.5-11

Lastly, complex concentration [AD] in Eq. 3.5-5 is replaced with Eq. 3.5-11, where FRET efficiency
data from Eq. 3.5-4 is fitted in Eq. 3.5-5 and pairwise FRET efficiency is then estimated.
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3.5.4. FRET chapter summary.
All FRET experiments are done in a cuvette containing 500 µl of sample with donor (YFP)
covalently bonded to the helicase from HCV NS3. The sample is excited at 450 nm and the
emission spectrum is collected with maximum emission at 520 nm. In the same cuvette, YFPNS3h is titrated with 1-2 µl of acceptor (TAMRA, MAX, Hexachlorofluorescein or TYE) labeled
oligonucleotide and subsequent spectrum is collected. An interaction between helicase and
oligonucleotide is assumed if decrease in donor emission at 520nm is observed. Using Eq. 3.5-4,
the FRETapp is calculated. Where 𝑘𝐷 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 ) is the maximum fluorescence emission at 520
nm from the sample containing only the donor and 𝑘𝐷𝐴 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 ) is the maximum fluorescence
emission at 520 nm from the sample containing both donor and acceptor. The calculated FRETapp
using Eq. 3.5-4 along with the acceptor concentration is then plotted and the data is fitted to Eq.
3.5-12 or 3.5-5 to estimate pairwise FRET efficiency (𝐸𝐷𝐴 ).

𝐹𝑅𝐸𝑇𝑎𝑝𝑝 =

1
(𝐾𝑑 + [A 𝑇 ] + n[D𝑇 ]) ± √(𝐾𝑑 + [A 𝑇 ] + n[D𝑇 ])2 − 4𝑛[𝐷𝑇 ][𝐴𝑇 ]
) ∙ 𝐸𝐷𝐴 ]
∙ [(
𝐷𝑇
2
Equation 3.5-12

FRET is assumed based on the estimated value of 𝐸𝐷𝐴 . An experiment with lower value for
𝐸𝐷𝐴 is assumed to conduct less FRET than an experiment with higher 𝐸𝐷𝐴 and since FRET is used
to estimate interaction between helicase and oligonucleotide, with more FRET we assume that
the helicase is binding closer or near the acceptor whereas with less FRET, helicase is binding
farther away from the acceptor.
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Additionally, it’s important to emphasize that the FRET theory used to fit the data using Eq
3.5-12 or Eq. 3.5-5 assumes that only one helicase molecule binds to the oligonucleotide at a
time, i.e. the helicase and oligonucleotide forms heterodimers. At the same time, in relating ADn
to the dissociation constant, we allowed the heterooligomer size to take an arbitrary value n. To
reconcile this two apparently contradicting assumptions with one another, we would add the
third assumption, which is that the helicase that binds closest to the acceptor is the only one
involved in FRET; any additional helicase up to order n is assumed to be so far away that it does
not transfer energy to the donor. (Please refer to reference (Raicu et al., 2007) for additional
details regarding the FRET theory.) As such, this analysis is to be regarded as preliminary, and
future work should attempt to refine the FRET theory.
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3.6.Differential scanning fluorimetry (DSF)
Typically, the DSF or thermal shift assay is used to detect the interaction of a protein and
a ligand. The interaction between protein and ligand is quantified on the assumption that the
protein is stabilized upon binding. The stability of the protein is then determined by measuring
the temperature at which it unfolds, and the unfolding of the protein is determined by the degree
of the fluorescence change. The observed fluorescence is due to a linear correlation between
unfolded protein and the SYPRO orange dye's measured fluorescence. The change in
fluorescence of the SYPRO orange dye employed in the test is proportional to the concentration
of hydrophobic groups exposed during protein unfolding (Chaires, 2008; Ericsson et al., 2006).
The raw data is simply the change in fluorescence as a function of temperature, with
fluorescence plotted on the Y-axis and temperature recorded on the X-axis. The data acquired
initially exhibits a low fluorescence, but as the temperature rises, the protein unfolds, increasing
the fluorescence. Numerous samples with varying ligand concentrations give data relating the
unfolding temperature to the ligand concentration. Multiple samples' data are then displayed on
a single graph, clearly illustrating the relationship between melting temperature and ligand
concentration. This is useful in determination of EC50 or compound needed to cause a change in
the melting temperature by 50% (EC50). The determination of EC50 is discussed in detail later in
Chapter 3.8.2.
3.6.1. Estimating melting temperature (Tm)
The raw data collected from the instrument with fluorescence on the y-axis and
temperature on the X-axis typically presents a sigmoidal curve. The inflection point in the middle
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of the sigmoidal curve corresponds to the halfway of the protein unfolding process, commonly
referred to as the melting temperature (Tm). Tm is at the inflection point with the steepest slope,
which could be calculated by taking the first derivative of the curve. Unfortunately, this method
doesn’t differentiate between noise, data, or an artifact with tendencies of providing false Tm
values. Therefore, curve fitting method proposed by Ng et al.(2019) was used via a software
called TSA CRAFT (https://sourceforge.net/projects/tsa-craft/). The curve fitting model based on
the Boltzmann equation is a sigmoidal function that is fitted to the sigmoidal curve from the raw
data providing Tm values. TSA-CRAFT, is open source and takes raw data from the instrument
modified into a CSV file as an input. The raw data as CSV file is then fitted to the Equation 3.6-1
and if the data fits the overall shape of a typical sigmoidal curve, a Tm value is then estimated.
𝐹𝑜𝑏𝑠 (𝑇) = 𝐹𝑚𝑖𝑛

𝐹𝑚𝑎𝑥 −𝐹𝑚𝑖𝑛
1+ 𝑒

𝑇 −𝑇
( 𝑚 )
𝑎

Equation 3.6-1

In equation above, Fobs is the observed fluorescence at each temperature (T), Fmin is the minimum
observed fluorescence, Fmax is the maximum observed fluorescence, and a is the hill slope.
3.6.2. Estimation of EC50
The Tm values collected from fitting Equation 3.6-1 were plotted against the ligand
concentration and fitted to equation below via prism:
𝑇𝑚 𝑜𝑏𝑠 =

∆𝑇𝑚 𝑚𝑎𝑥 [𝐿]
𝐸𝐶50 +[𝐿]

+ 𝑇𝑚 0

Equation 3.6-2

Equation 3.6.2 relates 𝑇𝑚 𝑜𝑏𝑠 to [L], EC50, and ∆𝑇𝑚 𝑚𝑎𝑥 . Data fit to this equation can be used to
estimate the amount of compound needed to cause a change in the melting temperature by 50%
(EC50). Again, Tm-obs is the Tm value calculated from Equation 3.6-1 at a specific ligand
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concentration [L], Tm-Max is the maximum change in Tm, and Tm-0 is the melting temperature of
Mac1 in the absence of ligand in equation 3.6-2.
3.6.3. Estimating binding affinity (Kd)
While it is straightforward to explore the interaction of a protein and a ligand using DSF,
obtaining the binding constant is not as straightforward. As a result, a novel approach suggested
by Bai et al. (2019) was employed to extract and calculate the binding constant from DSF data.
From unfolding curves, a single temperature is chosen near the unfolding transition and the
fraction of protein that is still folded. This results in constant temperature system based on
protein folding/unfolding and ligand binding/unbinding coupled equilibria as shown below:
[𝑈] + [𝐿] ↔ [𝐹] + [𝐿] ↔ [𝐹𝐿]
𝐾𝑈

𝐾𝐷

Equation 3.6-3

The above equation describes the relationship between a protein in its unfolded [U],
folded [F], or complexed [FL] state with a ligand [L]. The unfolded state of the protein can be
related to the folded state using an equilibrium constant for unfolding proteins, denoted as KU
(Bai et al., 2019; Lee et al., 2019). The folded state of the protein and ligand is related to the
formation of the protein-ligand complex via its equilibrium constant, denoted as kD, or
dissociation constant. Furthermore, the concentration of protein and ligand is related to the total
concentration as shown below.
[𝑃]𝑇 = [𝑈] + [𝐹] + [𝐹𝐿]
[𝐿]𝑇 = [𝐿] + [𝐹𝐿]
𝐾𝑈 =

[𝑈]
[𝐹]

𝐾𝐷 =

[𝐹][𝐿]

Equation 3.6-4
Equation 3.6-5

Equation 3.6-6

[𝐹𝐿]
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Equation 3.6-7

Once the data is collected, it is first normalized then it is fitted to following equation:
𝑓𝑢 =

[𝑈]
[𝑃]𝑇

[𝑈]

= [𝑈]+[𝐹]+[𝐹𝐿]

Equation 3.6-8

Equation 3.6-8 cannot be applied since the concentration of free ligand [F], free unfolded protein
[U] or bound complex [FL] is not known. Therefore equations 3.6-4, to 3.6-7 are applied to
equation 3.6-8 giving:
𝑓𝑢 =

[𝑈]
[𝐹][𝐿]
[𝑈]+[𝐹]+ (
)
𝑘𝑑

[𝑈]

=

[𝐿]
))
𝑘𝑑

[𝑈]

=

[𝑈]+[𝐹](1+ (

[𝑈]+

[𝑈]
[𝐿]
(1+ ( ))
𝑘𝑢
𝑘𝑑

=

1
1
[𝐿]
1+ (1+ )
𝑘𝑢
𝑘𝑑

Equation 3.6-9
Unfortunately, Equation 3.6-9 still needs to be further simplified because concentration
of Free ligand [L] is not known. The concentration of Free ligand [L] is calculated using quadratic
equation:
[𝐿] =

([𝐿]𝑇 −[𝑃]𝑇 − 𝐾𝑑 (1+𝐾𝑈 ))+√([𝐿]𝑇 −[𝑃]𝑇 − 𝐾𝑑 (1+𝐾𝑈 ))2 −4([𝐿]𝑇 𝐾𝑑 (1+𝐾𝑈 ))
2

Equation 3.6-10
The proportion of unfolded protein (𝑓𝑢 ) at various temperatures in the presence of varied ligand
concentrations may then be used to determine the dissociation constant using equation 3.6-9.
This equation is then plotted, with the fraction of unfolded protein on the Y-axis and ligand
concentration on the X-axis, and each point on the spectra represents fraction of unfolded
protein (𝑓𝑢 ) with ligand concentration [L].
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3.7.Selected Drugs from DSF Hits
Due to the recent pandemic, several labs around the world are trying to find drugs that
are already approved by the FDA to expediate the clinical trials. Below selected compounds from
the hits are described: Trifluoperazine (3.7.1), irinotecan (3.7.2), nifedipine (3.7.3), cefaclor and
cefatrizine (3.7.4), omeprazole and rabeprazole (3.7.5):
3.7.1. Trifluoperazine (antipsychotic drug)

Trifluoperazine is a widely used antipsychotic drug that is used to treat people with
schizophrenia. It is effective in small doses and considered safe since 1960s. It is believed to work
by blocking D1 and D2 receptors minimizing symptoms of schizophrenia (Marques et al., 2004).
Xiao at al. performed HT screening of approximately 1700 US FDA approved compounds against
human coronavirus strain OC43 and SARS-CoV-2. LLC-MK2 cells (Rhesus monkey kidney cells),
was transfected with human coronavirus (HCoV) strain OC43. SARS-CoV-2 virus was propagated
in Vero cells (African green monkey kidney cell). They measured IC50 (the Half-Maximal Inhibitory
Concentration), CC50 (the Half-Maximal Cytotoxic Concentration), and SI (Selectivity Index) via
immunofluorescence, quantitative RT-PCR and cell-cell fusion assay. They reported
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trifluoperazine 2HCl as one of compounds effective against OC43 and SARS-COV-2. They reported
CC50, IC50 and SI of >10, 3.36 and 3.08 µM respectively for OC43 and 29, 12 and 2.5 µM
respectively for SARS-CoV-2.
3.7.2. Irinotecan hydrochloride trihydrate (topoisomerase 1 inhibitor)

The goal of cancer chemotherapy is to eradicate cancer cells. [note chemotherapy
actually means “the treatment of disease by the use of chemical substances]. Most cancer
chemotherapy, however, uses cytotoxic agents meaning they are toxic to all living cells and their
mechanism of actions target essential part of cell cycle. During the cell cycle, a cell prepares itself
for cell division by replicating its genome. It is a continues process with checkpoints during which
the cell ensures there are no abnormalities before it progresses to next phase. During replication,
the DNA double helix supercoils when it is separated into two strands. Supercoiled DNA is
overwound, and if left unchanged, this torsion would eventually stop DNA replication. This
torsion in supercoiled DNA is relieved by enzymes called topoisomerases. There are two types of
topoisomerases called topoisomerases I and topoisomerases II. Topoisomerase II enzymes cleave
only one strand of the DNA, unwinds it and attaches it closing with one less coil. Topoisomerase
2 enzymes cleave both strands of DNA relaxing supercoil during DNA replication (Champoux,
2001).
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Irinotecan has been extensively studied as a topoisomerase I inhibitor since the late
1960s. It was approved for the treatment of cervical, lung, and ovarian cancer. Irinotecan inhibits
topoisomerase I by binding and forming ternary irinotecan–topoisomerase I–nicked DNA
complex and preventing topoisomerase release from DNA. Topoisomerases are usually active
during replication and inhibition of its release cause a collision with replication forks which results
in lethal double strand break. This DNA lesion acts as an initiator or apoptotic signal (Kciuk et al.,
2020).
The first protein recruited by this apoptotic signal is the ATM serine/threonine kinase. The
kinase then activated p53 tumor suppressor protein. P53 then activates the p53 upregulated
modulator of apoptosis (PUMA) protein, which is a pro-apoptotic protein. PUMA then activates
the BAX protein in cytosol and activated BAX protein binds to mitochondrial membrane with Bcl2 homologous antagonist BAK and opens VDAC voltage dependent anorectic channels. This
allows the release of Cytochrome C from mitochondria into cytosol (Kciuk et al., 2020).
After the release of Cytochrome C from mitochondria, it binds to apoptotic protease
activating factor 1 APAF-1 in presence of dATP and this forms a complex called apoptosome. this
apoptosome then interacts with Pro-Caspase-9 and activates it converting it into Caspase 9.
Caspase 9 then activates caspase 3 which acts as an endonuclease, cleaves cytosolic and nuclear
proteins and activates caspase-dependent DNase (Kciuk et al., 2020). This then leads to cleaved
DNA and cell death. Since cancer cells divide more frequently, they go through cell cycle more
frequently therefore they are affected more by this chemotherapy. The side effect of
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chemotherapy is caused by cells with similar growth rate as cancer cell however these side effects
are usually not permanent.
3.7.3. Nifedipine (calcium channel blocker)

Nifedipine is a calcium channel blocker in the dihydropyridine subclass that is prescribed
to patients as an antihypertensive medication (Pontremoli et al., 2005). During the depolarization
phase of smooth muscle cells, calcium ions enter via voltage-gated channels. Calcium ions are
taken up by cells, resulting in an increase in Ca2+ ion (Curtis & Scholfield, 2001). Intracellular
calcium then initiates a cascade that causes vessel contraction. When the concentration of
calcium ion (Ca2+) increases, it binds to calmodulins, forming a calcium-calmodulin complex (Ca2+
calmodulin). After that, the calcium-calmodulin complex interacts with myosin light chain kinases
(MLCK). When MLCK interacts with Ca2+ calmodulin, Ca2+ ions are transferred to MLCK, forming
Ca2+MLCK. Ca2+MLCK is a kinase that is activated and catalyzes the transfer of a phosphate group
from ATP to myosin, resulting in phosphorylated myosin. Phosphorylated myosin then interacts
with actin, causing smooth muscle cells to contract (Andersson & Högestätt, 2009). Nifedipine is
a calcium channel blocker that binds to voltage-gated channels, inhibiting cell Ca2+ uptake. A
decrease in intracellular Ca2+ ion effectively blocks the activation of the contraction cascade,
resulting in smooth muscle cell relaxation, dialysis, and decrease in blood pressure.
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3.7.4. Lactams: cefaclor and cefatrizine (antibiotics)

Cefaclor and cefatrizine belong to broad-spectrum cephalosporin class of β-lactam
antibiotics. β-lactam antibodies contain β-lactam ring in their molecular structure. β-lactam
antibiotics inhibiting the biosynthesis of cell walls which are composed of Peptidoglycan.
Peptidoglycan is a stacked layer of polysaccharides consist of alternating β-(1,4) linked Nacetylglucosamine (NAG) and N-acetylmuramic acid (NAM) (Sauvage & Terrak, 2016). Stacked
peptidoglycans are also cross-linked between the last glycine residue of one peptidoglycan and
the terminal alanine on the other strand. Formation of peptidoglycan is catalyzed by bifunctional
penicillin binding protein (PBP), with transglycosylase domain producing glycan strands and the
transpeptidase domain performing the crosslinking reaction. The mechanism for crosslinking
reaction includes serine at the active site forming an acyl intermediate with alanine. This acyl
intermediate is then attacked by glycine forming a cross-linked peptidoglycan (Shalaby et al.,
2020).
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The mechanism by which the PBP transpeptidase domain conducts the crosslinking
reaction is the same mechanism employed by the β-lactam family of antibiotics to inhibit this
enzyme. The catalytic serine attacks the carbonyl group of the β-lactam ring, causing ring opening
and formation of a stable covalent acyl-enzyme complex. The presence of an acyl-enzyme
complex blocks the catalytic site, causing peptidoglycan cross-linking to be inhibited (Sauvage &
Terrak, 2016). Bacterial cell walls become thinner due to a lack of cross linking between
peptidoglycan. Bacteria are thus unable to withstand osmotic impact, resulting in rupture and
death.
3.7.5. Imatinib methane sulfonate (tyrosine kinase inhibitor)

Imatinib Methane Sulfonate

Imatinib is an inhibitor specific to BCR-ABL tyrosine kinase. It is effective against chronic
myelogenous leukemia (CML) and gastrointestinal stromal (GIST) (Willig et al., 2020). Both CML
and GIST are caused by a genetic abnormality known as the Philadelphia Chromosome, which is
a cause of an abnormally expressed tyrosine kinase, resulting in uncontrolled cell proliferation
(Epstein et al., 2010).
The Philadelphia Chromosome is an abnormal chromosome 22 formed when a portion of
chromosome 9 is translocated to chromosome 22. The portion of chromosome 9 that is
translocated is an ABL protooncogene and it is translocated to chromosome 22 at the breakpoint
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cluster region (BCR), forming the BCR-ABL oncogene (Collins & Groudine, 1983). The
chromosome 22 that consists of the BCR-ABL fusion oncogene is called the Philadelphia
chromosome. The BCR-ABL oncogene encodes for a BCR-ABL tyrosine kinase. Tyrosine Kinases
are a family of enzymes that catalyze the phosphorylation of tyrosine residues or the transfer of
phosphate group from ATP to a tyrosine residue on a target protein. This target protein may play
an important role in cell proliferation, differentiation, metabolism, or apoptosis. Therefore,
tyrosine kinases are mediators of the signal transduction process that leads to the activation or
inactivation of important cell functions. In this case, BCR-ABL encodes for a BCR-ABL Tyrosine
kinase that allows the signal transduction process in infected cells to bypass the regulatory signals
controlling cell growth and differentiation (Epstein et al., 2010). This then results in uncontrolled
and unregulated cell proliferation and malignant transformation to become leukemic cells, which
causes the pathogenesis of CML. Imatenib is an inhibitor that specifically binds to the of BCR-ABL
gene encoded tyrosine kinase. It inhibits BCR-ABL activity by competitively interacting with the
ATP binding site on the tyrosine kinase blocking ATP from binding (Willig et al., 2020).
3.7.6. Benzimidazoles: omeprazole and rabeprazole (proton pump inhibitors)

Omeprazole was one of the first proton pump inhibitor approved for medical use in 1988,
and it was intended to address acid-related disorders. Subsequently several other proton pump
inhibitors (PPIs) were introduced including rabeprazole. Most PPIs are structurally and
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pharmacologically similar. They are benzimidazole derivatives in which a benzimidazole moiety
is linked to pyridine by a methyl sulfinyl group, with various substitutions on the pyridine or
benzimidazole rings. All PPIs are given in an inactive form which are modified and activated in
strong acidic conditions found in canaliculate of parietal cells. Parietal cells are epithelial cells in
the stomach that secrete hydrochloric acid (HCl) and intrinsic factor.
The mechanism of PPI activation is as follows: Due to acidic environment, second nitrogen
on benzimidazole gets protonated, forming a positive charge. Next, the lone pair on nitrogen of
pyridine transfers electron and forms a bond with 2nd carbon of imidazole on benzimidazole.
This leads to formation of cyclic intermediate between benzimidazole and pyridine and loss of
aromatic characteristic of imidazole. Next, the lone electron on nitrogen of imidazole transfer its
electrons reforming aromatic characteristic and breaking the sulfoxide ring leading to formation
of sulfonic acid intermediate (Figure 3.7-1). This sulfonic acid intermediate undergoes
intramolecular rearrangement to form pyridinium sulfonamide structure. This structure then
forms disulfide bond with proton pump leading to permanent inactivation and blocking the
release of stomach acid (Ward & Kearns, 2013).
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Figure 3.7-1: PPI Activation Mechanism: Omeprazole and Rabeprazole.
The mechanism of action of proton pump inhibitor was presented in (Ward & Kearns, 2013)
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4. Materials & Methods
4.1.Gene synthesis
To facilitate comparison between SARS-CoV-1 and SARS-CoV-2, a protein expression
vector was generated similar to the one used by Eglott et al. (2006). To this end, a codon
optimized open reading frame was synthesized by GenSript (Piscataway, NJ) that encodes the
Mac1 flanked by NheI and BamH1 restriction sites. This open reading frame was cloned into
pET21b to give plasmid pET21-COVID-Mac1. The pET11-COVID-Mac1 plasmid was used to
transform BL21(DE3) cells.

4.2.Protein purification (Mac1)
Colonies of BL21(DE3) cells harboring the pET21-COVID-Mac1 plasmid were used to
inoculate 3 ml of LB medium containing 100 mg/ml ampicillin. The starter culture was incubated
at 37 °C with shaking at 225 rpm. After the cells grew to an OD 600 of 1.0, they were transferred
to 1 liter of fresh medium containing ampicillin. After the cells reached an OD600 of 1.0 again,
protein production was induced with 1 mM isopropyl-β-D-thiogalactoside. After growing 16 h at
23 °C, the cells were harvested by centrifugation at 4,000 rpm, 4°C. The resulting cell pellet was
suspended in 25 mL of IMAC buffer (20 mM Tris pH 8, 0.5 M NaCl), sonicated on ice for five 1 min
bursts, with 2 min rests between, and clarified by centrifugation at 10,000g for 30 min. The
supernatant was loaded onto a 5 ml Ni-NTA column and the fractions were eluted with a step
gradient from 5 to 500 mM imidazole. Fractions containing the Mac1 domain protein (5 ml total)
were loaded on a 250 ml Sephacryl S300 gel filtration column and eluted with 10 mM MOPS, 150
mM NaCl. Concentration of the purified protein was determined by measuring absorbance at 260
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4.3.Protein purification (Nsp13-His-tag)
To produce Nsp13 with a His-tag on the N-terminal, a Nsp13 vector identical to that used
by Mickolajczyk et al. was employed (Mickolajczyk et al., 2020). This pET21b-COVID-N-His-nsp13
plasmid was used to transform BL21(DE3) cells. Transformed BL21(DE3) were used to start a 3 ml
starter culture that was grown overnight at 37 oC. Next day the starter culture was transferred to
a 1-liter fresh medium containing 1 ml of 50 mg/ml kanamycin. After the OD600 reached 0.7, the
temperature was then lowered to 23 oC (room temperature) and the culture was induced with 1
mL of 200 mM IPTG per liter of growth media. The cultures were left overnight (~16 hrs) at 23 oC
and harvested the next day by spinning down at ~5000 g for 15 minutes and the pellets was
resuspended in IMAC buffer (20 mM Tris pH 7, 0.5 M NaCl, 5mM imidazole). The resuspended
cells were sonicated on ice for five 1 min bursts, with 2 min rests between, and clarified by
centrifugation at 10,000g for 30 min. The supernatant was loaded onto a 5 ml Ni-NTA column
and the fractions were eluted with a step gradient from 5 to 300 mM imidazole. The fraction
collected at 300 mM imidazole was then dialyzed in GF buffer (20 mM Tris, pH 7, 50 mM NaCl, 1
mM EDTA, 0.1 mM DTT) + 20% glycerol and concentrated. The nsp13 protein (2 ml total) were
loaded on a 250 ml Sephacryl S300 gel filtration column and eluted with (20 mM Tris, pH 7, 50
mM NaCl, 1 mM EDTA, 0.1 mM DTT) + 20% glycerol. The protein was concentrated again and the
concentration of pure protein was estimated using an absorbance measurement at 260 nm and
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a molar extinction coefficient of 68785 M-1 cm-1 calculated using the ProtParam tool
(https://web.expasy.org/protparam/).

4.4.Isothermal Titration Calorimetry (ITC)
Binding of ADP-ribose to the SARS-CoV-2 Mac1 domain was measured using a Nano ITC
(TA Instruments). Before starting the measurement, samples of both ligand and protein were
diluted in 10 mM MOPS, 150 mM NaCl (pH 7) and were degassed at 400 mmHg for 30 minutes.
Measurements were taken at 20 °C by injecting 2.0 µl aliquots of 500 µM ADP-Ribose (Sigma) to
50 µM protein (175 µl initial volume) with 250 rpm stirring rate. Using Nano Analyze Software (v.
3.11.0), data were fitted by non-linear regression to an independent binding model. Briefly, after
baseline correction, background heats from ligand-to-buffer titrations were subtracted, and the
corrected heats from the binding reaction were used to find best fit parameters for the
stoichiometry of the binding (n), free energy of binding ( G), apparent enthalpy of binding ( H),
and entropy change ( S). Dissociation constants (Kd) were calculated from the G.

4.5.Differential Scanning Fluorimetry (DSF)
Assays were performed in 96-well PCR plates using an Eppendorf Mastercycler ep
Realplex Quantitative Realtime PCR thermocycler with each well containing 19 µl of Master-mix
and 1 µl of compound stock at 10 mM. The master-mix was prepared by adding 20 µl of 500 µM
Mac1, 2.5 µl 5000x SPYRO Orange protein gel stain (Sigma-Aldrich catalog #S5692) and 1977.5 µl
of buffer (20 mM MOPS, 25 mM NaCl, pH 7) with a final volume of 2 ml. The 96-well PCR plate
was then sealed with clear adhesive film and centrifuged at 1,100 RPM for 5 mins. In the
thermocycler, the temperature was raised from 20 °C to 95 °C at a rate of 2 °C per min while
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measuring fluorescence in the “TAMRA” channel. Each plate included both negative (DMSO) and
positive (ADP-ribose) controls. Tm’s were calculated either by finding the peaks in plots of dF/dT
vs T, or by fitting the data to equation 1 using either GraphPad Prism or TSA-craft
(https://sourceforge.net/projects/tsa-craft/). (Lee et al., 2019)
𝐹𝑜𝑏𝑠 = 𝐹𝑚𝑖𝑛

𝐹𝑚𝑎𝑥 −𝐹𝑚𝑖𝑛
1+𝑒

𝑇 −𝑇
( 𝑚 )
𝑎

(Equation 1)

In Eq. 1, Fobs is the observed fluorescence at each temperature (T), Fmin is the minimum
observed fluorescence, Fmax is maximum observed fluorescence, and a is a Hill slope.
Compound EC50 value were determined in a similar way as for the initial screening but by
varying the concentration of each compound. Concentration-response assays were also
performed in 96-well PCR plates with 19 µl of Mastermix with 1 µl of the highest concentration
of the compound in the first row and lowest concentration in last row. Observed Tm values (Tm
obs)

at each compound concentration (L) were fit to equation 2.
𝑇𝑚 𝑜𝑏𝑠 =

∆𝑇𝑚 𝑚𝑎𝑥 ∗[𝐿]
𝐸𝐶50 +[𝐿]

+ 𝑇𝑚

(Equation 2)

In equation, Tm max is the maximum change in Tm, where Tm is the melting temperature
of the protein in the absence of compounds, and EC50 is the ligand concentration causing a
change in Tm that is half of Tm max.

4.6.Molecular modeling & virtual screening
Computational ligand screening was performed on various forms of the Mac1 protein,
including both the unliganded (6WEY and 6VXS) and ADP-ribose-bound forms (6W02), using the
program AutoDock VINA. (Trott and Olson., et al. 2010) These protein structures were
computationally screened with NCI mechanistic set (library 1) and the NIH clinical collection NCI
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(library 2). The protein files were downloaded directly from the protein data bank and processed
as follows before submitting for screening. All solvent molecules (HETATM) were removed from
the files. Polar hydrogen atoms were added and Kollman charges were included in the protein
files. The converted protein and ligand file libraries (both pdbqt files) were uploaded to a parallel
computing cluster and run with the following parameters: Energy difference = 4 Number of
recorded modes = 20 Exhaustiveness was set to 12. Docking box location was configured prior
to using AutoDock tools. After the docking calculation was complete, the locations, orientations,
and binding affinities of the top candidates were examined by the aid of UCSF Chimera and
tabulated for comparison.

4.7.Nucleotide sequence of pET28-COVID-Nsp13
ATGGGCGCGGTGGGTGCGTGCGTTCTGTGCAATAGCCAAACCAGCCTGCGCTGCGGTGCGTGC
ATTCGTCGTCCGTTCCTGTGCTGCAAGTGCTGCTACGATCACGTTATCAGCACCAGCCACAAGCTGGTGC
TGAGCGTTAACCCGTATGTGTGCAACGCGCCGGGTTGCGACGTGACCGATGTTACCCAGCTGTACCTGG
GTGGCATGAGCTACTATTGCAAGAGCCACAAACCGCCGATTAGCTTCCCGCTGTGCGCGAACGGTCAAG
TTTTTGGCCTGTATAAGAACACCTGCGTGGGTAGCGACAACGTTACCGATTTCAACGCGATTGCGACCTG
CGACTGGACCAACGCGGGTGATTACATTCTGGCGAACACCTGCACCGAACGTCTGAAACTGTTCGCGGC
GGAAACCCTGAAGGCGACCGAGGAAACCTTTAAACTGAGCTACGGTATCGCGACCGTGCGTGAGGTTC
TGAGCGACCGTGAACTGCACCTGAGCTGGGAAGTGGGTAAACCGCGTCCGCCGCTGAACCGTAACTAC
GTGTTCACCGGTTATCGTGTTACCAAGAACAGCAAAGTGCAGATTGGCGAGTATACCTTTGAAAAGGGT
GACTACGGCGATGCGGTGGTTTATCGTGGTACCACCACCTACAAACTGAACGTGGGCGATTACTTCGTT
CTGACCAGCCACACCGTGATGCCGCTGAGCGCGCCGACCCTGGTTCCGCAGGAACACTATGTGCGTATC
ACCGGTCTGTACCCGACCCTGAACATTAGCGACGAGTTCAGCAGCAACGTTGCGAACTATCAGAAAGTG
GGTATGCAAAAATATAGCACCCTGCAAGGTCCGCCGGGTACCGGCAAGAGCCACTTTGCGATTGGCCTG
GCGCTGTACTATCCGAGCGCGCGTATTGTTTATACCGCGTGCAGCCATGCGGCGGTGGATGCGCTGTGC
GAAAAGGCGCTGAAATACCTGCCGATCGACAAATGCAGCCGTATCATTCCGGCGCGTGCGCGTGTTGAA
TGCTTCGACAAGTTTAAAGTGAACAGCACCCTGGAGCAGTATGTGTTCTGCACCGTTAACGCGCTGCCG
GAAACCACCGCGGACATCGTGGTTTTTGATGAGATTAGCATGGCGACCAACTACGATCTGAGCGTGGTT
AACGCGCGTCTGCGTGCGAAGCACTACGTTTATATTGGTGACCCGGCGCAACTGCCGGCGCCGCGTACC
CTGCTGACCAAGGGTACCCTGGAGCCGGAATATTTCAACAGCGTGTGCCGTCTGATGAAAACCATCGGT
CCGGATATGTTTCTGGGTACCTGCCGTCGTTGCCCGGCGGAAATTGTGGACACCGTTAGCGCGCTGGTT
TATGATAACAAGCTGAAAGCGCACAAGGACAAAAGCGCGCAGTGCTTCAAGATGTTTTACAAAGGTGT
GATCACCCACGACGTTAGCAGCGCGATCAACCGTCCGCAAATTGGCGTGGTTCGTGAGTTCCTGACCCG
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TAACCCGGCGTGGCGTAAGGCGGTTTTTATCAGCCCGTACAACAGCCAGAACGCGGTGGCGAGCAAAA
TTCTGGGTCTGCCGACCCAGACCGTTGATAGCAGCCAAGGCAGCGAATACGACTATGTGATCTTCACCC
AAACCACCGAAACCGCGCACAGCTGCAACGTGAACCGTTTTAACGTTGCGATTACCCGTGCGAAAGTGG
GTATCCTGTGCATTATGAGCGACCGTGATCTGTATGATAAACTGCAATTCACCAGCCTGGAAATCCCGCG
TCGTAATGTGGCGACCCTGCAACTCGAGCACCACCACCACCACCACTGA

4.8.Amino acid sequence of Nsp13-Histag encoded by pET28-COVID-Nsp13
Translation 611 a.a. MW=68110.32 g/mol
MGAVGACVLCNSQTSLRCGACIRRPFLCCKCCYDHVISTSHKLVLSVNPYVCNAPGCDVTDVTQLYL
GGMSYYCKSHKPPISFPLCANGQVFGLYKNTCVGSDNVTDFNAIATCDWTNAGDYILANTCTERLKLFAAET
LKATEETFKLSYGIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTKNSKVQIGEYTFEKGDYGDAVVY
RGTTTYKLNVGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYPTLNISDEFSSNVANYQKVGMQKYSTLQGPP
GTGKSHFAIGLALYYPSARIVYTACSHAAVDALCEKALKYLPIDKCSRIIPARARVECFDKFKVNSTLEQYVFCTV
NALPETTADIVVFDEISMATNYDLSVVNARLRAKHYVYIGDPAQLPAPRTLLTKGTLEPEYFNSVCRLMKTIGP
DMFLGTCRRCPAEIVDTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHDVSSAINRPQIGVVREFLTRNPAW
RKAVFISPYNSQNAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCNVNRFNVAITRAKVGILCIMSDRD
LYDKLQFTSLEIPRRNVATLQLEHHHHHH*

4.9.Nucleotide sequence of pET21-COVID-Nsp13
The Nsp13 vector was generated similar to the one used by Mickolajczyk et al.
(Mickolajczyk et al., 2020).
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGAGGTGCTGTTCCAGGGACCTC
ATATGGCTGTGGGTGCCTGCGTCCTGTGCAACTCTCAGACTTCTCTGAGGTGCGGTGCTTGCATCAGGC
GTCCCTTCCTGTGCTGCAAGTGCTGCTACGACCACGTCATCTCTACTTCACACAAGCTGGTGCTGTCCGTC
AACCCATACGTGTGCAACGCTCCTGGTTGCGACGTGACTGACGTCACCCAGCTGTACCTGGGTGGCATG
TCCTACTACTGCAAGAGCCACAAGCCTCCCATCAGCTTCCCACTGTGCGCCAACGGTCAGGTGTTCGGCC
TGTACAAGAACACCTGCGTGGGTTCTGACAACGTCACTGACTTCAACGCTATCGCCACCTGCGACTGGAC
TAACGCTGGCGACTACATCCTGGCCAACACTTGCACCGAACGTCTGAAGCTGTTCGCTGCCGAGACCCT
GAAGGCTACTGAGGAAACCTTCAAGCTGTCATACGGAATCGCCACTGTGAGAGAGGTCCTGTCTGACCG
CGAACTGCACCTGTCATGGGAGGTCGGCAAGCCTAGGCCACCTCTGAACAGAAACTACGTGTTCACCGG
CTACCGTGTCACTAAGAACTCCAAGGTGCAGATCGGAGAGTACACCTTCGAAAAGGGCGACTACGGAG
ACGCTGTGGTCTACAGGGGCACCACTACCTACAAGCTGAACGTGGGAGACTACTTCGTCCTGACTTCCC
ACACCGTGATGCCACTGAGCGCCCCTACTCTGGTCCCCCAGGAACACTACGTGCGCATCACCGGCCTGTA
CCCAACTCTGAACATCAGCGACGAGTTCTCCAGCAACGTCGCTAACTACCAGAAAGTGGGTATGCAGAA
GTACTCTACCCTGCAGGGTCCTCCTGGAACTGGCAAGTCACACTTCGCTATCGGACTGGCCCTGTACTAC
CCTTCCGCTAGAATCGTCTACACTGCTTGCTCTCACGCTGCTGTGGACGCTCTGTGCGAAAAGGCCCTGA
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AGTACCTGCCCATCGACAAGTGCTCACGCATCATCCCAGCTAGGGCCAGAGTCGAATGCTTCGACAAGT
TCAAGGTGAACTCCACCCTGGAGCAGTACGTGTTCTGCACTGTCAACGCTCTGCCCGAAACTACCGCCGA
CATCGTGGTCTTCGACGAGATCTCTATGGCTACCAACTACGACCTGTCAGTGGTCAACGCTCGCCTGCGT
GCCAAGCACTACGTCTACATCGGAGACCCTGCTCAGCTGCCTGCCCCCAGAACTCTGCTGACCAAGGGT
ACTCTGGAGCCAGAATACTTCAACTCTGTGTGCCGCCTGATGAAGACCATCGGACCAGACATGTTCCTG
GGTACTTGCAGGAGATGCCCTGCTGAAATCGTGGACACCGTCTCTGCCCTGGTGTACGACAACAAGCTG
AAGGCTCACAAGGACAAGTCAGCCCAGTGCTTCAAGATGTTCTACAAGGGCGTGATCACCCACGACGTC
TCTTCAGCCATCAACCGTCCTCAGATCGGAGTGGTCCGCGAGTTCCTGACTCGTAACCCTGCTTGGAGGA
AGGCCGTCTTCATCTCTCCCTACAACTCACAGAACGCTGTGGCCTCCAAGATCCTGGGACTGCCCACTCA
GACCGTCGACTCCAGCCAGGGTAGCGAATACGACTACGTGATCTTCACCCAGACTACCGAGACTGCTCA
CTCTTGCAACGTGAACCGTTTCAACGTCGCTATCACCAGGGCCAAGGTCGGCATCCTGTGCATCATGTCC
GACAGGGACCTGTACGACAAGCTGCAGTTCACCAGCCTGGAGATCCCTCGCCGTAACGTGGCCACTCTG
CAGTAA

4.10.

Amino acid sequence of His-Nsp13 encoded by pET21-COVID-Nsp13

Translation 624 a.a. MW=69425.81 g/mol
MGSSHHHHHHSSGLEVLFQGPHMAVGACVLCNSQTSLRCGACIRRPFLCCKCCYDHVISTHKLVLS
VNPYVCNAPGCDVTDVTQLYLGGMSYYCKSHKPPISFPLCANGQVFGLYKNTCVGSDNVTDFNAIATCDWT
NAGDYILANTCTERLKLFAAETLKATEETFKLSYGIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTK
NSKVQIGEYTFEKGDYGDAVVYRGTTTYKLNVGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYPTLNISDEFS
SNVANYQKVGMQKYSTLQGPPGTGKSHFAIGLALYYPSARIVYTACSHAAVDALCEKALKYLPIDKCSRIIPAR
ARVECFDKFKVNSTLEQYVFCTVNALPETTADIVVFDEISMATNYDLSVVNARLRAKHYVYIGDPAQLPAPRT
LLTKGTLEPEYFNSVCRLMKTIGPDMFLGTCRRCPAEIVDTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHD
VSSAINRPQIGVVREFLTRNPAWRKAVFISPYNSQNAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCN
VNRFNVAITRAKVGILCIMSDRDLYDKLQFTSLEIPRRNVATLQ*

4.11.

Malachite green assay

4.11.1. Theory
Malachite green assay can only be used to quantify a reaction in which inorganic
phosphate is released or used as part of the reaction. In this assay a complex is formed between
malachite green, ammonium molybdate and free inorganic phosphate under acidic conditions.
Free inorganic phosphate binds to ammonium molybdate forming a phosphomolybdate complex
which then interacts with three molecules of malachite green dye causing a change in color.
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Under acidic conditions ATP can be acid catalyzed, to prevent this from happening Sodium citrate
is added to neutralize the sample. The sample is then left to develop color for 10 minutes and
the absorbance at 630nm is collected. The resulting change in absorbance at 630nm is directly
correlated to the concentration of inorganic phosphate in the solution.
4.11.2. Protocol
Materials:
1. 3x ml 4.2% Ammonium Molybdate in 4.0N HCl.
2. 1x ml 0.045% Malachite Green
3. 0.1x 35% Sodium Citrate.
Mix 3x ammonium Molybdate with 1x Malachite Green making a phosphate reagent with
0.002% Tween 20. To test a 100 µl sample for free phosphate, add 800ul of phosphate reagent
and immediate add 0.1x sodium citrate. Let the reaction sit for 10 minutes until the color
develops and take the absorbance reading at 630nm.
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4.12.

FRET oligonucleotide sequence
Substrate

Name

5’-TGGCGACGGCAGCGAT[TAM]

3TAM

5’-[TAM]TGGCGACGGCAGCGA

5TAM

5’-[HEX]TGGCGACGGCAGCGAGGC-3’

HEX18

T[TAM]
5’-TGGCGACGGCAGCGA
3’-ACCGCTGCCGTCGCTTTTTTTTTTTTTTTT-5’

3TAM:5’15

5’-[TAM]TGGCGACGGCAGCGA
3’-ACCGCTGCCGTCGCTTTTTTTTTTTTTTTT-5’

5TAM:5’15

5’-TGGCGACGGCAGCGAT[TAM]
3’-TTTTTTTTTTTTTTTACCGCTGCCGTCGCT-5’

3TAM:3’15

5’-[TAM]TGGCGACGGCAGCGA
3’-TTTTTTTTTTTTTTTACCGCTGCCGTCGCT-5’

5TAM:3’15

5’-TGGCGACGGCAGCGAT[TAM]
3’-TTTTTTTTTTTTTTTACCGCTGCCGTCGCT-5’

3TAM:3’10

5’-[TAM]TGGCGACGGCAGCGA
3’-TTTTTTTTTTACCGCTGCCGTCGCT-5’

5TAM:3’10

5’-TGGCGACGGCAGCGAT[TAM]
3’-TTTTTACCGCTGCCGTCGCT-5’

3TAM:3’5

5’-[TAM]TGGCGACGGCAGCGA
3’-TTTTTACCGCTGCCGTCGCT-5’

5TAM:3’5

5’-[HEX]TGGCGACGGCAGCGAGGC-3’
3’-TTTTTTTTTTTTTTTACCGCTGCCGTCGCT-5’

HF18:3’15

5’-[HEX]TGGCGACGGCAGCGAGGC-3’
3’-TTTTTTTTTTACCGCTGCCGTCGCT-5’

HF18:3’10

TYE45
[TYE]TGGCGACGGCAGCGAGGCACCGATCACATGTTTTTTTTTTTTTTT-3’
3’-ACCGCTGCCGTCGCT
[TYE]TGGCGACGGCAGCGAGGCACCGATCACATGTTTTTTTTTTTTTTT-3’

TYE45:comp15

3’-ACCGCTGCCGTCGCTCCGTG
[TYE]TGGCGACGGCAGCGAGGCACCGATCACATGTTTTTTTTTTTTTTT-3’

TYE45:comp20

3’-ACCGCTGCCGTCGCTCCGTGGCTAG
[TYE]TGGCGACGGCAGCGAGGCACCGATCACATGTTTTTTTTTTTTTTT-3’

TYE45:comp25

3’-ACCGCTGCCGTCGCTCCGTGGCTAGTGTAC
[TYE]TGGCGACGGCAGCGAGGCACCGATCACATGTTTTTTTTTTTTTTT-3’

TYE45:comp30

3’-ACCGCTGCCGTCGCTCCGTGGCTAGTGTACAAAAA
[TYE]TGGCGACGGCAGCGAGGCACCGATCACATGTTTTTTTTTTTTTTT-3’

TYE45:comp35
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5. Using FRET to determine the binding of NS3h to ssDNA and dsDNA
5.1.Introduction
The Hepatitis C virus is a blood-borne pathogen that infects the liver. It is transmitted via
blood and it is transported to the liver via the bloodstream. The focus of this study is the hepatitis
C virus nonstructural protein 3 (NS3). NS3 and NS4A are co-translated as part of a larger
polyprotein but are then cleaved into two distinct mature proteins. NS3 is a 70 kDa, 630aa
multifunctional protein having an N-terminal serine protease and a C-terminal helicase (Raney et
al., 2010). The protease found at NS3's N-terminal is 180 amino acids long, whereas the helicase
located at the NS3's C-terminal is 430 amino acids long. Despite being covalently bound as part
of the same nonstructural protein, both helicase and serine protease can be expressed, and
isolated independently of each other.
Non-Structural Protein 3 is a critical component in HCV replication. The helicase domain
of the NS3 protein is referred to as NS3h. Helicases are recognized as motor proteins that utilize
the energy generated by nucleotide hydrolysis to catalyze the separation of double-stranded
nucleic acids. In the work presented here, the binding of NS3h with DNA was monitored using
FRET. FRET is a method that makes use of fluorescence to identify the interaction between two
molecules. In all the FRET assays studied here, the donor is Yellow Fluorescent Protein (YFP),
covalently attached to the helicase domain of nonstructural protein 3 from the Hepatitis C Virus.
FRET in our studies is characterized as pairwise FRET efficiency and is estimated based on donor
quenching. Estimated pairwise FRET efficiency was used to examine factors effecting binding,
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such as the length of the duplex, the length of a single-stranded overhang, and whether the
overhang had a 5’ or 3’ end.

5.2.Examining factors that could indirectly affect the donor emission.
Typically, the magnitude of a chemical reaction or an experiment is determined by the
measurable change occurring due to the chemical process. The measurable change is then
observed and collected as data, and the data is analyzed, adjusted, and fitted to an equation to
give parameters that provide information pertaining to the chemical reaction. One of the serious
mistakes one can make during this process is collecting data that is contaminated by the factors
effecting the measurable change other than the actual chemical reaction. In a typical FRET
experiment, binding between two molecules is estimated based on the observed fluorescence
emission of both the acceptor and donor. However, it is possible that fluorescence emission
might be contaminated by factors other than the transfer of energy between acceptor and donor.
Of course, it is already known that some of the factors that contaminate the results of FRET assays
are direct excitation and bleed through, but the correction for these contaminations is not
needed as FRET in this study is measured based on donor quenching. In this section of this
chapter, factors that could indirectly affect the fluorescence emission of the donor are examined.
Such factors include: effect on donor fluorescence emission due to helicase binding onto the
unlabeled oligonucleotide possible direct interaction of the oligonucleotide with yellow
fluorescent protein and effect on donor fluorescence in the presence of an acceptor. Additionally,
for comparison, a positive control titration of YFP-NS3h with a TAMRA labeled oligonucleotide
was also included.
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The effect on donor fluorescence emission due to helicase binding onto the
oligonucleotide or possible interaction of the oligonucleotide with yellow fluorescent protein was
examined by adding an unlabeled oligonucleotide into a cuvette with a sample containing YFPNS3h. In brief, concentrated and purified YFP-NS3h was dissolved in helicase dilution buffer (25
mM MOPS, 5 mM MgCl2, 1 mM DTT, 0.01 mg/ml BSA, and 0.01% Tritron X 100 at pH 7) to make
a 500 µl sample with a YFP-NS3h concentration of 100 nM. This sample was then transferred into
the cuvette. In a separate Eppendorf tube, an 18 nucleotide long unlabeled oligonucleotide was
also dissolved in the helicase dilution buffer, making a 2 µM unlabeled oligonucleotide solution.
The cuvette was placed in the Varian Cary Eclipse Fluorescence Spectrophotometer and the
sample was excited at 450 nm. Emission was collected in the range of 460-650 nm. At 450 nm,
the yellow fluorescent protein is excited and it emits between 520-530 nm. After the initial scan,
for each subsequent scan, a 1 µl aliquot of sample containing unlabeled oligonucleotide was
added to the cuvette, the sample was excited, and emission between 460-650 nm was collected.
After taking 17 subsequent spectrums, no change in YFP-NS3h was observed (fig. 5.2-1A).
Next, the effect on donor fluorescence in the presence of an acceptor was examined by
adding an 18 nucleotides long TAMRA labeled oligonucleotide into a cuvette with a sample
containing free yellow fluorescent protein. In brief, concentrated and purified yellow fluorescent
protein was dissolved in helicase dilution buffer, making a 500 µl sample with a YFP concentration
of 100 nM. This sample was then transferred into the cuvette. In a separate Eppendorf tube, an
18 nucleotides long TAMRA labeled oligonucleotide was also dissolved in the helicase dilution
buffer, making a 2 µM labeled oligonucleotide solution. The cuvette with the YFP sample was
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excited at 450 nm and emission was collected in the range of 460-650 nm. After the initial scan,
for each subsequent scan, a 1 µl aliquot of sample containing labeled oligonucleotide was added
to the cuvette, the sample was excited, and emission between 460-650 nm was collected. After
taking 10 subsequent spectrums, no change in YFP-NS3h was observed (data not shown).
Lastly, the donor fluorescence was observed by adding an 18 nucleotides long TAMRA
labeled oligonucleotide to the cuvette with a sample containing 100 nM YFP-NS3h. In brief,
concentrated and purified YFP-NS3h was dissolved in helicase dilution buffer, making a 500 µl
sample with a YFP-NS3h concentration of 100 nM. This sample was then transferred into the
cuvette. In a separate Eppendorf tube, an 18 nucleotides long TAMRA labeled oligonucleotide
was also dissolved in the helicase dilution buffer, making a 2 µM labeled oligonucleotide solution.
The cuvette with the YFP sample was excited at 450 nm and emission was collected in the range
of 460-650 nm. After the initial scan, for each subsequent scan, a 1 µl aliquot of sample containing
TAMRA labeled oligonucleotide was added and emission was collected. After taking 16
subsequent spectrums, a decrease in YFP-NS3h emission was observed (fig. 5.2-1B).
The FRETapp for each experiment was then calculated by using equation 3.5-4 and the data
is plotted in fig.5.2-1C. The data that was calculated using equation 3.5-4 was then fitted to
equation 3.5-5 to estimate pairwise FRET efficiency (EDA), which is shown in the form of a
histogram in fig. 5.2-1D.
The purpose of this section was to identify factors that could indirectly affect the
fluorescence emission of the donor. The first experiment was done to examine the effect on
donor fluorescence emission due to helicase binding onto the oligonucleotide or possible
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interaction of the oligonucleotide with yellow fluorescent protein. Upon adding 17 1 µl aliquots
of unlabeled oligonucleotide, no change in YFP-NS3h was observed. This data suggests that when
the YFP-helicase binds onto the oligonucleotide, the binding of the oligonucleotide doesn’t affect
YFP emission. This data could also be interpreted as either no interaction between YFP and
unlabeled oligonucleotide or no effect on donor emission due to the presence of unlabeled
oligonucleotide.
Next, the effect on donor fluorescence in the presence of an acceptor was examined by
adding an 18 nucleotides long TAMRA labeled oligonucleotide into a cuvette with a sample
containing free yellow fluorescent protein. Upon adding 17 1 µl aliquots of TAMRA labeled
oligonucleotide, no change in YFP-NS3h was observed.
This data suggests that the presence of an acceptor molecule in the same sample as the
donor doesn’t affect the fluorescence emission. This data could also be interpreted to mean that
there is no interaction between donor and acceptor, or at least not enough to actually affect
donor emission.
Lastly, the donor fluorescence was observed by adding an 18 nucleotides long TAMRA
labeled oligonucleotide to the cuvette with a sample containing 100 nM YFP-NS3h. A decrease in
YFP-NS3h emission was observed after adding 17 1 µl aliquots of TAMRA labeled oligonucleotide.
This data suggests that both YFP-NS3h (donor) and TAMRA labeled oligonucleotide (acceptor) are
needed to see a change in donor fluorescence emission. The change in donor emission is due to
helicase binding onto the oligonucleotide, bringing both acceptor and donor close enough so that
the energy is transferred between donor and acceptor.
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Figure 5.2-1 NS3h Titration with unlabeled DNA, and a TAMRA labeled oligonucleotide.
Panel A depicts a series of emission spectra taken with each addition of an unlabeled
oligonucleotide into 100 nM of YFP-NS3h. The experiment in panel B was carried out in the same
way as in panel A, except that the unlabeled oligonucleotide was replaced with a TAMRA-labeled
18 nucleotide long oligonucleotide. These experiments were conducted in a cuvette containing a
500 µl sample of YFP-NS3h dissolved in helicase buffer at a concentration of 100 nM. After adding
1 µl of 2 µM unlabeled or labeled oligonucleotide, the sample was excited at 450 nm and the
emission spectrum was collected. In total, 17 spectra were collected after each addition of
oligonucleotide. FRETapp for both experiments were calculated using equation 3.5-4 and the plot
is presented in panel C. The data in Panel C was then fitted to Equation 3.5-5 to give the Pairwise
FRET efficiency EDA shown in Panel D as a histogram representing energy transfer between donor
and acceptor, and next to it is a cartoon representation of how binding of YFP-NS3h to 3’TAMRA
labeled oligonucleotide is imagined.
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5.3. Estimating dissociation constant and stoichiometry constant.
The objective of this experiment is to estimate dissociation constant and the
stoichiometry constant from FRETapp using Eq. 3.5-5 or 3.5-12. The experiment was done in a
similar manner as other FRET titration assays. The donor fluorescence was observed by adding
an 18 nucleotides long HEX labeled oligonucleotide to the cuvette with a sample containing YFPNS3h. In brief, concentrated and purified YFP-NS3h was dissolved in helicase dilution buffer,
yielding a 500 µl sample with a YFP-NS3h concentration of 50 nM. This sample was then
transferred into the cuvette. In a separate Eppendorf tube, an 18 nucleotides long HEX labeled
oligonucleotide was also dissolved in the helicase dilution buffer, making a 2 µM labeled
oligonucleotide solution. The cuvette with the YFP sample was excited at 450 nm and emission
was collected in the range of 460-600 nm. After the initial scan, for each subsequent scan, a 1 µl
aliquot of sample containing HEX labeled oligonucleotide was added and emission was collected.
In total, 17 subsequent spectrums were collected and a decrease in YFP-NS3h emission was
observed with each addition of an oligonucleotide. The assay was then repeated with 75 and 100
nM concentrations of YFP-NS3h.
In total, three samples containing 50 nM, 75 nM, and 100 nM YFP-NS3h were titrated and
their emission spectra were recorded as shown in Fig. 5.3-1 A, B, and C, respectively. A decrease
in donor emission at 520nm was observed with each titration, and the maximums at 520 nm
were used to calculate the FRETapp using Eq. 3.5-4. In Eq. 3.5-4, 𝑘𝐷 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 ) is the maximum
fluorescence emission at 520 nm from the first sample containing only the donor and
𝑘𝐷𝐴 (𝜆𝐷 𝑒𝑥 𝜆𝐷 𝑒𝑚 ) is the maximum fluorescence emission at 520 nm from the subsequent samples
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containing both donor and acceptor. The calculated FRETapp using Eq. 3.5-4 along with the
acceptor concentration from each titration is then plotted (Fig. 5.3-1 D) and the data is fitted to
Eq. 3.5-5 or 3.5-12 to estimate pairwise FRET efficiency (𝐸𝐷𝐴 ) (Fig. 5.3-1 E) dissociation constant
and stoichiometry constant. The resultant dissociation constants of 18.3 ± 5.9 nM and
stoichiometry coefficients of 3.8 ± 0.3 were estimated using equations 3.5-5 or 3.5-12.
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Figure 5.3-1.Estimated dissociation constant and stoichiometry coefficients.
Three different concentrations of YFP-NS3h (donor) were titrated with HF18 (acceptor) and
emission spectra were recorded as shown in Panels A, B, and C. The maximums at 520 nm in
Panels A, B, and C were used to calculate FRETapp with equation 3.5-4. FRETapp and oligonucleotide
concentration were plotted (Panel D), and the data was fitted to Equation 3.5-5 to estimate FRET
efficiency (EDA), dissociation constant, and stoichiometry constant. The resultant dissociation
constants of 18.3 ± 5.9 nM and stoichiometry coefficients of 3.8 ± 0.3 were estimated using
equations 3.5-5 or 3.5-12. Panel E is the estimated EDA for each experiment shown in Panel D.
Its important to emphasize that the FRET theory used to fit the data in panel E of fig. 5.31 assumes that only one helicase molecule binds to the oligonucleotide at a time, i.e. the helicase
and oligonucleotide forms heterodimers. At the same time, in relating ADn to the dissociation
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constant, we allowed the heterooligomer size to take an arbitrary value, n. To reconcile these
two apparently contradicting assumptions with one another, we would add the third assumption,
which is that the helicase that binds closest to the acceptor is the only one involved in FRET; any
additional helicase up to order n is assumed to be so far away that it does not transfer energy to
the donor. This allows us, as the first approximation, to extract approximating information on n
from the law of mass action without unnecessarily complicating the fret theory represented by
equations 3.5-5. (Please refer to the reference Raicu et al., (2007) for additional details regarding
the fret theory.) As such, this analysis is to be regarded as preliminary, and future work should
attempt to refine the FRET theory so as to include liner oligomers of size n, thereby improving
the fit of the experimental fata shown in 5.3-1 Panel D.

5.4.Examine NS3h binding with partially dsDNA.
The purpose of this assay was to examine if different FRET app are observed with TAMRA
labeled on either end of the junction of partial dsDNA. The experiment was done using two
different partial double-stranded oligonucleotides labeled with TAMRA either next to or farther
from the junction. Typically, more FRET should be observed with an oligonucleotide that has an
acceptor molecule located right next to the helicase binding site than farther away. If this turns
out to be false, one explanation for the deviation could be that the oligonucleotide is wrapping
around the helicase. This appears unlikely because the helicase is a motor protein that moves the
DNA. Wrapping the DNA around would hinder its movement. Another explanation for the
deviation could be helicase binding to the double-stranded DNA. However, this is also improbable
because NS3h is an SF2 helicase and they are known to bind to single-stranded DNA or RNA.
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The effect of titrating YFP-NS3h with a partial dsDNA with an acceptor located on either
end of the junction was examined by adding 5’TAM-3’tail-10 or 3’TAM-3’tail-10 oligonucleotide
into a cuvette with a sample containing 125 nM YFP-NS3h. The experiment was conducted by
dissolving concentrated and purified yellow fluorescent protein in helicase dilution buffer,
making a 500 µl sample with a YFP concentration of 125 nM. This sample was then transferred
into the cuvette. In a separate Eppendorf tube, 5’TAM-3’tail-10 TAMRA labeled oligonucleotide
was also dissolved in the helicase dilution buffer, making a 5 µM TAMRA labeled oligonucleotide
solution. The cuvette with the YFP sample was excited at 450 nm and emission was collected in
the range of 460–650 nm. After the initial scan, for each subsequent scan, a 1 µl aliquot of sample
containing labeled oligonucleotide was added to the cuvette, the sample was excited, and
emission between 460-650 nm was collected. In total, 6 subsequent spectrums were collected
and a decrease in YFP-NS3h emission was observed with each addition of an oligonucleotide (fig.
5.4-1 A and B). The assay was then repeated with 3’TAM-3’tail-10.
The maximums at 520 nm from each titration were extracted and FRET app was calculated
using equation 3.5-4. Calculated FRETapp was then plotted against the oligonucleotide
concentration in fig. 5.4-1C. This data was then fitted to equation 3.5-5 in order to obtain pairwise
FRET efficiency (EDA). As expected, more FRETapp was estimated from the oligonucleotide with
TAMRA located next to the junction so that the helicase binds onto the ssDNA next to the
acceptor, causing more donor fluorescence quenching. Lower FRETapp was estimated with an
acceptor located at the far end of the junction or further away from the ssDNA helicase binding
site.
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Figure 5.4-1 Titration of YFP labeled NS3h with TAMRA-labeled on 3’ or 5’ end of partial dsDNA.
The emission spectrums of YFP-NS3h titration with 5’TAM-3’tail-10 or 3’TAM-3’tail-10
oligonucleotide are shown in panels A and B, respectively. A decrease in fluorescence at 520 nm
and an increase at 580 nm were observed. The maximums at 520 nm from each titration were
extracted and FRETapp was calculated using equation 3.5-4. Calculated FRETapp was then plotted
against the oligonucleotide concentration in panel C. This data was then fitted to equation 3.5-5
in order to obtain pairwise FRET efficiency (EDA). The EDA value for each oligonucleotide is shown
as a histogram in panel D. Panel E depicts the line structure of two different oligonucleotides
used in this experiment.

5.5.NS3h seems to bind to ssDNA in a specific orientation.
NS3h is a SF2 helicase that translocates unidirectionally in a 3’ to 5’ direction. In order to
translocate on DNA, the helicase needs to make specific conformational changes upon ATP
hydrolysis in order to move forward. Since the SP2 helicase family moves unidirectionally in the
3’ to 5' direction, it must also bind to the ssDNA with a specific orientation. To examine if helicase
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binds to ssDNA with a specific orientation, YFP-NS3h was titrated with a TAMRA-labeled
oligonucleotide at either 3’ or 5' end. If no difference in FRET app is observed, this would suggest
that YFP-NS3h doesn’t differentiate among these nucleotides upon biding. However, if a different
FRETapp is observed, this would suggest the helicase binds to the DNA with a specific orientation.
To examine if YFP-NS3h binds to the DNA in a specific orientation, the helicase was
titrated with TAMRA labeled on either the 5’ end or 3' end of an 18 nucleotides long
oligonucleotide. The experiment was done in a similar manner as others. The experiment was
conducted by dissolving concentrated and purified yellow fluorescent protein in helicase dilution
buffer, making a 500 µl sample with a YFP concentration of 100 nM. This sample was then
transferred into the cuvette. In a separate Eppendorf tube, 5’TAM oligonucleotide was also
dissolved in the helicase dilution buffer, making a 2 µM TAMRA labeled oligonucleotide solution.
The cuvette with the YFP sample was excited at 450 nm and emission was collected in the range
of 460–650 nm. After the initial scan, for each subsequent scan, a 1 µl aliquot of sample
containing labeled oligonucleotide was added to the cuvette, the sample was excited, and
emission between 460-650 nm was collected. The assay was then repeated with 5’TAM. In total,
17 subsequent spectrums were collected with each titration, and a decrease in YFP-NS3h
emission was observed with each addition of an oligonucleotide (fig. 5.5-1 A and B).
The maximums at 520 nm from each titration were extracted and FRET app was calculated
using equation 3.5-4. Calculated FRETapp was then plotted against the oligonucleotide
concentration in fig. 5.5-1C. This data was then fitted to equation 3.5-5 in order to obtain EDA fig.
5.5-1D.
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Figure 5.5-1 YFP-NS3h Titration with 3’ and 5’ TAM
The emission spectrums of YFP-NS3h titration with 3’TAM and 5’TAM oligonucleotides are shown
in panels A and B, respectively. The maximums at 520 nm from each titration were extracted and
FRETapp was calculated using equation 3.5-4. Calculated FRETapp was then plotted against the
oligonucleotide concentration in panel C. This data was then fitted to equation 3.5-5 in order to
obtain pairwise FRET efficiency, EDA. The EDA value for each oligonucleotide is shown as a
histogram in panel D.
The experiment was conducted to examine if the helicase binds to ssDNA with a specific
orientation. For this experiment, YFP-NS3h was titrated with a TAMRA-labeled oligonucleotide
covalently bound to the ssDNA at either 3’ or 5' end. Based on different estimates of pairwise
FRET efficiency (EDA) from each nucleotide, it seems that helicase was not bound randomly but
with a specific orientation.
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5.6. Using FRET to examine the effect of increasing the overhang on partial dsDNA.
The experiment was designed to determine if the size of the overhang on a partial dsDNA
affects the pairwise FRET efficiency. In other words, the location of the junction at which the
ssDNA meets with dsDNA remains the same while the length of the ssDNA changes. It was
expected that by increasing the available binding space for the helicase, more helicase would
bind and hence more FRET would be detected.
To investigate how the available size of the overhang on a partial dsDNA oligonucleotide
affects the helicase binding, YFP-NS3h was titrated with several partial dsDNA oligonucleotides
with varying overhang sizes while maintaining the oligonucleotide's double strand size constant.
The experiment was conducted in a similar fashion to previous ones. In brief, the experiment was
conducted by dissolving concentrated and purified yellow fluorescent protein in helicase dilution
buffer, making a 500 µl sample with a YFP concentration of 100 nM. This sample was then
transferred into the cuvette. In a separate Eppendorf tube, 5’TAM-3’tail-5 oligonucleotide was
also dissolved in the helicase dilution buffer, making a 2 µM TAMRA labeled oligonucleotide
solution. The cuvette with the YFP sample was excited at 450 nm and emission was collected in
the range of 460–650 nm. After the initial scan, for each subsequent scan, a 1 µl aliquot of sample
containing labeled oligonucleotide was added to the cuvette, the sample was excited, and
emission between 460-650 nm was collected. The assay was then repeated with 5 more samples:
5’TAM-3’tail-10, 5’TAM-3’tail-15, 3’TAM-3’tail-5, 3’TAM-3’tail-10, and 3’TAM-3’tail-5. In total,
10-20 subsequent spectrums were collected with each titration, and a decrease in YFP-NS3h
emission was observed with each addition of an oligonucleotide.
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The maximums at 520 nm from each titration were extracted and FRET app was calculated
using equation 3.5-4. Calculated FRETapp was then plotted against the oligonucleotide
concentration in fig. 5.6-1A and C. This data was then fitted to equation 3.5-5 in order to obtain
EDA fig. 5.6-1B and D.

Figure 5.6-1 Titration of YFP-NS3h with various length ssDNA overhang on partial dsDNA.
YFP-NS3h was titrated with various length overhangs at the 3’ end of partial dsDNA with TAMRA
labeled on either end of the duplex. Emission spectra was collected and FRET app was calculated
from donor quenching. (A, C) FRETapp was then fitted to binding isotherms to determine E DA as
shown in panel B and D.

The experiment was conducted to evaluate the effect of increasing the overhang size on
a partial dsDNA without increasing the dsDNA size. In other words, the junction where ssDNA
and dsDNA meet doesn’t change. It was expected that by increasing the available binding space
for the helicase, more helicase would bind and hence more FRET would be detected. Contrary to
our expectations, longer overhangs while keeping the junction at the same length resulted in
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reduced FRET. This might be because extra helicase proteins may be binding but they are
orientated in such a manner that they cannot participate in FRET.

5.7.Using FRET to identify the effect of increasing the duplex size
The experiment was conducted to determine the impact of moving the junction on a
partial dsDNA without increasing the total DNA size. It was assumed that more FRET would be
observed with smaller duplex. Chapter 4.12 contains the sequences of all the oligonucleotides
utilized in this study.
To evaluate the impact of increasing the duplex size on a partial dsDNA without increasing
the total DNA size, helicase was titrated using 45 nucleotides long TYE labeled oligonucleotide
duplexed with 15, 20 and 25 bases long complementary strands. The experiment was conducted
in a similar fashion to previous ones. The experiment was conducted by dissolving concentrated
and purified yellow fluorescent protein in helicase dilution buffer, making a 500 µl sample with a
YFP concentration of 100 nM. This sample was then transferred into the cuvette. In a separate
Eppendorf tube, 5’TYE oligonucleotide was also dissolved in the helicase dilution buffer, making
a 5 µM TYE labeled oligonucleotide solution. The cuvette with the YFP sample was excited at 450
nm and emission was collected in the range of 460–600 nm. After the initial scan, for each
subsequent scan, a 1 µl aliquot of sample containing labeled oligonucleotide was added to the
cuvette, the sample was excited, and emission between 460-600 nm was collected. The assay
was then repeated using three more sample containing: 5’TYE-comp15, 5’TYE-comp20, and
5’TYE-comp25. In total, 7 subsequent spectrums were collected with each titration and a
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decrease in YFP-NS3h emission was observed with each addition of an oligonucleotide (fig. 5.7-1
A, B, C, and D).
The maximums at 520 nm from each titration were extracted and FRET app was calculated
using equation 3.5-4. Calculated FRETapp was then plotted against the oligonucleotide
concentration in fig. 5.7-1E. This data was then fitted to equation 3.5-5 in order to obtain EDA fig.
5.7-1F.
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Figure 5.7-1 Titration of YFP-NS3h with varied duplex size on partial dsDNA.
Titrations of YFP-NS3h were performed using 1 µl aliquots of 5 µM dsDNA. TYE45, TYE45Comp15, TYE45-Comp20, and TYE45-Comp25 dsDNA were used for titration, and samples were
excited at 450 nm and emission spectra were obtained as shown in panels A, B, C, and D,
respectively. Panel E shows the calculate FRETapp from donor quenching. Panel F is calculated
pairwise FRET efficiency.
The purpose of this experiment was to assess the effect of increasing the duplex size on
a partial dsDNA without increasing the overall DNA size. With smaller duplexes, more FRET was
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observed suggesting helicase is binding towards the junction or multiple helicases are binding on
the ssDNA occupying the free space leading to helicase binding closer to the acceptor.

5.8.Summary
In this chapter, FRET was utilized to examine the interaction between helicase and
oligonucleotide, and it was calculated as pairwise FRET efficiency based on the decrease in donor
intensity due to fluorescence quenching. But before any FRET measurements were taken, factors
that could indirectly affect the fluorescence emission of the donor were examined. Those factors
include: change in donor fluorescence emission due to helicase binding onto the oligonucleotide,
possible interaction of the oligonucleotide with yellow fluorescent protein, and effect on donor
fluorescence in the presence of an acceptor alone.
Based on our data, no donor quenching was observed when YFP-NS3h was titrated with an
unlabeled oligonucleotide or when free YFP was titrated with a TAMRA-labeled oligonucleotide,
suggesting the donor quenching is not affected by oligo binding into the binding site of the
helicase and there is no interaction between donor and accepter (YFP and TAMRA) by
themselves. Donor quenching is observed only when both donor and acceptor are bound to their
respective molecules (helicase and DNA) and donor quenching is the result of helicase binding to
the oligonucleotide.
The next assay was to examine whether less FRET is observed from an acceptor and donor
located farther apart than those located closer to each other. This experiment was done using
two different partially dsDNA with TAMRA labeled on either end of the junction. This assisted us
in determining that the oligonucleotide behaves as expected upon binding. The results show that
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an acceptor located further away from a partial dsDNA junction exhibits less FRET than an
acceptor located directly adjacent to the junction or closer to helicase binding site.
Afterwards, the binding orientation of the helicase was examined. For this experiment, YFP-NS3h
was titrated with a TAMRA-labeled oligonucleotide covalently bound to the ssDNA at either 3’ or
5' end. Based on different estimates of pairwise FRET efficiency (EDA) from each nucleotide, it
seems that helicase must be bound with an orientation facing one way on the ssDNA.
Lastly, two experiments were done to examine how the size of the overhang versus the
duplex affects pairwise FRET efficiency. It was expected that increasing the size of the overhang
would allow more helicase to bind and hence more FRET would be detected. Contrary to our
expectations, longer overhangs resulted in reduced FRET. This might be because multiple helicase
proteins are bound but they are not orientated in such a manner that they can participate in
FRET. Whereas as expected, the size of the duplex correlated with FRET efficiency, greater
pairwise FRET efficiency was estimated with a smaller duplex and lower pairwise FRET efficiency
with a longer duplex.
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6. Variable nsp3 Mac1 Domain of SARS-CoV-2 retains the ability to bind ADP-ribose
6.1.Introduction
Antivirals designed to combat the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) will most likely target viral non-structural proteins required for viral replication. The
positive sense RNA genome of SARS-CoV-2 is 30,000 nucleotides long and contains numerous
open reading frames. The majority of the proteins that comprise the viral replicase are encoded
by the "rep 1ab" reading frame. Rep 1ab encodes for a 7,096 amino acid-long polyprotein that is
eventually cleaved by the viral proteases into 15 mature proteins. Parts of the SARS-CoV-2 rep
1ab polyprotein are remarkably similar to the rep 1ab protein of other coronaviruses (Figure 6.11), indicating that drugs targeting the SARS-CoV nonstructural proteins may be effective against
SARS-CoV-2. The largest variance occurs in a Nsp3 protein domain suspected of binding ADPribose, referred here as the "mac1" domain to distinguish it from the two downstream "SARS
unique macrodomains (SUDs)," which do not bind ADP-ribose.
Nsp3 is a large membrane-bound multidomain protein known to be essential for viral
replication and transcriptional complex formation (van Hemert et al., 2008), as well as for the
development of double membrane complexes (Angelini et al., 2013) It is encoded by Orf1a or
Orf1b as part of a large polyprotein and is cleaved into mature non-structural proteins by a
papain-like protease (Ziebuhr et al., 2000). The majority of variation in nsp3 between Coronavirus
1 and Coronavirus 2 occurs in the macrodomains near the protein's N-terminus. Macrodomains
in general are three-layered α/β/α / sandwich folds that are not limited to one function. While
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SARS-CoV-1 has three macrodomains in tandem, only the MAC1 macrodomain binds ADP ribose.
The Mac1 domain's amino acid sequences differ by 26% between SARS-CoV-1 and SARS-CoV-2.

Figure 6.1-1 Sequence divergence between potential drug targets in SARS-CoV and SARS-CoV2.
The SARS-CoV-2 rep 1ab peptide sequence was aligned with each of the PDB files listed, which
describe an atomic structure of a homologous region of the SARS-CoV-1 rep 1ab polyprotein.
Nsp’s are shown in sequence as black arrows (note: there is no “nsp11”, and the translational
frameshift occurs after nsp10). The percent of amino that differ in each protein is plotted. Nsp1
is and interferon antagonist. (Almeida et al., 2007) The Nsp3 Mac1 domain is studied here, the
Nsp3 SUD consists of tandem macrodomains that bind G-quadruplex structures, (Kusov et al.,
2015) Nsp dC is the C-terminus of the SUD, (M. A. Johnson et al., 2010) Nsp3pro is a papain-like
protease, (Báez-Santos et al., 2014) and Nsp3 RBD is another possible RNA binding domain.
(Serrano et al., 2009) Nsp5 is the main viral protease. (Akaji et al., 2011) Nsp7 and Nsp8 are
polymerase cofactors (Kirchdoerfer & Ward, 2019) Nsp9 is an RNA binding protein (M. P. Egloff
et al., 2004) Nsp10 is a zinc-binding cofactor for Nsp14 and Nsp16 (Ma et al., 2015) Nsp12 is the
RNA polymerase (Kirchdoerfer & Ward, 2019). Nsp13 is a helicase (Jia et al., 2019). Nsp14 is a 3’5’ exonuclease and a 7-methyltransferase (Ma et al., 2015). Nsp15 is an RNA endonuclease
(Ricagno et al., 2006). Nsp16 is an RNA cap 2’-O-Methyltransferase (Decroly et al., 2011).
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Many of the 47 variant residues in the 180 amino acid long SARS Mac1 domain are
clustered near its N-terminus in a region that is particularly variable in the three Coronaviridae
genera (Figure 6.1-2). Mac1 domains from coronaviruses that cause the common cold (alpha
coronaviruses) and the beta coronaviruses like SARS-CoV and Middle East respiratory syndrome
corona-virus (MERS-CoV) all bind ADP ribose. However, the same domain in gamma
coronaviruses does not bind ADP-ribose.
Although the Mac1 domain of SARS-CoV-1 is known to bind and catalyze the hydrolysis of
ADP-ribose 1" phosphate, the significant variation prevents the use of the SARS-CoV-1 Mac1
domain structures as scaffolds to design compounds that might target this nsp3 region in SARS
CoV-2. This is especially important given that the same nsp3 domain from gamma coronaviruses
or even the Mac2 and Mac3 domains of the same coronaviruses do not bind or hydrolyze ADPribose. This chapter examines the binding of ADP-ribose and similar nucleotides to a
nonstructural protein 3 (nsp3) macrodomain which might be utilized to find antiviral drugs. The
binding between SARS-CoV-2 Mac1 domain and ADP-ribose was investigated utilizing
recombinant pure protein and isothermal titration calorimetry (ITC).
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Figure 6.1-2 Variation in the Mac1 domains of coronaviruses.
Variation in the Mac1 domains of coronaviruses. Mac1 structures were aligned using the
“MatchMaker” function of UCSF Chimera (version 1.14) (Pettersen et al., 2004a). Amino acids are
colored by class. βsheets are denoted with green boxes, and αhelices are denoted with yellow
boxes.

6.2.Purification and Isolation of Mac1 domain
In order to determine the binding of ADP-ribose to the Mac1 domain, the Mac1 domain
was isolated and purified using a NiNTA and a gel filtration column. The detailed explanation of
gene synthesis and the protocol for protein purification are discussed in the materials and
methods section (Chapter 4.2). Briefly, the pET11-COVID-MacroX plasmid was used to transform
BL21 (DE3) cells. Transformed BL21(DE3) were used to start a 3 ml starter culture until the OD600
reached 1 and then transferred to a 1L fresh medium containing 100 mg/ml ampicillin. After the
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OD600 reached 1, the cells were induced using 1 mM IPTG and harvested the next morning. The
protein was purified using a step gradient on a NiNTA column with a final concentration of 500
mM Imidazole. To verify the expression of Mac1 domain, 10 µl sample from each IMAC fraction
was loaded on to 15% SDS gel (Figure 6.1-1).
After the expression of mac1 domain was verified using SDS gel, The eluted fractions at
500 mM imidazole were then concentrated and loaded onto a 250 ml Sephacryl S300 gel filtration
column for further purification and eluted with 10 mM MOPS and 150 mM NaCl. Concentration
of the purified protein was determined by measuring absorbance at 260 nm using a molar
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extinction coefficient calculated with the ProtParam tool (https://web.expasy.org/protparam/).

Figure 6.2-1 15% SDS PAGE of SARS-CoV-2 Mac1 domain.
Panel A: 15% SDS PAGE showing 10 µL samples of: a soluble crude lysate of induced BL21(DE3)
cells harboring the plasmid p21-COVID-Mac1 (lane C), proteins the do not bind a Ni-NTA column
(F), and fractions eluted from a NiNTA column during an imidazole step gradient from 0 mM
(lanes 1-3), 5 mM (lanes 4-6), 40 mM (lanes 7-9), and 500 mM (lanes 10-12). Protein markers
(lane M) are 116, 66.2, 45, 35, and 25 kDa.
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6.3.Determine optimal conditions for ITC experiments.
Purified Mac1 was used in all ITC experiments to determine the binding of the Mac1 to ADPr.
The starting ligand and proteins concentration were based on the instructions provided in
(Velázquez‐Campoy et al., 2004) However multiple conditions were employed to determine
optimum ratio between ligand and protein concentrations. Prior to the start of the experiment,
samples of ligand and protein were diluted in 10 mM MOPS and 150 mM NaCl at pH 7 and
degassed for 30 minutes at 400 mm Hg. At a temperature of 20 °C, measurements were
conducted by injecting 2.0 μL aliquots of 500 μM ADP-ribose into various concentrations of
protein in a 175 µL starting volume stirred at 250 rpm. The data gathered is depicted below.
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Figure 6.3-1 Mac1 titration with ADP-ribose.
Panel A, B and C top: Titration thermograph of 500 µM ADP added to 50 µM Mac1 dissolved in
10 mM MOPS 150 mM NaCl pH7. The titration thermogram represented as the amount of heat
released per unit of time after each injection. The relationship between the quantity of heat
generated by each injection and the ratio of total ligand to total protein concentration is shown
underneath it. Panel A and B bottom: The circles plot experimental data, while the line represents
model's best fit to n identical and independent binding sites. Data fit best to the independent
model with dissociation constant of 6.6 ± 3.3 μM, 5.5 ± 2.7 μM and 1.4 ± 1.3 μM, stoichiometric
constant of 0.7 ± 0.1, 0.2 ± 0.1, and 0.7 ± 0.1 enthalpy of -66.8 ± 12.9 (kJ/mol), -63.8 ± 34.7
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(kJ/mol) and -72.7 ± 20.1 (kJ/mol), -TΔS of 37.7 (kJ/mol), 34.3 (kJ/mol) and 39.9 (kJ/mol) Gibbs
free energy of -29.1 (kJ/mol), -29.5 (kJ/mol) and -32.8 (kJ/mol) for panel A and B respectively.
According to the experiment conducted with various concentrations of the Mac1, 50 µM
for the Mac1 and 500 µM for ADP-ribose appears to be the optimal conditions that were used
for the remainder of the ITC binding studies
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Figure 6.3-2 Mac1 titration with ADP-ribose.
Panel A and B top: 50 µM Mac1 titrated with 500 µM ADP-ribose dissolved in 10mM MOPS
150mM NaCl pH7. The titration thermogram is represented as the amount of heat released per
unit of time after each injection. The relationship between the quantity of heat generated by
each injection and the ratio of total ligand to total protein concentration is shown underneath it.
In Panel A and B, bottom, the circles plot experimental data, while the line represents the model's
best fit to n identical and independent binding sites. Fitting the data to an independent model
gives us the dissociation constant of 12.8 ± 4.2 μM and 19.1 ± 6.2 μM, stoichiometric constant of
0.66 ± 0.1 and 0.76 ± 0.1, enthalpy of -86.0 ± 5.2 (kJ/mol) and -70.0 ± 22.6 (kJ/mol), -TΔS of 59.0
(kJ/mol) and 43.6 (kJ/mol) Gibbs free energy of -27.0 (kJ/mol) and -26.4 (kJ/mol) for panel A and
B respectively.
Repeated ITC experiments revealed that the purified recombinant protein bound ADPribose Figure 6.3-3 with a dissociation constant of 16 ± 4 µM (uncertainty is the standard
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deviation of Kd’s from two independent titrations). To examine binding specificity, similar
titrations were repeated with related nucleotides such as: ATP (Fig. 6.3-3), ATP-glucose (Fig. 6.34), AMP (Fig. 6.3-5), Adenosine (Fig. 6.3-6), cAMP (Fig. 6.3-7) and ADP (Fig. 6.3-8).
6.3.1. ATP binding to Mac1

Figure 6.3-3 ATP titration with Mac1 domain.
Top: 50 µM Mac1 titrated with 500 µM ATP dissolved in 10mM MOPS 150mM NaCl pH7. The
titration thermogram is represented as the amount of heat released per unit of time after each
injection. The relationship between the quantity of heat generated by each injection and the ratio
of total ligand to total protein concentration is shown underneath it. In bottom panel, the circles
plot experimental data, while the line represents the model's best fit to n identical and
independent binding sites. Fitting the data to an independent model gives us the dissociation
constant of 2.7 ± 1.7 μM, stoichiometric constant of 1.1 ± 0.08, enthalpy of -11.0 ± 1.3 (kJ/mol),
-TΔS of -20.23 (kJ/mol) and Gibbs free energy of -31.24 (kJ/mol).
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6.3.2. ATP-Glucose binding to Mac1

Figure 6.3-4 Mac1 titration with ATP-Glucose.
Panel A and B top: 50 µM Mac1 titrated with 500 µM ATP-glucose dissolved in 10mM MOPS
150mM NaCl pH7. The titration thermogram is represented as the amount of heat released per
unit of time after each injection. The relationship between the quantity of heat generated by
each injection and the ratio of total ligand to total protein concentration is shown underneath it.
In Panel A and B, bottom, the circles plot experimental data, while the line represents the model's
best fit to n identical and independent binding sites. Fitting the data to an independent model
gives us the dissociation constant of 7.5 ± 3.7 μM and 8.3 ± 6.7 μM, Stoichiometric constant of
0.7 ± 0.1 and 0.64 ± 0.17, Enthalpy of -15.2 ± 3.1 (kJ/mol) and -11.0 ± 5.6 (kJ/mol), -TΔS of -13.6
(kJ/mol) and -17.5 (kJ/mol) Gibbs free energy of -28.8(kJ/mol) and -28.8 (kJ/mol) for panel A and
B respectively.
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6.3.3. AMP binding to Mac1

Figure 6.3-5 Mac1 titration with AMP.
Top: 50 µM Mac1 titrated with 500 µM AMP dissolved in 10mM MOPS 150mM NaCl pH7. The
titration thermogram is represented as the amount of heat released per unit of time after each
injection. The relationship between the quantity of heat generated by each injection and the ratio
of total ligand to total protein concentration is shown underneath it. In bottom panel, the circles
plot experimental data, while the line represents the model's best fit to n identical and
independent binding sites. Fitting the data to an independent model gives us the dissociation
constant of 5.6 ± 2.1 μM, stoichiometric constant of 0.8 ± 0.07, enthalpy of -12.2 ± 1.7 (kJ/mol),
-TΔS of -17.3 (kJ/mol) and Gibbs free energy of -29.4 (kJ/mol).
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6.3.4. Adenosine binding to Mac1

Figure 6.3-6 Mac1 titration with Adenosine.
Panel A and B top: 50 µM Mac1 titrated with 500 µM adenosine dissolved in 10mM MOPS 150mM
NaCl pH7. The titration thermogram is represented as the amount of heat released per unit of
time after each injection. The relationship between the quantity of heat generated by each
injection and the ratio of total ligand to total protein concentration is shown underneath it. In
Panel A and B, bottom, the circles plot experimental data, while the line represents the model's
best fit to n identical and independent binding sites. Fitting the data to an independent model
gives us the dissociation constant of 8.5 ± 3.1 μM and 11.7± 5.4 μM, stoichiometric constants of
0.2 ± 0.1 and 0.1 ± 0.1, enthalpy of -34.5 ± 15.9 (kJ/mol) and -33.99 ± 20.6 (kJ/mol), -TΔS of 2.9
(kJ/mol) and 0.8 (kJ/mol) Gibbs free energies of -31.5 (kJ/mol) and -34 (kJ/mol) for panel A and B
respectively.
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6.3.5. cAMP binding to Mac1

Figure 6.3-7 Mac1 titration with cAMP.
Panel A and B top: 50 µM Mac1 titrated with 500 µM cAMP dissolved in 10mM MOPS 150mM
NaCl pH7. The titration thermogram is represented as the amount of heat released per unit of
time after each injection. The relationship between the quantity of heat generated by each
injection and the ratio of total ligand to total protein concentration is shown underneath it. In
Panel A and B, bottom, the circles plot experimental data, while the line represents the model's
best fit to n identical and independent binding sites. Fitting the data to an independent model
gives us the dissociation constant of 0.7 ± 0.1 and 0.7 ± 0.1, enthalpy of -10.5 ± 1.9 (kJ/mol) and
-15.1 ± 5.9 (kJ/mol), -TΔS of -18.4 (kJ/mol) and -14.0 (kJ/mol) Gibbs free energy of -28.8 (kJ/mol)
and -29.1 (kJ/mol) for panel A and B respectively.
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6.3.6. ADP binding to Mac1
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Figure 6.3-8 Mac1 titration with ADP.
Panel A and B top: 50 µM Mac1 titrated with 500 µM ADP
D dissolved in 10mM MOPS 150mM NaCl
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Figure 6.4-1 Thermodynamic data for all nucleotides were obtained using ITC.
Panel A. Comparison of the thermodynamics of ADP-ribose binding by Mac1 domains from SARSCoV-2, SARS-CoV-1 (M.-P. Egloff et al., 2006), MERS-CoV (Cho et al., 2016a), and an alpha
coronavirus (Piotrowski et al., 2009). ITC experiments like those shown in panel A were repeated
tree times with each of the nucleotide listed. Means are plotted and error bars are standard
deviations. Average (±SD) dissociation constants were 10 ± 4 µM for ADP-ribose, 7 ± 3 µM for
ADP, 3 ± 3 µM for ATP, 6 ± 2 µM for AMP, 8 ± 5 µM for ADP-glucose, 8 ± 5 µM for cAMP, and 10
± 4 µM for adenosine. The same data from panel B is shown in panel C but as part of a
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thermodynamic optimization plot. On the right, structures of all the nucleotides used specifically
in these ITC studies.
All nucleotides lacking the ribose moiety bound with similar affinities, but none bound
with an enthalpy change like that seen with ADP-ribose, suggesting specific interaction between
ADP ribose and Mac1 domain.
To recap, the total enthalpy change is calculated as the sum of the positive and negative
enthalpic contributions. The positive enthalpy changes are due to the formation of hydrogen
bonds and van der Waals interactions between the ligand and the protein, while the unfavorable
enthalpic contribution is due to the ligand being desolvated or removed from solution in order
to form a complex (FREIRE, 2008). Based on the structure (PDB ID 6W02) of the SARS-CoV-2 Mac1
domain bound to ADP-ribose determined by Michalska. et al. (2020) and in comparison, to
unliganded Mac1, notable conformational differences were observed. The notable
conformational changes occur in three surface-exposed loops in or near the ligand-binding
pocket. These loops connect strand β2 with helix α2 (the β2-α2 loop), strand β4 with helix α4
(β4-α4 loop), and strand β5 with helix α5 (β5-α5 loop). Not all changes in conformation are due
to the direct interaction of protein with the ADP ribose however these conformational changes
lead to an opening of binding pocket allowing the amide N atom of G252 to participate in a
hydrogen bonding interaction with the 1’-hydroxyl of the ribose moiety of ADP-ribose. G252 on
SARS-CoV2 Mac1 Domain corresponds to V33 residue in Chikungunya macrodomain, which Eckei
et al. (2017) proposed is needed for de-ADP-ribosylation activity based on results for site directed
mutagenesis. N244 on the loop that connects strand β2 with helix α2 (the β2-α2 loop) also
directly interacts with the distal ribose moiety.
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The direct interaction between both ribose moieties of ADP ribose and the pocket of
Mac1 domain leads to very favorable enthalpic interaction seen in ITC data. On the opposite end,
the binding of ADP ribose also leads to very unfavorable entropic energy due to restriction in
degrees of freedom of the ligand when bound to the macrodomain.
The energetics of ADPr binding to the Mac1 domain are similar among beta coronavirus
but significantly different from alpha coronavirus. There is some favorable Enthalpic driven
binding of ADP-ribose with macrodomain of alpha coronavirus however it is significantly less than
beta coronavirus suggesting that the binding of ADPr in beta coronavirus is enthalpically driven.
Additionally, the entropic penalty of binding for beta coronavirus is significantly more whereas it
is favorable for alpha coronavirus.

6.5.Optimization of DSF Assay conditions.
DSF has been used previously to study ligand binding to viral macrodomains (Cho et al.,
2016b; Malet et al., 2009). In DSF experiments using SARS-CoV-2 Mac1, the presence of ADPr
raised the Mac1 melting temperature in a concentration-dependent manner (Fig. 6.6-1a). To
estimate the ligand concentrations needed to alter melting temperatures by 50% (EC50), melting
temperatures were fit to Eq. 3.6-2 (Fig. 6.6-1b). Such EC50 values do not, however, describe
protein-ligand affinity because DSF assays do not directly measure binding. The isothermal
analysis recently described by Bai et al. was therefore used to estimate binding affinities. Fits of
the fraction of protein unfolded at various temperatures in the presence of various ligand
concentrations Eq. 3.6-9 (Fig. 6.6-1C) were used to estimate a dissociation constant (Kd) and
equilibrium unfolding constant (Ku). Kd estimated using Eq 3.6-9 from DSF data at high
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temperature when fitted to the Van’t Hoff relationship (Fig. 6.6-1D), were in good agreement
with the dissociation constant describing the interaction of ADPr and Mac1 (10 µM) determined
at 23 °C (Frick et al., 2020).
Dimethyl sulfoxide (DMSO) did not change the melting curve even at concentrations as
high as 10% (v/v) and similar results were also obtained when titrations with ADPr were repeated
in various buffers, with the pH ranging from 6.5 to 8.0, or in the presence of various
concentrations of divalent metal cations (Mg2+ or Mn2+). In contrast, the ionic strengths of the
assay buffers influenced the results, with the largest Tm values and lowest EC50 values being
obtained at the lowest ionic strengths (Fig. 6.5-1C). Based on these results, DSF assays were
subsequently performed in 20 mM MOPS pH 7 buffer containing 25 mM NaCl to reduce possible
non-specific interactions with ligands. Z’ factors were always above 0.5 for each plate and
typically above 0.7. Plate-to-plate variability was negligible (Fig. 6.5-1D).
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Figure 6.5-1 Optimization of DSF assay conditions.
The DSF assay was optimized by measuring ADP-ribose binding to the MAC1 domain under a
variety of conditions, beginning with the use of various buffers ranging in pH from 6.5 to 8.0.
(Panel A). Similarly, the impact of two divalent cations, manganese and manganese, on the EC 50
or Tm values for ADP-ribose was determined with no obvious effect (Panel B). Finally, the binding
was influenced by the concentration of salt, with the lowest ionic strengths producing the
greatest Tm values and the lowest EC50 values (Panel C). Z’ factors were always above 0.5 for each
plate and typically above 0.7. Plate-to-plate variability was negligible (Panel D).

6.6.DSF to monitor the binding of ADP-Ribose with Mac1.
Purified SARS-CoV-2 Mac1 protein was prepared as described previously (Section 6.2). The
conditions of DSF assay and the protocol is discussed in Section 6.5 and 4.1.4. Briefly, All DSF
studies were carried out in a 96-well PCR plate using Eppendorf thermofluor in a similar manner.
Mac1 was mixed in buffer containing SYPRO Orange dye, and an equal amount of protein-SYPRO
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mixture was then added to each well on a plate containing a different concentration of
compound. The temperature was raised from 20 °C to 95 °C at a rate of 2 °C per min while
measuring the fluorescence in the “TAMRA” channel.
Each assay was repeated multiple times and data was normalized and plotted with
fluorescence on y-axis and temperature on x-axis as shown on Figure 6-6-1 Panel A. Tm’s were
calculated by fitting the data to equation 3.6.1 using either GraphPad Prism or TSA-CRAFT
Two methods were used to estimate the binding affinity of Mac1 domain. First the T m
values that were obtained using equation 3.6-1 were plotted against ADP-ribose concentration.
This data was then fitted to Equation 3.6-2 to obtain EC50 and non-linear regression to estimate
Tm max from the melting temperature of Mac1 in the absence of ligand (T m 0). Tm max is the
maximum change in the melting temperature, and EC50 is the concentration of ligand needed to
cause a change in the melting temperature by 50%. The second method used to estimate binding
affinity is based on calculating the dissociation constant (Kd) of Mac1 and ADPr. The dissociation
constant (Kd) of Mac1 and ADPr and the equilibrium constant describing protein unfolding (Ku)
were estimated using isothermal analysis as described by Bai et al. (2019). Briefly, normalized
melting curves were used to calculate the fraction of protein unfolded at a particular temperature
(fu), and those values fitted to the total ligand (Lt) and protein (Pt) concentrations using non-linear
regression and Equation 3.6-9.
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Figure 6.6-1 Methods used to estimate the binding affinity of Mac1 domain.
(A) Normalized SPYRO Orange fluorescence in the presence of 5 µM Mac1 protein at various
temperatures in the presence of indicated concentrations of ADPr. Data are fit to equation 3.6-1
using non-linear regression with GraphPad Prism. (B) Tm values were obtained from direct fitting
to Eq. 3.6-1 and this data is then plotted and fitted to Eq. 3.6-2. (B) Isothermal analysis of percent
unfolded protein at each indicated temperature was collected and data was fit to Eq. 3.6-9 to
estimate Ku and Kd. Uncertainties are standard errors of the curve fits. (C) Van’t hoff plot of
estimated Kd values from panel C (open circles) and the Kd for ADPr binding to Mac1 that was
previously determined at 23°C using isothermal titration calorimetry (filled circle) (Frick et al.,
2020).

6.7.DSF to estimate the binding of various nucleotides with Mac1.
Optimized DSF conditions of 20 mM MOPS at pH 7 buffer containing 25 mM NaCl were
used in the assay to compare the binding of various nucleotides using ADP-Ribose as a positive
and DMSO as a negative control. The purified SARS-CoV-2 Mac1 protein was then titrated with a
variety of nucleotides comparable to ADP-ribose to assess if the DSF assay accurately reproduces
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the structure-activity relationships established in previous ITC investigations (Section 6.3 and
Table 6.7-1) (Frick et al., 2020). All nucleotides tested were previously shown to bind Mac1. The
main differences observed with ITC reflected the fact that binding of only ADP-ribose was
significantly enthalpy driven, while the other nucleotides were bound by Mac1 with smaller
favorable enthalpy, but with counterbalancing decreases in binding entropy so that the free
energy changes (and Kd) were similar to ADP ribose (Frick et al., 2020). The majority of nucleotides
altered Tm, except for ADP-glucose and AMP, which did not until the sample was saturated with
ligand. In contrast to the Kd values determined in ITC tests, the EC50 values for each nucleotide
varied significantly, with ADP-ribose having a much lower EC50 value than the other nucleotides
(Table I).

Compounds
ADP-ribose
ADP-glucose
ADP
ATP
AMP
cAMP
NADH

Tm max (°C)

EC50 (µM)

Kd (ITC)

7±0.9
~2 @ 500 µM
6.2±1
5.6 ±0.7
~2 @ 500 µM
1.9 ± 0.8
5.8 ±0.4

63 ± 21
> 500
314 ±43
483 ± 129
> 500
746 ± 340
410 ± 76

10±6
9.5±5
3.4±0.6
2.4±1
5.6±2
6.1±3
44±20

Table 6.7-1 Effects of various nucleotides on SARS-CoV-2 Mac1.
Tm max and EC50 values obtained in concentration response assays using the DSF assay and
dissociation constant obtained via ITC. Most nucleotides caused Tm to change, with the notable
exception of ADP-glucose and AMP, which did not unless the sample was saturated with 500 µM
ligand concentration.

6.8. Summary
The study's relevance arises mostly from the discovery that the SARS-CoV-2 Mac1 domain
binds ADP-ribose. While SARS-CoV and SARS-CoV-2 have a 26 percent amino acid sequence
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difference, their structures are quite similar, which may account for their ability to bind ADPribose. This is the first step in justifying antiviral search for compounds that bind in lieu of ADPribose. However, further research is needed to fully grasp the antiviral potential of such drugs,
since the biological function of ADP-ribose binding remains unknown. Some work with alpha
coronaviruses suggests that ADP-ribose binding by the Mac1 domain is not required for viral
replication (Keep et al., 2018). However, studies with other (+) RNA viruses suggest that
macrodomains are essential for virulence (Abraham et al., 2018). Additionally, this study is
significant because the synthetic codon-optimized plasmid yields up to 100 mg of soluble Mac1
domain protein per liter of E. coli culture, and this protein maintains a strong affinity for ADPribose. The protein might be employed in structural and screening research. Screening
experiments using the SARS-CoV-2 protein may be more efficient due to the SARS-CoV-2 protein's
somewhat stronger affinity for ADP-ribose (Kd = 10 M) than the SARS-CoV protein's affinity for
ADP-ribose (Kd = 24 M). The recombinant protein reported here together with detailed structural
information might also be useful to others developing SARS-CoV-2 diagnostics and/or
therapeutics.
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7. Discovery of Drug-like Ligands for the Mac1 Domain of SARS-CoV-2
7.1. Introduction
Direct acting antivirals (DAAs) are desperately needed to treat COVID-19 patients and
stem the devastation caused by the current Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) pandemic. DAAs are typically developed from potent inhibitors of viral enzymes or
high-affinity ligands of viral proteins. For example, the first FDA-approved DAA against SARS-CoV2, remdesivir (Agostini et al., 2018) is a phosphonamidite prodrug that is converted to a
nucleoside triphosphate non-obligate chain terminator that inhibits the SARS-CoV-2 RNA
dependent RNA polymerase, halting SARS-CoV-2 replication (Shannon et al., 2020). Based on
past experiences with other viruses, any effective DAA therapy will likely involve a cocktail of
more than one antiviral agent because drug resistance evolves rapidly (de Clercq, 2004, 2013b,
2013a). It is therefore essential that methods are developed to rapidly identify small-molecule
drug-like ligands for as many SARS-CoV-2 proteins as possible. Even if such ligands are not
developed into drugs, they will be useful as molecular probes to study the biological role of SARSCoV-2 proteins.
In the previous chapter, the Mac1 of SARS-CoV-2 was characterized, primarily because it
is the most different nsp3 domain from its nearest relative, SARS-CoV (Egloff et al., 2004). This
domain binds ADP-ribose and has a weak hydrolytic activity (Saikatendu et al., 2005) that
removes ADP-ribose that is covalently attached to proteins (Alhammad & Fehr, 2020). Claverie
recently proposed that this activity might be linked to the cytokine storm syndrome commonly
found in COVID-19 patients (Claverie, 2020). The results of a screening campaign designed to find
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drug-like Mac1 ligands are reported here, which might facilitate DDA design that could be useful
molecular probes.

7.2.Screening of drugs and drugs-like compounds via DSF
Two high-throughput screens were designed to identify such ligands. Both were used to
screen libraries of drugs and drug-like compounds, including the National Institutes of Health
(NIH) clinical collection (726 compounds), the National Cancer Institute (NCI) mechanistic set
(540 compounds) and Sigma-Aldrich’s 1280 compound Library of Pharmacologically Active
Compounds (LOPAC).
The first assay used differential scanning fluorimetry (DSF, aka the thermal shift, or
ThermoFluor assay) (Huynh & Partch, 2015) methods to examine the melting temperature (Tm)
of SPYRO Orange-saturated SARS-CoV-2 Mac1 in the presence of each compound in an assay that
can be performed in standard quantitative PCR thermocyclers. In an orthogonal screen, various
high-resolution Mac1 domain structures were used with AutoDock VINA19 to identify
compounds bound with the highest affinity to all structures, and lastly, ITC was used as a second
orthogonal study to examine protein-ligand binding.
The conditions of the DSF assay and the protocol used to purify Mac1 is discussed in detail
in Chapter 3. Briefly, DSF assays were performed in 96-well PCR plates using a Quantitative
Realtime PCR System with each well containing 19 µl of Master-mix (5 µM Mac1) and 1 µl of
either a compound stock (10 mM for screening) or DMSO. The 96-well PCR plate was then sealed,
centrifuged, and placed in QR-PCR. The temperature was raised from 20°C to 95°C while
measuring the fluorescence in the "TAMRA" channel. Each plate included both negative (DMSO)
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and positive (ADPr) controls. The DSF assay was optimized for HTS to yield Z’-Factors between
0.5 and 0.75. In the screening of the NCI, NIH and LOPAC collections, about 1%, 5%, and 1% of
compounds tested influenced apparent melting temperature, respectively (Fig. 7.2-1).

Figure 7.2-1 DSF screens of FDA-approved drugs and drug-like compounds for SARS-CoV-2 Mac1
ligands.
Tm values calculated by fitting melting curves to Eq.3.6-1 (open circles) obtained for Mac1 in the
presence of each compound in (A) the NCI library, (B) the NIHcc, and (C, D) the LOPAC1280.
Assays yielding a “typical” melting curve, as defined by the TSA-CRAFT algorithm, are noted (filled
circles).
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The results of the screening show that a substantial proportion of compounds in various
libraries impact the measured protein melting temperature, which was especially noticeable with
the NIHcc. These abnormal melting curves are associated with substances that interfere with the
assay's fluorescence, either directly or indirectly by their enhancement of the SPYRO Orange
reporter dye's fluorescence. To exclude the possibility of such compounds in further trials, the
TSA-CRAFT software application was used to determine what it refers to as "typical" curves
(filled-circles, Figs. 7.2-2). Later, it was discovered that such interfering substances may also be
detected by plotting Tm values against the initial fluorescence seen in the melting curve (Fig. 7.22).
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Hydrazine carbothioamide). In contrast, a few compounds in the NIH collection significantly
increased the melting temperature of Mac1. Two noteworthy hits relevant to current COVID-19
research were the ACE inhibitor telmisartan (Rothlin et al., 2020) and two steroids, estradiol
valerate and the anti-inflammatory corticosteroid flunisolide (Fig. 7.2-3) (Breithaupt-Faloppa et
al., 2020b; Grandi et al., 2020).
B. Lactams

A. Steriods

Estradiol valerate

C. Benzimidazoles

Cefaclor
Telmisartan

Flunisolide

Cefatrizine
Rabeprazole

D. Others

Omeprazole

Nifedipine

Irinotecan

Trifluoperazine

Figure 7.2-3 Selected hit compounds from the NIH clinical collection.
(A) Steroids raise the apparent Tm of SARS-CoV-2 Mac1. (B) Two lactam antibiotics that lowered
the apparent Tm of SARS-CoV-2 Mac1. (C) Benzimidazoles altering the SARS-CoV-2 Mac1 Tm (D)
four additional hits for which binding could be confirmed using ITC.
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Selected compounds identified to induce a change in melting temperature were followed
by concentration response assays (red and green circles, Fig. 7.3-1). Although many of the
selected compounds that yielded high Tm values were reproduced (green circles, Fig. 7.3-1) upon
cherry-picking, their concentration-response curves often looked unusual. For example, the
addition of estradiol valerate led to flattened regions with sharp peaks (Fig. 7.2-4A).
One possibility for erratic results is that compounds may be unstable when stored as
DMSO solutions in microplates. However, when new aliquots of selected compounds were
purchased, abnormal melting curves were again observed with estradiol valerate, and no effects
were observed with flunisolide (Fig. 7.2-4A and B, respectively). In contrast, fresh batches of both
lactams (Cefaclor and Cefatrizine) and two benzimidazoles (rabeprazole and omeprazole) yielded
the same effects seen with the screening library (Fig. 7.2-4C, D, F, G, respectively). However, fresh
telmisartan yielded a different effect, lowering the apparent Tm as was seen with related
compounds (Fig. 7.2-4E), suggesting that a possible degradation product led to the Tm increase
observed using the library sample.
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Figure 7.2-4 Concentration response assays.
Concentration response analysis of each compound is DSF assays are shown, along with EC50
values. The direction of the arrow represents increase (to the right) or decrease (to the left) in
Tm upon increase in ligand concentration.
Although ligands that reduce a protein’s Tm are often assumed to bind and stabilize
unfolded structures, (Layton & Hellinga, 2010), nevertheless some of these hits were examined
in more detail. Interestingly, many of the hits that lowered Tm values were members of similar
chemical classes. For example, two were lactam antibiotics (Fig. 7.2-3B), and two others were
benzimidazoles chemically resembling telmisartan (Fig. 7.2-3C). Many reproduced well upon
cherry-picking and depressed the Tm values when interacting with SARS-CoV2 Mac1 in a
concentration-dependent manner (Fig. 7.2-4).
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7.3.Orthogonal “Virtual” Screen.
The orthogonal "virtual" screen used the SARS-CoV-2 Mac1 crystal structures (PDB files
6WEY, 6W02, and 6VXS) as targets in the AutoDock Vina program. PDB file 6W02 is a co-structure
with ADP-ribose, but the other two were done in the absence of ADP-ribose. Each was searched
free of ligands. Binding sites were not restricted but, for most compounds, minimum binding
energy (best fit) values were obtained for structures in which the compound docked near the
ADPr binding site. Plots of AutoDock Vina scores vs. Tm could be used to identify compounds for
follow-up assays (Fig. 7.3-1). First, there was a clear correlation between the number of hits and
AutoDock Vina scores, with more hits clustering at lower energies. Second, when cherry-pick
assays were performed on hits, those with lower energy scores (12/15) were more likely to be
reproducible than compounds with higher-energy scores (3/9) (Fig. 7.3-1).
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Figure 7.3-1 Comparison of DSF and AutoDock screening results.
Plot of Tm values derived using TSA-CRAFT for samples in the NIHcc plotted versus AutoDock Vina
binding energies obtained for each compound after docking with PDB file 6WEY. “Typical”
melting curves are filled circles. Compounds selected for follow-up (cherry pick) analysis are
highlighted. The dotted line is arbitrary cutoffs differentiating high or low energy scores.
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The two methods outlined above could therefore be used in future screening campaigns
to identify compounds that more likely bind Mac1 and could be differentiated from those that
likely do not. As evidence, all nucleotides that were hit yielded results similar to those seen with
ADPr.

7.4. ITC with selected compounds
After confirming the results with fresh compounds, ITC was used as a second orthogonal
assay to examine protein-ligand binding. Unfortunately, most of these compounds had little to
no solubility in the buffer conditions used for ITC, therefore results labeled with *asterisk are
compounds with low solubility and compounds with no solubility were not included. The
conditions and protocol followed to do the experiment are covered in-depth in Chapter 3. Briefly,
samples of ligand and protein were diluted in 10 mM MOPS and 150 mM NaCl at pH 7 and
degassed for 30 minutes at 400 mmHg. At a temperature of 20 °C, 2.0 μL aliquots of 500 μM
compounds were injected into 50 μM of protein in a 175 µL starting volume stirred at 250 rpm.
The ITC was performed and data was collected on select compounds, including *nifedipine (Fig.
7.4.1), trifluoperazine (Fig. 7.4.2), irinotecan (Fig. 7.4.3), *imatinib methane sulfonate (Fig. 7.4.4),
two steroids: *estradiol (Fig. 7.4.5) and *flunisolide (Fig. 7.4.6), and three benzimidazoles:
*telmisartan (Fig. 7.4.7), rabeprazole (Fig. 7.4.8) and omeprazole (Fig. 7.4.9).
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7.4.1. *Nifedipine binding to Mac1
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Figure 7.4-1 Mac1 titration with nifedipine.
Panel A and B top: 50 µM Mac1 titrated with 500 µM nifedipine dissolved in 10mM MOPS
150mM NaCl pH7. The titration thermogram is represented as the amount of heat released per
unit of time after each injection. The relationship between the quantity of heat generated by
each injection and the ratio of total ligand to total protein concentration is shown underneath it.
In Panel A and B, bottom, the circles plot experimental data, while the line represents the model's
best fit to n identical and independent binding sites. Fitting the data to an independent model
gives us the dissociation constant of 23 ± 8.1 μM and 6.4 ± 1.9 μM, the stoichiometric constant
of 2.4 ± 0.2 and 1.3 ± 0.1, the enthalpy of –232 ± 25 (kJ/mol) and -471 ± 32 (kJ/mol), -TΔS of 205
(kJ/mol) and 443 (kJ/mol) Gibbs free energy of -26.2 (kJ/mol) and -28.9 (kJ/mol) for panel A and
B respectively. Panel C is the histogram of energetics from Panel A and B in comparison to ADPribose. Panel D is the chemical structure of nifedipine.
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7.4.2. Trifluoperazine binding to Mac1
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Figure 7.4-2 Mac1 titration with trifluoperazine.
Panel A and B top: 50 µM Mac1 titrated with 500 µM trifluoperazine dissolved in 10mM MOPS
150mM NaCl pH7. The thermogram represented as the amount of heat released per unit of time
after each injection. The relationship between the quantity of heat generated by each injection
and the ratio of total ligand to total protein concentration is shown underneath it. Panel A and B
bottom: The circles plot experimental data, while the line represents model's best fit to n
identical and independent binding sites. Fitting the data to independent model gives us the
dissociation constant of 18.9 ± 12.8 μM, 14.1 ± 13.1 μM and 14.9 ± 6.8 μM, stoichiometric
constant of 1.8 ± 0.3, 1.9 ± 0.4 and 1.0 ± 0.1, enthalpy of –22.6 ± 6.3 (kJ/mol), –10.3 ± 2.7 (kJ/mol)
and -24.9 ± 5.2 (kJ/mol), -TΔS of -4.1 (kJ/mol), -17.5 (kJ/mol) and -2.5 (kJ/mol) Gibbs free energy
of -26.7 (kJ/mol), -27.8 (kJ/mol) and -27.4 (kJ/mol) for panel A, B and C respectively. Panel D is
the histogram of energetics from Panel A, B and C in comparison to ADP-ribose with the chemical
structure of trifluoperazine.
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7.4.3. Irinotecan binding to Mac1
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Figure 7.4-3 Mac1 titration with irinotecan.
Panel A: 50 µM Mac1 titrated with 500 µM irinotecan dissolved in 10mM MOPS 150mM NaCl
pH7. The titration thermogram represented as the amount of heat released per unit of time after
each injection. The relationship between the quantity of heat generated by each injection and
the ratio of total ligand to total protein concentration is shown underneath it. Panel A bottom:
The circles plot experimental data, while the line represents model's best fit to n identical and
independent binding sites. Fitting the data to independent model gives us the dissociation
constant of 26 ± 16 μM, Stoichiometric constant of 2.8 ± 0.3, Enthalpy of –5.3 ± 0.9 (kJ/mol), -TΔS
of -20.9 (kJ/mol) Gibbs free energy of -26.2 (kJ/mol). Panel B is the histogram of energetics from
Panel A in comparison to ADP-ribose with the chemical structure of irinotecan.
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7.4.4. Imatinib methane sulfonate binding to Mac1
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Figure 7.4-4 Mac1 titration with imatinib methane sulfonate.
Panel A top: 50 µM Mac1 titrated with 500 µM imatinib methane sulfonate dissolved in 10mM
MOPS 150mM NaCl pH7. The titration thermogram represented as the amount of heat released
per unit of time after each injection. The relationship between the quantity of heat generated by
each injection and the ratio of total ligand to total protein concentration is shown underneath it.
Panel A bottom: The circles plot experimental data, while the line represents model's best fit to
n identical and independent binding sites. Fitting the data to independent model gives us the
dissociation constant of 9.1 ± 4.2 μM, Stoichiometric constant of 1.2 ± 0.1, Enthalpy of -99.8 ±
12.47 (kJ/mol), -TΔS of 71.81 (kJ/mol) and Gibbs free energy of -28.0 (kJ/mol). Panel B is the
histogram of energetics from Panel A in comparison to ADP-ribose with the chemical structure
of imatinib methane sulfonate.
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7.4.5. *Estradiol binding to Mac1
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Figure 7.4-5 Mac1 titration with estradiol.
Panel A top: 50 µM Mac1 titrated with 500 µM estradiol dissolved in 10mM MOPS 150mM NaCl
pH7. The titration thermogram represented as the amount of heat released per unit of time after
each injection. The relationship between the quantity of heat generated by each injection and
the ratio of total ligand to total protein concentration is shown underneath it. Panel B bottom:
The circles plot experimental data, while the line represents model's best fit to n identical and
independent binding sites. Fitting the data to independent model gives us the dissociation
constant of 29.5 ± 16.4 μM, Stoichiometric constant of 2.1 ± 0.3, Enthalpy of -228.4 ± 55.5
(kJ/mol), -TΔS of 203 (kJ/mol) and Gibbs free energy of -25.6 (kJ/mol). Panel B is the histogram
of energetics from Panel A in comparison to ADP-ribose with the chemical structure of estradiol.
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7.4.6. *Flunisolide binding to Mac1

A
1000

2000

3000
1000
750
100

Energy (kJmol-1)

-10
-20

50
0
-50
-100
-750
-1000

-100

-400
0

ni
so

Kd (M)= 52.825.0
n
= 0.50.4
1
2
3
4
[L]T/[M]T

Fl
u

-300

os

e

-200

AD
Prib

Q(kJmol-1)

-30
0

ΔG (kJ/mol)
ΔH (kJ/mol)
-TΔS (kJ/mol)

lid
e

0

dQdT (µJ/s)

B

Time (s)

5

Figure 7.4-6 Mac1 titration with flunisolide.
Panel A top: 50 µM Mac1 titrated with 500 µM flunisolide dissolved in 10mM MOPS 150mM NaCl
pH7. The titration thermogram represented as the amount of heat released per unit of time after
each injection. The relationship between the quantity of heat generated by each injection and
the ratio of total ligand to total protein concentration is shown underneath it. Panel B bottom:
The circles plot experimental data, while the line represents model's best fit to n identical and
independent binding sites. Fitting the data to independent model gives us the dissociation
constant of 53 ± 25 μM, Stoichiometric constant of 0.5 ± 0.4, Enthalpy of -980 ± 1972 (kJ/mol), TΔS of 950 (kJ/mol) and Gibbs free energy of -24.2 (kJ/mol). Panel B is the histogram of energetics
from Panel A in comparison to ADP-ribose with the chemical structure of flunisolide.
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7.4.7. *Telmisartan binding to Mac1

A

B
3000

-20
-40
-60
-80
0

-50

2

4

6

ta
n
ar
is
m

Kd (M)= 22.9  8.6
n
= 2.3  0.2

Te
l

-400

-800
0

0

-100
-200
-400
-600

-200

-600

ΔG (kJ/mol)
ΔH (kJ/mol)
-TΔS (kJ/mol)

50

A
D
Pr ib
os
e

Q(kJmol-1)

600
400
200
100
Energy (kJ/mol)

dQdT (µJ/s)

0

Time (s)
1000
2000

[L]T/[M]T

Figure 7.4-7 Mac1 titration with telmisartan.
Panel A top: 50 µM Mac1 titrated with 500 µM telmisartan dissolved in 10mM MOPS 150mM
NaCl pH7. The titration thermogram represented as the amount of heat released per unit of time
after each injection. The relationship between the quantity of heat generated by each injection
and the ratio of total ligand to total protein concentration is shown underneath it. Panel B
bottom: The circles plot experimental data, while the line represents model's best fit to n
identical and independent binding sites. Fitting the data to independent model gives us the
dissociation constant of 22.9 ± 8.6 μM, Stoichiometric constant of 2.3 ± 0.2, enthalpy of -574.0 ±
69.3 (kJ/mol), -TΔS of 547.8 (kJ/mol) and Gibbs free energy of -26.2 (kJ/mol). Panel B is the
histogram of energetics from Panel A in comparison to ADP-ribose with the chemical structure
of telmisartan.
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7.4.8. Rabeprazole binding to Mac1
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Figure 7.4-8 Mac1 titration with rabeprazole.
Panel A, B and C top: 50 µM Mac1 titrated with 500 µM rabeprazole dissolved in 10mM MOPS
150mM NaCl pH7. The titration thermogram represented as the amount of heat released per
unit of time after each injection. The relationship between the quantity of heat generated by
each injection and the ratio of total ligand to total protein concentration is shown underneath it.
Panel A, B and C bottom: The circles plot experimental data, while the line represents model's
best fit to n identical and independent binding sites. Fitting the data to independent model gives
us the dissociation constant of 16.2 ± 6.8 μM, 33.3 ± 14.1 μM and 14.9 ± 7.4 μM, Stoichiometric
constant of 0.9 ± 0.1, 1.8 ± 0.2 and 1.8 ± 0.2, Enthalpy of –48.9 ± 9.5 (kJ/mol), –30.05 ± 6.2 (kJ/mol)
and -21.1 ± 3.4 (kJ/mol), -TΔS of 22.33 (kJ/mol), 4.7 (kJ/mol) and -6.3 (kJ/mol) Gibbs free energy
of -26.6 (kJ/mol), -25.3 (kJ/mol) and -27.4 (kJ/mol) for panel A, B and C respectively. Panel D is
the histogram of energetics from Panel A, B and C in comparison to ADP-ribose with the chemical
structure of rabeprazole.
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7.4.9. Omeprazole binding to Mac1
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Figure 7.4-9 Mac1 titration with omeprazole.
Panel A and B top: 50 µM Mac1 titrated with 500 µM omeprazole dissolved in 10mM MOPS
150mM NaCl pH7. The titration thermogram represented as the amount of heat released per
unit of time after each injection. The relationship between the quantity of heat generated by
each injection and the ratio of total ligand to total protein concentration is shown underneath it.
Panel A and B bottom: The circles plot experimental data, while the line represents model's best
fit to n identical and independent binding sites. Fitting the data to independent model gives us
the dissociation constant of 4.8 ± 3.7 μM and 14 ± 6.4 μM, Stoichiometric constant of 3.8 ± 0.2
and 0.9 ± 0.1, Enthalpy of –6.2 ± 0.5 (kJ/mol) and -24 ± 5.0 (kJ/mol), -TΔS of -24.2 (kJ/mol) and
3.7 (kJ/mol) Gibbs free energy of -30.4 (kJ/mol) and -27.6 (kJ/mol) for panel A and B respectively.
Panel C is the histogram of energetics from Panel A and B in comparison to ADP-ribose. Panel D
is the chemical structure of omeprazole.
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7.5. Discussion

Figure 7.5-1 Representative structures obtained using AutoDock Vina Virtual Screening.
Top panels show the top 20 binding modes for selected compounds, and the bottom panels show
the top binding mode for each compound compared to the ADP-ribose bound in PDB file 6W02.
The ADP-ribose binding cleft is highlighted in yellow on the protein surfaces shown in the top
panels. Results are shown for (A) two steroids, (B) two lactam antibiotics, and (C) two
benzimidazoles in the NIH clinical collection. Structures are displayed using UCSF-Chimera
(Pettersen et al., 2004b).
Nifedipine, estradiol, flunisolide, and telmisartan were among the compounds with a poor
solubility. Regardless, the binding of compounds with poor solubility was estimated, and the
resulting enthalpy and entropy energies were quite high. The elevated enthalpy values are assumed
to be due to non-specific hydrophobic interaction between the protein and ligand. It is possible that
these hydrophobic compounds are binding in the ADP-ribose binding site however it is more likely
they are binding into hydrophobic area on the protein surface. The binding of hydrophobic
molecule to a hydrophobic area on the protein results in hydrophobic interaction or Val der Waals
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forces (van Oss et al., 1980) resulting in favorable enthalpy. Additionally, binding of hydrophobic
compounds such as lactams and steroids was also virtually obtained showing different binding
modes (Fig. 7.5-2).
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Figure 7.5-2 Thermodynamic data of selected compounds obtained using ITC.
Panel A shows the data in terms of histograms. The same data are shown in Panel B, but in a
thermodynamic optimization plot, with the molecular structure of each molecule on the right.
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Trifluoperazine, rabeprazole, omeprazole, irinotecan, and imatinib were among the more
soluble drugs studied in ITC. These molecules, with the exception of imatinib, were soluble and
bound with comparable affinities to the other nucleotides examined in Chapter 6. Imatinib is a
chemotherapeutic drug that is used to treat cancer. It is a tyrosine kinase inhibitor that inhibits
the enzyme by occupying a position near to the ATP binding site, resulting in a closed
conformation and inhibition of ATP binding to the active site, hence lowering the enzyme's
activity and preventing the cell from proliferating (B. Peng et al., 2005).
According to imatinib's thermodynamic data, it binds to the Mac1 domain with a greater
enthalpy and entropy than ADP-ribose (Fig. 7.5-1). The favorable enthalpy and unfavorable
entropy values do reflect ligand-protein binding through favorable hydrogen bonding or van der
waals forces and an unfavorable entropic interaction owing to degree of freedom constraint
caused by ligand binding. However, activity tests will be required to determine if Imatinib affects
Mac1 binding to ADP-ribose. Additionally, imatinib is an intriguing hit since it has been indicated
as a potential therapeutic agent in COVID studies (Emadi et al., 2020.; Gasmi et al., 2020; MoralesOrtega et al., 2020).

7.6.Summary
In previous chapter, binding between ADP-ribose and Mac1 was identified using ITC and
DSF along with binding of other nucleotides. This chapter focused on the results of a screening
campaign designed to find drug-like Mac1 ligands, which might facilitate DDA design that could
be useful molecular probes. Two high-throughput screens were designed to identify such ligands.
Both were used to screen libraries of drugs and drug-like compounds, including the National
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Institutes of Health (NIH) clinical collection (726 compounds), the National Cancer Institute (NCI)
mechanistic set (540 compounds) and Sigma-Aldrich’s 1280 compound Library of
Pharmacologically Active Compounds (LOPAC).
All the compound libraries were screened using DSF, which was optimized previously, yet
further optimization was needed to exclude compounds that interfere with the SYPRO orange
dye. Two methods were used to identify interfering compounds: TSA-Craft and a plot of Tm
values against the initial fluorescence seen in the melting curve. After excluding interfering
compounds, a dose response assay was done on the selected few remaining compounds. After
confirming that the compound induces a change in the melting temperature of Mac1, new
compounds were bought and dose response was repeated to confirm the results. Unfortunately,
not all compounds were able to reproduce the results, probably due to degradation in DMSO
solution.
The most interesting hits in these screens were the steroids and telmisartan (Fig. 7.2-3).
There seems to be a clear sex difference in COVID-19 disease severity, and an interaction
between a sex hormone and a SARS-CoV-2 protein might help explain this difference (Grandi et
al., 2020), (Breithaupt-Faloppa et al., 2020a). Similarly intriguing is the possibility that the ACE
inhibitor telmisartan, which shares the receptor needed for SARS-CoV-2 to infect cells, might be
an antiviral (Rothlin et al., 2020). Unfortunately, the poor aqueous solubility of the steroids and
telmisartan confounded the ability to examine their interaction with SARS-CoV-2 Mac1. However,
other benzimidazoles were also hit (Fig. 7.2-3C), and they could be verified as ligands using ITC.
Rabeprazole and omeprazole elicit their antacid effects by targeting proton pumps, but there is
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no evidence that proton pump inhibitors affect the severity of COVID-19 (Patel & Sengupta,
2020). Similarly, no peer-review studies have been published reporting antiviral effects for the
other three hits confirmed using ITC: nifedipine, trifluoperazine, and irinotecan. Caution should
also be exercised because each verified compound lowered the apparent T m of Mac1, indicating
that they might bind the protein’s unfolded state. It’s worth noting, however, that similar
destabilizing compounds were found to inhibit macrodomains in other assays not based on
thermal shifts, (Wazir et al., 2021) suggesting that the destabilizing compounds might bind a
folded protein that assumes a different conformation. X-ray crystallography is presently being
used to examine that possibility.
In an orthogonal virtual study, AutoDock virtual binding energy was estimated for all the
compounds in the library. Interestingly, most of the cherry-picked compounds that induce
change in the melting temperature had lower AutoDock energy. Close examination of molecular
models generated by AutoDock Vina reveals that the steroids (Fig. 7.5-2A), β-lactams (Fig. 7.52B) and benzimidazoles (Fig. 7.5-2C) can each occupy the ADP-ribose-binding cleft on SARS-CoV2 Mac1. The larger compounds in each class make more contacts with amino acids in the cleft,
explaining their higher binding energies.
After confirming the results with fresh compounds, ITC was used as a second orthogonal
assay to examine protein-ligand binding. Unfortunately, most of the compounds that were
purchased had little to no solubility in the buffer conditions used for ITC. Regardless, methods
such as dissolving compounds in DMSO first and sonication was used to force solvation of the
compounds along with running ITC immediately after solvation. Therefore, the energetics of
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these compounds should be interpreted with caution. However, there were other compounds
that were able to dissolve readily. Imatinib is one of the compounds that is soluble in conditions
used with ITC and has favorable enthalpy and unfavorable entropy values comparable to ADPRibose.
The next step in this project will be to examine the effects of hit compounds on cells
harboring SAR-CoV-2 or surrogate reporter viruses. Some of the compounds above might inhibit
SARS-CoV-2 replication because Shimizu et al. showed that small molecules, found in virtual
screens targeting the homologous nsp3 macrodomain from Chikungunya virus, inhibit replication
of Chikungunya replicons (Shimizu et al., 2020). However, further optimization would most likely
be necessary for these probes to be useful in cellular studies. Fortunately, all hits reported here
are FDA approved drugs with hundreds of analogs available to facilitate such work. Alternatively,
this optimized DSF assay could be used to screen larger, more diverse libraries for more attractive
probe candidates.
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8. SARS-CoV-2 Helicase
8.1.Introduction
The raging COVID-19 pandemic caused by SARS-CoV-2 has killed millions of patients
worldwide. Currently, there are no effective drugs available for treating coronavirus infections.
Antivirals designed to combat the SARS-CoV-2 will most likely target viral non-structural proteins
required for viral replication. SARS-CoV-2 viral genome is a capped, 30,000 nucleotides long
positive sense RNA with numerous open reading frames encoding total of 27 proteins. Upon
infection viral genome is directly translated encoding for nonstructural proteins (nsps), which are
essential for viral survival, starting with ORF1a. ORF1a encodes a single large polyprotein that is
processed into 11 nonstructural proteins. If the ribosome slips, 5 more non-structural proteins
are translated by ORF1ab (Irigoyen et al., 2016 Plant et al., 2013). In total, ORF1ab encodes for
16 non-structural proteins that are involved in forming a replication and transcription complex
essential for viral replication.
The SARS-CoV-2 replication and transcription complex is essential for viral replication and
consists of several non-structural proteins, including RNA-dependent RNA polymerase (Nsp12),
a helicase (nsp13), and two auxiliary factors: nsp7 and nsp8. Among the 16 nonstructural
proteins, Nsp13 is one of the proteins with the greatest degree of sequence conservation. The
high degree of sequence conservation for nsp13 within the Coronavirus family suggests its critical
role in the viral lifecycle. As a result, nsp13 is a prospective target for the development of antiviral
drugs (Lehmann et al., 2015).
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The Nsp13 helicase is a member of the SF1 helicase superfamily that unwinds RNA and
DNA duplexes unidirectionally in the 5' to 3' direction (Seybert et al., 2000; Weber & McCullagh,
2021), with dNTP hydrolysis facilitating the translocation. Nsp13 is composed of a zinc-binding
domain (ZBD) at the N-terminus, two RecA1 (1A) and RecA2 (2A) helicase core domains, and an
inserted domain 1B connected to the ZBD by a "stalk" region (Hao et al., 2017; Jia et al., 2019).
Additionally, nsp13 is thought to be involved in mRNA capping and to play several functions
throughout the coronavirus life cycle (Ivanov, Thiel, et al., 2004; Ivanov & Ziebuhr, 2004). This
study examines the activity of the SARS-CoV-2 helicase (nsp13) and if helicase is stimulated in the
presence of oligonucleotides.

8.2.Purification of His-Nsp13 and Nsp13-His.
Initially, a codon optimized open reading frame was synthesized by GenScript
(Piscataway, NJ) that encodes for nsp13 with a His-tag on the C-terminal. This open reading frame
was cloned into pET28 to give the plasmid pET28-COVID-Nsp13. The nucleotide sequence of the
nsp13, the protein sequence of the nsp13, and the more detailed protocol for protein purification
are discussed in the materials and methods section (Chapter 4). Briefly, the pET28-COVID-Nsp13
plasmid was used to transform BL21 (DE3) cells. Transformed BL21(DE3) bacteria were used to
start a 3 mL starter culture, which was then transferred to a 1-liter fresh medium containing 1
mL of 50 mg/mL kanamycin. After the OD600 reached 0.7, the cells were induced using 1 mM IPTG
and harvested the next morning.
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Figure 8.2-1 15% SDS gel on BL21(DE3) whole cell before and after induction.
The plasmid pET28-COVID-Nsp13 carrying BL21(DE3) whole cell was loaded onto a 15% SDS gel.
The samples were taken before and after induction with IPTG to examine the protein expression.
Lane 1 is the protein marker with a molecular weight of 116 kDa, 66.2 kDa, 45.0 kDa, 35.0 kDa,
25.0 kDa, 18.4 kDa, and 13.4 kDa. Lane 2 is the containing cells before induction. Lane 3 is the
sample containing cells taken 2 hours after induction and Lane 3 is the sample containing cells
taken 16 hours after induction.
To verify the expression of the nsp13, 100 µl samples of media containing uninduced cells
at an O.D. of 0.6 were reserved along with other samples taken 2 hours and 16 hours after
induction. A reserved sample of the whole cell was then centrifuged, and the pallet was
resuspended with a loading buffer containing 1x SDS. The mixture was then heated at 95 ºC for
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10 minutes. 10 µl of the mixture was aliquoted out and mixed with 2 µl of 6x SDS loading dye. 10
µl sample was then loaded on to a 15% SDS gel. The molecular mass of the protein of interest is
70 kDa and the ladder used for the gel was Thermo Scientific Unstained Protein Molecular Weight
Marker (Part number 26610). The Thermo Scientific Unstained Protein Molecular Weight
Markers are a mixture of seven purified proteins ranging from 14.4 kDa to 116 kDa.
Unfortunately, it seemed that there was no difference in the samples taken before or after
induction and the protein band at 68 kDa was missing suggesting no protein expression. Other
cell types such as Origami (DE3) and Rosetta (DE3) were also used in an attempt to express pET28COVID-Nsp13, but no protein expression was detected.
Throughout the protein prep, 500–100 µl samples of cells, culture medium (LB), pellet,
and crude extract were collected. 10 µl of each sample with 2 µl of 6xSDS dye was heated and
then loaded onto the 15% SDS gel. The gel ran at 50 volts for 2.5 hours, or until the blue dye
reached 15% of the way from the bottom. The gel was then stained using Coomassie Blue Staining
solution. Additionally, the samples that were loaded onto the gel were either lysed using a bugbuster or sonicated to examine the difference. The sample lysed using bug-buster seemed to
have more protein than the sample lysed using sonication. But the difference was not significant,
so sonication was used to lyse the cells.
SDS gel analysis revealed the presence of a big band with a comparable size to our protein
of interest, in addition to some leaky expression. The fraction collected at 300 mM imidazole
(Sample 11 in Fig. 8.2-2) was then dialyzed in GF buffer (20 mM Tris, pH 7, 50 mM NaCl, 1 mM
EDTA, 0.1 mM DTT) + 20% glycerol and concentrated. The concentration of pure protein was
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estimated using an absorbance measurement at 260 nm and a molar extinction coefficient
calculated using the ProtParam tool (https://web.expasy.org/protparam/). The next step was to
verify if the protein was active via an ATPase assay.
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Figure 8.2-2. 15% SDS gel SARS-CoV-2 Nsp13.
15% SDS gels were loaded with 13 samples, each containing 10 µl of sample with 2 µl of 6x SDS
dye. The gel ran at 50 volts for 2.5 hours, or until the blue dye reached 15% of the way from the
bottom. Afterwards, the gel was stained with Coomassie Blue Staining solution thereby
identifying our protein in each sample. The contents of the sample are represented in the table
below the gel. Sample 1 is the protein marker with a molecular weight of 116 kDa, 66 kDa, 45
kDa, 35 kDa, 25 kDa, 18 kDa, and 13 kDa. Samples 3-7 were lysed using a bug-buster, whereas
samples 8 and beyond were lysed using a sonicator. Sample 10 was flowthrough from NiNTA, and
sample 11 contained purified protein eluted at 300 mM Imidazole, Sample 12 was protein eluted
at 40 mM imidazole and sample 13 was purified HCV helicase (NS3h). The arrow in the gel
represents the band with 69kDa protein, suggesting a protein of interest.
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8.3.ATPase assay to evaluate His-nsp13 activity.
Purified protein was then utilized to evaluate the activity of nsp13. The activity of nsp13
was assessed using the malachite green assay. A detailed protocol for malachite green assay is
discussed in detail in Chapter 4. Briefly, 3 ml of master mix was made containing 2 µM nsp13
dissolved in 25mM of MOPS, 5mM MgCl2, 1mM DTT, 0.01 mg/ml of BSA, and 0.01% Tritron X 100
at pH 7. Separately, in 8 200 µl PCR tubes, ATP was serial diluted and dissolved in the same buffer
mentioned above. 50 µl of master mix was then transferred into the first three columns of a 96well plate. The next step was to add 50 µl of ATP solution as the timer was started. The reaction
was stopped after 5, 10 and 20 minutes upon adding phosphate reagent and immediately adding
sodium citrate to each sample using a multi-channel pipette. After malachite green reagents
were added, the plate was put on a shaker for 5–10 min as the color developed. After the color
was developed, absorbance was taken at 630 nm. The initial reaction rate was approximated by
taking the slope from 0 to 5 minutes. The slope calculated from 0 to 5 mins correlated with
substrate concentration was then plotted and the data points were fitted to the MichaelisMenten equation, giving Vmax of 0.09018 mM/min, Km of 0.94 mM, and kcat of 90 min-1.
Km is the Michalis-Menten constant with units of mM it is defined as the substrate
concentration at half of the Vmax. The Km in this experiment could be considered as an estimate
of dissociation constant assuming the dissociation rate from enzyme substrate complex to
enzyme product is very small, or in other words, if there is a rapid equilibrium between enzyme,
substrate, and enzyme substrate complex.
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Figure 8.3-1 Kinetic assays with nsp13.
(A) The activity of nsp13 was measured by adding different concentrations of ATP and stopping
the reaction upon adding malachite green reagent. The reaction containing different
concentrations of ATP was stopped at 5, 10, and 15 min. The initial velocity was calculated by
taking the slope between zero and five minutes. (B) The velocity along with the substrate
concentration was plotted and the data was fitted to the Michaelis-Menten equation to give Vmax
and Km.
The Vmax for this reaction is calculated in terms of mM/min. Vmax is the rate of the reaction
at which the enzyme is fully saturated with substrate and increasing the substrate concentration
further would not impact the rate at which the product is formed. The shape of the curve is
hyperbolic, typical of enzyme kinetic studies, suggesting two different reaction orders.
Unfortunately, it is not very apparent in this specific case, even at the 1.5 mM ATP concentration.
A further increase in concentration of up to 5 or 10 mM of ATP may be required to fully see the
hyperbolic shape of the initial first order reaction transitioning into zero order reaction as
substrate concentration increases.
Kcat was calculated by dividing the Vmax with the total enzyme concentration in the
reaction, giving 90 min-1. Kcat is the catalytic rate constant, or turnover number, that tells us how
many substrate molecules are converted into products by a single enzyme per unit of time. In
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this case, the Kcat of 90 min-1 tells us that 90 molecules of ATP are converted to ADP in a minute.
Lastly, the enzyme specificity constant (Kcat/Km) was measured to be 96 mM-1 min-1. In this case,
the specificity constant is not very useful as it is used to compare relative rates of an enzyme
acting on an alternating, competing substrate, and in this assay, no alternative substrate to ATP
was used or compared.

8.4. Nsp13 is stimulated in the presence of 18-20 bases long oligonucleotides.
In the last section, the activity of purified nsp13 was measured, in this section the
influence of oligonucleotide on helicase activity was investigated. The assay was performed in a
similar manner as any ATPase activity assay but with an addition of oligonucleotide before adding
ATP. Briefly, master mix 1 was made containing 2 µM nsp13 dissolved in 25 mM MOPS, 5 mM
MgCl2, 1 mM DTT, 0.01 mg/ml BSA and 0.01% Tritron X 100 at pH 7. Master mix 2 was made
containing 5 mM ATP dissolved in 25 mM MOPS, 5 mM MgCl2, 1 mM DTT, 0.01 mg/ml BSA and
0.01% Tritron X at pH 7. Lastly, in separate tubes, 100 µl of sample containing 15 µM of each
nucleotide dissolved in the same buffer mentioned above. The reaction was assembled by first
transferring 50 µl of master mix into first 3 columns of 96 well plate, Next, 25 µl of individual
oligonucleotide was added to each row and lastly 25 µl of master mix 2 containing ATP was
added. The reaction was stopped after 5-10 minutes upon adding malachite green reagents to
each sample using multi-channel pipette. After malachite green reagents were added, the plate.
was put on a shaker for 5-10 mins as the color developed. After the color was developed,
absorbance was taken at 630 nm.
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Figure 8.4-1 Nsp13 is stimulated in the presence of 18-20 bases long oligonucleotide.
Different oligonucleotides were added to the sample containing nsp13 to examine its effect on
the enzyme activity. Each assay was done in triplicate and measurements were taken 5-10
minutes after the reaction was initiated after adding ADP to the reaction mixture containing
nsp13 with one oligonucleotide.
From the data, it seems that oligonucleotides between 18 and 20 base pairs tend to
stimulate the enzyme, whereas longer chains of the same bases have no effect. It is possible that
the oligonucleotides forms a convoluted structure restricting the interaction between helicase
and bases, leading to no change in enzyme activity.

8.5. Nsp13 Chapter Summary
Antivirals designed to combat SARS-CoV-2 will most likely target viral non-structural
proteins required for viral replication. Nsp13 is part of the replication and transcription complex
with high sequence conservation among coronaviruses. As a result, nsp13 is a prospective target
for the development of antiviral drugs. In this chapter, nsp13 was expressed in BL21(DE3) and
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purified using a NiNTA column. The variant that was successfully expressed was similar to the
one used by Mickolajczyk et al. (Mickolajczyk et al., 2020). This variant had his-tag added towards
the n-terminal, whereas the other variant His-tag on the c-terminus. The concentration of the
purified protein was then measured by taking the absorbance at 260 nm using a molar extinction
coefficient calculated with the ProtParam tool (https://web.expasy.org/protparam/).
After concentrating, the purified protein was then utilized to evaluate the activity of
nsp13. The activity of nsp13 was assessed using the malachite green assay. The enzyme activity
was measured based on ATP concentration, and the reaction of ATP hydrolysis was measured
based on the linear correlation of inorganic phosphate concentration in the sample and the color
change of malachite green dye used in the malachite green assay. Different concentrations of
ATP affect the rate at which the helicase hydrolyzes ATP. Measurements of inorganic phosphate
were taken at 5-, 10-, and 20-minute intervals. The time interval and concentration of liberated
phosphate were then plotted, and the rate of ATP hydrolysis was calculated based on the firsttime interval between 0 and 5 minutes. The initial rates of hydrolysis with various concentration
of ATP were then plotted and fitted to the Michalis-Menten equation to estimate Vmax of 0.09
mM/min and Km of 0.94 mM values. Km and helicase concentration were used to calculate kcat of
90 min-1. Lastly, the effect of oligonucleotides was measured on helicase activity, and based on
the data, it seems that oligonucleotides between 18 and 20 base pairs tend to stimulate the
enzyme, whereas longer chains of the same bases have no effect.
These ATPase assays were just the first step taken to make sure that the helicase activity
can be measured in a quantitative manner and, using oligonucleotides, based on the data
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oligonucleotides do in fact stimulate helicase activity. The next step in this study is to screen
compounds to see if the activity of the helicase can be influenced. If the compound does seem
to inhibit helicase activity, that compound might not only affect the SARS-CoV-2 helicase but all
coronavirus family helicases due to high sequence conservation.
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Research Experience
University of Wisconsin- Milwaukee (Spring 2017- Fall 2021)
Graduate student under the supervision of Prof. David Frick.
---------------------------------------------------------------------------------------------------------------------------------2021




Transformed, expressed, and purified (NiNTA 10 ml column and size exclusion 250 ml column)
o SARS-CoV2 helicase in IPTG inducible NOVA blue(DE3), Rosetta(DE3) and BL21(DE3).
o The SARS-CoV-2 helicase was assumed via SDS polyacrylamide gel and western blot.
ATPase assay
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o



Malachite green assay to examine the ATPase activity of SARS-CoV2 helicase and HCV
helicase in the presence and absence of DNA or RNA.
o Characterized the kinetic parameters (Km, Vmax and Kcat) of SARS-CoV-2 helicase.
o ADP-Glo assay to examine the ATPase activity of SARS-CoV2 helicase.
In collaboration with Prof. Hossain Group.
o Binding Assay:
o HDAC glow kit was used to screen ~20 potential inhibitors of HDAC 1, 2, 3, 4, 6, and 8.
o Upon reduced activity, additional experiments were conducted to measure IC50’s with
selected potential inhibitors.

---------------------------------------------------------------------------------------------------------------------------------2020











Kinetic assays
o Examine the activity of LDH from rabbit muscle and bovine heart muscle by measuring
the decrease in NADH concentration at 340 nm.
ATPase assay
o ADP-Glo kinase assay kit was used to examine the activity of three-part CMV Helicase
and examine which combination and concentration of three is most active.
o Titer Glo assay kit was used to examine the activity of SARS-CoV2 helicase and HCV
helicase.
Expressed and purified (NiNTA 10ml column and Size exclusion 250ml column)
o SARS-CoV2 helicase, protease and Mac1.
Transformation
o IPTG inducible BL21(DE3) with SARS-CoV2 helicase and protease.
Binding Assays
o Isothermal titration calorimetry to estimate the complete thermodynamic profile of
ADP-ribose and similar nucleotides binding to Mac1 of SARS-CoV2.
o Isothermal titration calorimetry to estimate the complete thermodynamic profile of
select drugs and drug like compounds binding to Mac1 of SARS-CoV2.
o Thermofluor assay to determine IC50 for Mac1 with ADP-ribose.
o Thermofluor assay to screen library of 2,500 compounds with Mac1.
Activity based screening assay
o Examine the activity of Mac1 in the presence of alpha-NAD. (Wazir et al., 2021)
In collaboration with Prof. Sobolev group
o Designed experiments to test and quantify the antibacterial properties of UV activated
surface.
o Bacterial plaque assays

-----------------------------------------------------------------------------------------------------------------------------------2019


Cloning (Insert digestion, purification, Ligation), expression and transformation of Halo-tag
NS3h.
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o







Design a plasmid that can be used in transforming BL21(DE3) cells that encodes for Nterminal Halo Tag, with TEV protease cleavage site, helicase and His tag at the C
terminal (HaloTag-Tev-NS3h-Histag).
Binding assay
o PIFE and/or Polarization binding assay with Nud3, and F18, F38
o PIFE and/or Polarization binding assay with Nud12 and F18
o PIFE and/or Polarization binding assay with Nudc and F18
Kinetic Assay
o Examine the activity of Nud12 by measuring the change in concentration of NADH at
340 nm.
In collaboration with Prof. Popa group
o Magnetic tweezer assay
o Examine helicase unwinding activity using partially dsDNA (42nt ssDNA with 356nt long
dsDNA) in the presence of ATP.

----------------------------------------------------------------------------------------------------------------------------------2018





Learned how to transfect, grow and store HEK cells with the help of another graduate student.
Binding assay
o PIFE assays on DNA B with 18 nucleotides long Hexachlorofluorescein labeled
oligonucleotide.
o FRET assay using with CFP-NS3h with labeled Oligonucleotide
o Binding and FRET between CFP, YFP and MCH labeled NS3h.
ATPase assay
o With DnaB helicase from bacteria

----------------------------------------------------------------------------------------------------------------------------------2017






Expressed and Purified (NiNTA 10ml column and Size exclusion 250ml column)
o Arabinose induced DH5 alpha cells for Venus
o Arabinose induced DH5 alpha cells for Sapphire
o IPTG induced GFP in Rosetta cells.
o IPTG induced GFP-MAVS in Rosetta cells.
o IPTG induced YFP-NS3h in BL21 cells
o Protein concentration was determined via Bradford assay and using Beers law.
Binding Assay
o FRET assays to examine binding of YFP-NS3h with labeled oligonucleotides with different
fluorophores.
o Native gel shift assay using different percentage polyacrylamide to examine binding
between YFP-NS3h and oligonucleotide.
o PIFE assay to examine the binding of NS3h with labeled oligonucleotides
o FRET assay to examine binding of YFP-NS3h with labeled oligonucleotides under
different pH conditions.
In collaboration with Prof. Raicu group
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o

Use of multiphoton FRET microscopy to examine the binding of helicase with
oligonucleotide using gel samples cut out from Native gel shift assay.

Eskra Technical Products

Summer and fall 2016

Research assistant under the supervision of Mike Eskra.




Test, synthesize and paste various composition of graphite material for cathode to design a
solid-state Lithium-Ion battery.
Assemble lithium-ion Battey in the vacuum hood.
Test and synthesize wet acid batteries.

University of Wisconsin- Milwaukee

Spring 2016

Research assistant under the supervision of Prof. Graham Moran.
Most experiments were repeat of experiments done by graduate students in the same lab.





Protein prep: extraction and purification of protein from BL21(DE3) using Bio Rad BioLogic LP
System with NiNTA, size exclusion and ion exchange column.
Detect the change in the concentration of substrate using HPLC in the presence and absence of
Enzyme.
Detect the binding of LDH and MDH with 6-NADH by measuring a shift in absorbance from
340nm to 360nm upon binding.
Also tried crystalizing proteins.

Marquette University

Summer 2014- Fall 2015

Internship under the supervision of Prof. Chris Dockendorff.



Purpose: Synthesis of primary amine-oxazole oxazoline precatalyst that can be used to preform
Syn-aldol chemistry.
Main Techniques used:
o Thin Layer Chromatography to monitor the progress of a chemical reaction.
o Biotage Isolera One flash chromatograph, to separate compound of interest from
impurities. Uses UV 254 and 210 nm detector SNAP 50g column 50ml/min.
o Shimadzu LC-MS with photodiode array, and dual ESI/DUIS MS probe used to identify
the purity of the compound.
o Varian 300MHz and 400MHz NMR and Thermo/Nicolet IR spectrometer used to identify
compound.

Specialized molecular biology and microbiology techniques
PCR, qRT-PCR, Western Blot, Molecular Cloning, Plasmid Extraction, Cell Transformation, RNA Extraction,
Protein Purification (Sonication, Ammonium Sulfate Precipitation, Dialysis, Affinity Purification, SizeExclusion), Chromatographic Separation (FPLC, HPLC), SDS-PAGE, Nucleic Acid Electrophoresis, Enzyme
Activity Measurement and Kinetic Characterization, FRET binding assay, Protein polarization assay,
Bradford Assay, Preparation of E.coli DH5α competent cells, Fluorescence Microscopy Technology, Basic
Fermentation Technique, etc.

204

Biochemistry relevant teaching experience
Chem 603
Spring 2021 - Fall 2021
Assist and teach students topics in biochemistry: PCR, restriction enzyme digests and ligation, E.coli
transformation, protein expression and purification, in-vitro fluorescent enzyme assays, In vitro
activity assays including characterization of the kinetic parameters (Km, Vmax and Kcat) for HCV and
EcGR.
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